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A B S T R A C T
Background
For many subfertile women, assisted reproductive techniques (ART) is the only hope for a pregnancy and live birth. The combined
oral contraceptive pill (OCP) given prior to the hormone therapy in an IVF cycle may result in better pregnancy outcomes of ART.
Objectives
To assess whether pre-treatment with combined OCPs, progestogens or estrogens in ovarian stimulation protocols affects outcomes in
subfertile couples undergoing ART.
Search methods
We searched the Cochrane Menstrual Disorders and Subfertility Group Specialised Register, The Cochrane Central Register of Con-
trolled Trials, MEDLINE, EMBASE, CINAHL, PsycINFO. Other electronic resources on the Internet, reference list of relevant articles
were also searched as well as the ESHRE abstracts (2008). All these searches were conducted in November 2008.
Selection criteria
Randomised controlled trials of pre-treatment with combined OCP, progestogen or estrogen in subfertile women undergoing IVF/
ICSI.
Data collection and analysis
Two authors independently extracted the data and assessed risk of bias. We calculated Peto odds ratios for dichotomous data and
weighted mean difference for continuous variables. Authors of trials were contacted in case of missing data.
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Main results
No evidence of effect was found with regard to the number of live births when using a pre-treatment. However, the combined OCP
in GnRH antagonist cycles, compared to no pre-treatment, is associated with fewer clinical pregnancies (Peto OR 0.69, 95% CI 0.50
to 0.9; P = 0.03) and more days and a higher amount of gonadotrophin therapy (respectively: MD 1.44, 95% CI 1.15 to 1.72; P <
0.00001; and MD 231.14, 95% CI 161.50 to 300.78; P < 0.00001). Also compared to placebo or no pre-treatment, a progestogen
pre-treatment in GnRH agonist cycles, is associated with more clinical pregnancies (Peto OR 1.95, 95% CI 1.20 to 3.17; P = 0.007)
and fewer ovarian cysts (Peto OR 0.21, 95% CI 0.12 to 0.35; P < 0.00001). At last, in estrogen pre-treated GnRH antagonist cycles,
compared to no pre-treatment, more oocytes are retrieved (MD 2.01, 95% CI 1.76 to2.25; P < 0.00001), but a higher amount of
gonadotrophin therapy is needed (MD 207.08, 95% CI 167.77 to 246.39; P < 0.00001). For the other outcomes no evidence of effect
was found or there were not enough studies available in the subgroup for pooling.
Authors’ conclusions
There was evidence of improved pregnancy outcomes with progestogen pre-treatment and poorer pregnancy outcomes with a combined
OCP pre-treatment. However, we conclude that major changes in ART protocols should not be made at this time, since the number
of overall studies in the subgroups is small and reporting of the major outcomes is inadequate.
P L A I N L A N G U A G E S U M M A R Y
Pre-treatments in IVF/ICSI cycles
In vitro fertilisation (IVF) and intra cytoplasmic sperm injection (ICSI) are important techniques for women who have trouble getting
pregnant. IVF and ICSI cycles consist of a few steps. First the woman receives hormone therapy to stimulate her ovaries in producing
egg cells. When a few egg cells are mature enough to be fertilized, the woman receives a single hormone injection. This triggers the
ovaries to release the egg cells, so they can be gathered by the clinician. The eggs are then fertilised outside the woman’s body and
become embryos. At last one or two embryos are transferred into the womb.
Before the first step in IVF or ICSI cycles (hormone therapy), a pre-treatment with a combined oral contraceptive pill (OCP) can be
given. A combined OCP contains both progestogen and oestrogen. Pre-treatment with a progestogen or oestrogen alone could also
be used before the hormone therapy. These pre-treatments suppress the woman’s own hormone production. This might improve the
woman’s response to the hormone therapy in IVF/ICSI cycles. In this way, adverse events such as cyst formation and the number of
pregnancy losses might be reduced and pregnancy outcomes might be improved.
The aim of this review is to assess if pre-treatments with a combined OCP or a progestogen or oestrogen influence these outcomes in
IVF/ICSI cycles. This is done by pooling results of more than one study, which will hopefully provide a more solid conclusion. We
were able to include 23 studies: a reasonable number. However, due to the formation of subgroups, we have only pooled results of five
studies maximum.
Pre-treatment with a combined OCP seems to result in fewer clinical pregnancies. More days of gonadotrophin therapy and a higher
amount of gonadotrophins are needed. This is mainly important with regard to the financial aspect of the IVF/ICSI treatment. A pre-
treatment with progestogen is associated with more clinical pregnancies and fewer ovarian cysts. Ovarian cysts are frequent reasons for
cycle cancellation. In oestrogen pre-treated cycles more eggs are retrieved, but a higher amount of gonadotrophin therapy is needed.
A limitation of this review is that most included studies were small and of poor quality.
The need for a pre-treatment with oral contraceptives should be clearly explained to the woman undergoing IVF, because this might
be hard to understand when you are trying to get pregnant.
For definitions of terminology see our Glossary.
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B A C K G R O U N D
For definitions of terminology see our Glossary.
Description of the condition
For subfertile women, assisted reproductive techniques (ART)
such as in vitro fertilisation (IVF) and intra cytoplasmic sperm
injection (ICSI) can be a way to achieve pregnancy. Pregnancy and
live birth rates are higher with IVF than with expectant manage-
ment (Pandian 2005).
An IVF cycle has the following stages: ovarian stimulation, oocyte
retrieval, fertilisation of the egg and transfer of the embryo. Ovar-
ian stimulation involves the administration of gonadotrophins.
These hormones stimulate growth and maturation of the follicle.
Gonadotrophins include follicle stimulating hormone (FSH) and
luteinising hormone (LH). There are two different gonadotrophin
preparations; human menopausal gonadotrophin (hMG) which
consists of both FSH and LH, and a more recent therapy, recom-
binant follicle stimulating hormone (rFSH). There is insufficient
evidence of difference between these treatments in ongoing preg-
nancy or live birth rate and other aspects with relation to IVF (Van
Wely 2003).
There are a number of undesirable events associated with go-
nadotrophin therapy that can complicate treatment and out-
comes: ovarian hyperstimulation syndrome, premature LH-surge
and multiple pregnancy (Dodson 1989). In some women under-
going IVF therapy these problems occur because the endogenous
FSH and LH production is too dominant (Awadalla 1987). Go-
nadotrophin releasing hormone analogues (GnRHa) have been
administered to inhibit the production of endogenous FSH and
LH (Dodson 1989; Awadalla 1987). GnRH is a hormone that oc-
curs naturally in the woman’s body and that regulates the produc-
tion of gonadotrophins. There are two different kinds of GnRH
analogues: agonists or antagonists. The difference lies in their
mechanism of action. GnRH agonists bind to the GnRH-recep-
tors in the pituitary gland and initially stimulate the release of
gonadotrophins (‘flare-up’). Negative feedback causes a decrease
in the number of GnRH-receptors, which results in the release of
fewer gonadotrophins. In a traditional treatment protocol, GnRH
agonists are administered prior to commencing gonadotrophins,
ensuring that the flare-up will be over by the time gonadotrophins
are injected. Conversely, GnRH antagonists can be started after
gonadotrophin therapy has been administered because they bind
competitively to the receptor, causing immediate suppression of
the endogenous production of FSH and LH (Tarlatzis 2006).
Therefore GnRH analogues can prevent a premature LH-surge
and synchronize the follicle cohort.
The authors of a Cochrane Review comparing GnRH agonists
with GnRH antagonist cycles, concluded that the use of GnRH
antagonists results in a reduction in the incidence of severe ovarian
hyperstimulation syndrome and fewer days of GnRH analogue
and hMG treatment, however this is at the expense of a statistically
significantly (albeit slightly) lowered ongoing pregnancy rate (OR
0.82, 95% CI 0.69 to 0.98, P=0.03) (Al-Inany 2006).
When a few follicles reach maturity after gonadotrophin stim-
ulation and GnRH analogue treatment, human Chorionic Go-
nadotrophin (hCG) is administered to trigger ovulation and 34
to 36 hours later, oocyte retrieval is undertaken and the egg is fer-
tilised outside the body. Following fertilisation, the embryos are
either transferred on day two or three (cleavage stage) or on day
five or six (blastocyst stage). Luteal phase support is typically pro-
vided as a progestogen or a hCG treatment, or as a combination
of both.
Description of the intervention
Oral contraceptive pills (OCP) are widely used by women of dif-
ferent ages to prevent pregnancy. They are also indicated for a
range of menstrual and gynaecological conditions, such as acne
vulgaris, polycystic ovary syndrome and menorrhagia (Arowojolu
2007; Harwood 2007; Irvine 1999). Combined pills consisting of
oestrogen and progestogen reduce the women’s own production of
FSHandLHbyway of a negative feedback (Cohen 1979;Gaspard
1984). The combined OCP suppresses gonadal function and, in
the absence of a LH-surge, no flare-up or premature ovulation
will occur. Only progestogen has a contraceptive effect (Erkkola
2007). Progestogen has the ability to slow GnRH pulsatility of
the pituitary gland, thereby reducing gonadotrophin surges and,
according to dose, inhibiting ovulation (Anderson 1990; Erkkola
2007; Le Nestour 1993; Moudgal 1985). Estrogen is added in
the combined OCP to regulate the bleeding patterns, though it is
also capable of reducing FSH levels (De Ziegler 1998; Le Nestour
1993).
Most of progestogen-only pills do not inhibit ovulation although
higher doses of progestogen may do so (Erkkola 2007).
How the intervention might work
The combined oral contraceptive pill (OCP) given prior to go-
nadotrophin in an in vitro fertilisation cycle assists synchronisation
of the follicular development and prevents the occurrence of spon-
taneous LH-surges (Gonen 1990). Huirne reports similar data as
well as a reduction of the occurrence of large follicles prior to day
eight (Huirne 2006a). In a further study, both the combined OCP
and progestogen have a suppressive effect on LH and FSH secre-
tion. However, oestrogen administration (in a dosage of 4mg/day)
does not suppress serum LH and FSH values (Cédrin-Durnerin
2007).
It is found that the resulting pituitary suppression of combined
OCPs in GnRH antagonist cycles is associated with slower follic-
ular growth and lowered serum estradiol levels in the early part of
the cycle. This results in a longer duration of rFSH stimulation
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and a higher total rFSH consumption than in antagonist cycles
without pre-treatment (Cédrin-Durnerin 2007).
Combined oral contraceptive pre-treatment in an ovarian stimu-
lation protocol before IVF can reduce cyst formation, shorten the
length of GnRH analogue treatment and reduce the amount of go-
nadotrophin needed, without negatively affecting the pregnancy
rate (Biljan 1998). Pituitary suppression seems to occur earlierwith
progestogen pre-treatment and fewer ovarian cysts are formed,
when compared with no pre-treatment (Engmann 1999). Com-
bined oral contraceptive pre-treatment can be used for scheduling
oocyte retrieval on days of the working week, which is important
with antagonist cycles (Barmat 2005; Gonen 1990;Huirne 2006).
Scheduling is of benefit for the clinicians and people in the labo-
ratory, since these people usually do not work on weekends.
Why it is important to do this review
There is some debate regarding the effects of the combined OCP
upon pregnancy rate. Higher rates of clinical pregnancy and live
birth have been reported when dual suppression protocols and
GnRH analogues were compared to a GnRH analogue protocol
without the use of oral contraceptives in non RCTs (Damario
1997; Keltz 2007). However, other non randomised studies have
found no evidence of effect with regard to pregnancy rate (Bellver
2007; Galera 2004).
As illustrated, there is a lack of consensus regarding whether pre-
treatment with combined oral contraceptives in ovarian stimula-
tion protocols improves rates of pregnancy and live birth. Fur-
thermore, the effects of pre-treatment with progestogen or oe-
strogen on IVF outcomes is unclear. The results of many smaller
randomised controlled trials can be pooled in a systematic review
and may provide a more definitive answer regarding the role of
the combined oral contraceptive pill, progestogens or estrogens in
assisted reproductive therapy.
O B J E C T I V E S
To determine whether pre-treatment with the combined oral con-
traceptive pill, a progestogen or an oestrogen in ovarian stimula-
tion protocols affects outcomes in subfertile couples undergoing
any form of assisted reproductive therapy.
M E T H O D S
Criteria for considering studies for this review
Types of studies
• Only truly randomised controlled trials (RCTs) were
included in this review. We included both published and
unpublished studies and we excluded trials with quasi-
randomisation.
• Cross-over trials were included in this review, but excluded
from analysis unless pre-crossover data are available, as the design
is inappropriate in this context.
Types of participants
Women of any age with subfertility, regardless of any cause, un-
dergoing assisted reproductive therapy.
We only excluded two types of participants from this review.
The first is women with premature ovarian failure, because these
women require a totally different ovarian stimulation protocol.
The second is women who participated in ovarian stimulation
protocols as oocyte donors.
Types of interventions
1. Pre-treatment with a combined OCP prior to
gonadotrophins with or without GnRH analogues (agonist or
antagonist) versus no pre-treatment or placebo prior to
gonadotrophins with or without GnRH analogues (agonist or
antagonist)
2. Pre-treatment with progestogen prior to gonadotrophins
with or without GnRH analogues (agonist or antagonist) versus
no pre-treatment or placebo prior to gonadotrophins with or
without GnRH analogues (agonist or antagonist)
3. Pre-treatment with oestrogen prior to gonadotrophins with
or without GnRH analogues (agonist or antagonist) versus no
pre-treatment or placebo prior to gonadotrophins with or
without GnRH analogues (agonist or antagonist)
4. Pre-treatment with a combined OCP prior to
gonadotrophins with or without GnRH analogues (agonist or
antagonist) versus pre-treatment with a progestogen prior to
gonadotrophins with or without GnRH analogues (agonist or
antagonist)
5. Pre-treatment with a combined OCP prior to
gonadotrophins with or without GnRH analogues (agonist or
antagonist) versus pre-treatment with an oestrogen prior to
gonadotrophins with or without GnRH analogues (agonist or
antagonist)
6. Pre-treatment with a progestogen prior to gonadotrophins
with or without GnRH analogues (agonist or antagonist) versus
pre-treatment with an oestrogen prior to gonadotrophins with or
without GnRH analogues (agonist or antagonist)
We excluded studies that compare different doses of the same pre-
treatment.
Types of outcome measures
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Primary outcomes
• Number of live births per woman randomised - defined as
the delivery of a fetus with signs of life after twenty completed weeks
of gestational age, counted as live birth event. When there are
multiple live births (e.g. twins or triplets), these are counted as one
live birth event (Griffin 2002).
Secondary outcomes
• Number of ongoing pregnancies per woman randomised -
defined as evidence of a gestational sac with fetal heart motion at
twelve weeks or later, confirmed with ultrasound. When there are
multiple gestational sacs in one patient, these are counted as one
ongoing pregnancy (Griffin 2002).
• Number of clinical/ongoing pregnancies per woman
randomised - defined as evidence of a gestational sac with fetal
heart motion at six weeks or later, confirmed with ultrasound. When
there are multiple gestational sacs in one patient, these are counted as
one clinical pregnancy (Griffin 2002).
• Number of oocytes retrieved per woman randomised
• Days of gonadotrophin treatment per woman randomised
• Amount of gonadotrophins administered per woman
randomised
Adverse outcomes
• Number of pregnancy loss per woman randomised - defined
as the sum of the number of spontaneous abortions (pregnancy loss
before twenty completed weeks of gestation) and the number of
stillbirths (pregnancy loss after twenty completed weeks of gestation)
(Griffin 2002).
• Number of women with ovarian cyst formation - defined as
any intraovarian sonolucent structure with a mean diameter of 15
mm or more confirmed with ultrasound at least one week after start
pituitary suppression (Biljan 1998).
• Number of multiple pregnancies per woman randomised -
when there are multiple gestational sacs in one patient, these are
counted as one multiple pregnancy.
• Number of ovarian hyperstimulation (OHS) syndrome per
woman randomised - defined as a condition that can occur from
drugs used in ART, through stimulating a large number of follicles in
the ovary to develop and ovulate (MDSG Module 2008).
Search methods for identification of studies
We obtained all studies that describe (or might describe) ran-
domised controlled trials of pre-treatment with combined oral
contraceptive pills, progestogen or oestrogen therapy prior to
GnRH analogues (agonists or antagonists) and gonadotrophins or
gonadotrophins alone in women undergoing in vitro fertilisation,
using the following search strategies.
Electronic searches
• The Menstrual Disorders and Subfertility Group (MDSG)
Specialised Register of controlled trials has been searched for any
relevant trials using the terms ’in vitro fertilization’ or
’intracytoplasmic sperm injection’ or ’ART’ or ’controlled
ovarian’ AND ’oral contraceptive’ or ’combined oral
contraceptives’ or ’progestogen’ or ’oestrogen’ in the titles,
abstracts and keywords; 1947 -17 November 2008 (Appendix 1).
We searched the following electronic databases using Ovid soft-
ware:
• Cochrane Central Register of Controlled Trials
(CENTRAL); from inception - 17 November 2008 (Appendix
2);
• MEDLINE; 1950 - 17 November 2008 (Appendix 3). We
combined this search with the Cochrane highly sensitive search
strategy for identifying randomised trials (Higgins 2008);
• EMBASE; 2007 - 17 November 2008 (Appendix 4). We
combined this search with trial filters developed by the Scottish
Intercollegiate Guidelines Network (SIGN);
• Cumulative Index to Nursing and Allied Health Literature
(CINAHL); 1982 - 17 November 2008 (Appendix 5). We
combined this search with trial filters developed by the Scottish
Intercollegiate Guidelines Network (SIGN); and
• PsycINFO; 1806 - 17 November 2008 (Appendix 6).
We did not restrict the search by language. We managed output
of these searches with a reference manager, Endnote (EndNote).
Through this program, duplicates can be found and removed.
Searching other resources
In addition, we searched some other resources than the electronic
databases mentioned above to obtain more relevant trials. We ac-
cessed all the web sites on 18 November 2008, except for Open-
SIGLE.
• Trial registers for ongoing and registered trials: Current
Controlled Trials (http://www.controlled-trials.com),
ClinicalTrials.gov (http://clinicaltrials.gov/ct2/home), and The
World Health Organisation International Trials Registry
Platform Search Portal (http://www.who.int/trialsearch).
• Citation indexes (http://scientific.thomson.com/products/
sci).
• PubMed (http://www.ncbi.nlm.nih.gov/pubmed); we
combined this search with random control filters for PubMed
(Higgins 2008).
• Conference abstracts on the ISI Web of Knowledge (http://
isiwebofknowledge.com).
• ClinicalStudyResults provides clinical trial results of
marketed pharmaceuticals (http://www.clinicalstudyresults.org).
• Open System for Information on Grey Literature (http://
opensigle.inist.fr, accessed on 26 November 2008).
• All the reference lists of the studies obtained with the
electronic databases.
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• Handsearching of the abstracts of the 24th annual meeting
of the European society of human reproduction and embryology
in Barcelona (Spain), 6 to 9 July 2008 (ESHRE 2008).
Data collection and analysis
Selection of studies
Two review authors (BS and SvO) independently scanned the titles
and abstracts of all the studies found with the search to exclude
those which did not meet the inclusion criteria. We discussed any
disagreement or doubt, whether a study is eligible for inclusion
or not, with a third review author (CF) to achieve consensus. We
obtained full text of those RCTs deemed eligible for inclusion
where possible, and subjected them to critical appraisal of their risk
of bias. Where appropriate, we included them in this systematic
review.
Subsequently, we constructed a table of Characteristics of included
studies for those trials considered suitable for inclusion. We pro-
duced another table, Characteristics of excluded studies, for those
that did not satisfy the inclusion criteria. In this table we listed the
reasons for exclusion.
Data extraction and management
The review authors (BS andSvO) independently extracted the data
using data extraction forms, which we designed for this particular
review (Appendix 7; Appendix 8). We resolved any discrepancies
by discussion and the help of a third review author (CF).
The data extraction forms included risk of bias criteria and
methodological details. The information about the studies is in-
cluded in the review and presented in the tables of Characteristics
of included studies. We managed the data using Review Manager
5 software (RevMan).
We extracted the following information from the studies selected
for the review:
Trial characteristics
• Quality of allocation concealment
• Method of randomisation
• Trial design: cross-over or parallel
• Blinding of investigator, patient and outcome assessors
• Details on dropouts and intention-to-treat analysis used
• Presence of power calculation
• Duration, timing and location of the trial (single or multi
centre)
• Number of patients randomised, excluded, analysed and
lost to follow-up
• Source of funding
Characteristics of participants
• Women’s age
• Body Mass Index (BMI)
• Cause of subfertility
• Duration of subfertility
• Previous number of ART treatment cycles
• Poor response to ovarian stimulation
Characteristics of interventions
• Preparations used for pre-treatment, pituitary
desensitization and ovarian stimulation
• Dosage of preparations
• Length of each different treatment in days
• Treatment protocol (timing of administration of pre-
treatments, gonadotrophins and GnRH analogues)
• Type of protocol (long versus short agonist protocol; single
versus multiple antagonist protocol; fixed versus flexible
antagonist protocol)
Types of outcome measures
As described above (see Criteria for considering studies for this
review).
Assessment of risk of bias in included studies
We assessed and reported on the risk of bias of included studies in
accordance with the Cochrane Handbook for Systematic Reviews
of Interventions (Higgins 2008) which recommends the explicit
reporting of the following domains:
• Sequence generation
Was sequence generation adequate (e.g. use of a random number table,
a computer random number generator or coin tossing), inadequate
(e.g. use of date of birth or clinical record number) or unclear (insuf-
ficient information about the process of sequence generation)?
• Allocation concealment
Was allocation concealment adequate (e.g. use of central allocation
or opaque sealed envelopes), inadequate (e.g. use of an open random
allocation schedule, date of birth or case record number) or unclear
(insufficient information about the process of allocation concealment)?
• Blinding of participants, providers and outcome assessors
Was blinding adequate (e.g. participants and researchers were all
blinded and it was unlikely that blinding could have been broken,
either participants or some researchers are not blinded but outcome
assessment was blinded or no blinding was used but this is not likely
to influence outcomes), inadequate (e.g. no blinding or incomplete
blinding and outcomes are likely to be influenced by this) or unclear
(insufficient information about the process of blinding)?
• Incomplete outcome data
Were outcome data addressed adequately (e.g. there were no missing
outcome data, reasons for missing outcome data were unlikely to be re-
lated to true outcome or missing outcome data were balanced in num-
bers across intervention groups), inadequate (e.g. reasons for missing
outcome data were likely to be related to true outcome) or unclear (in-
sufficient information about the process of addressing outcome data)?
• Selective outcome reporting
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Was the study free of selective reporting? Adequate (e.g. the study pro-
tocol is available and all pre-specified outcomes have been reported or
the study protocol is not available but it is clear that all pre-specified
outcomes have been reported), inadequate (e.g. not all pre-specified
primary outcomes have been reported) or unclear (insufficient infor-
mation about the process of outcome reporting).
• Other sources of bias for RCTs
Was the study free of other bias? Adequate (the study seems to be free of
other bias), inadequate (e.g. extreme baseline imbalance, a potential
source of bias related to the specific study design used or early stopping)
or unclear (insufficient information about other sources of bias).
By using a simple form (Appendix 7; Appendix 8) two review
authors (BS and SvO) separately assessed these domains as ’yes’
(indicating a low risk of bias), ’unclear’ (indicating an uncertain
risk of bias) or ’no’ (indicating a high risk of bias).
The assessments of the two review authors were compared and we
resolved any discrepancies in the interpretation of the risk of bias
of a study by discussion with a third review author. We did not
automatically exclude any study as a result of a rating of ’Unclear’
or ’No’. Where it was unclear, we contacted authors of studies
about the methods used and also sought any missing data.
We presented the results of the risk of bias assessment in the tables
of Characteristics of included studies within the review, including
commentary about each of the domains. This led to an overall
assessment of the risk of bias of included studies (Figure 1; Figure
2).
Figure 1. Methodological quality graph: review authors’ judgements about each methodological quality
item presented as percentages across all included studies.
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Figure 2. Methodological quality summary: review authors’ judgements about each methodological quality
item for each included study.
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Measures of treatment effect
For dichotomous data, we expressed results for each study as Peto
odds ratios (OR) with 95% confidence intervals (CI). For contin-
uous variables, we reported the data as a weighted mean difference
(WMD) with 95% confidence intervals.
Unit of analysis issues
In order to avoid analysis errors, we only pooled data that report
outcomes per woman randomised.
Dealing with missing data
In case of missing data in the included studies, we contacted the
original investigators by e-mail or post to request relevant missing
information. If we did not receive a reply, we sent a reminder to
the authors a couple of weeks later. Furthermore, we contacted
the members of the MDSG-group to ask if they know any of the
authors personally or have contact details.
We reported the data according to intention-to-treat where possi-
ble.
Assessment of heterogeneity
Before any meta-analysis was done, we judged whether there was
sufficient similarity between the eligible studies in their design and
clinical characteristics to ensure that pooling is valid. We assessed
statistical heterogeneity in the results of trials by using the Chi2
test. A low P value (or a large Chi2 statistic relative to its degree
of freedom) will potentially provide evidence of heterogeneity of
intervention effects and show that results are not influenced by
chance alone (Higgins 2008).
We used the I2 statistic to assess the impact of the heterogeneity
on the meta-analysis. We interpreted the result of the I2 statistic
as follow:
• 0% to 40%: might not be important;
• 30% to 60%: may represent moderate heterogeneity;
• 50% to 90%: may represent substantial heterogeneity; and
• 75% to 100%: considerable heterogeneity (Higgins 2008).
If we found marked clinical or statistical heterogeneity (I2 more
than 50%), we explored reasons for this heterogeneity by using
sensitivity analysis.
Assessment of reporting biases
To investigate the potential for publication bias, we planned to use
a funnel plot, but due to the small number of studies per subgroup
this was not possible.
Data synthesis
We carried out statistical analysis using Review Manager 5
(RevMan).We used fixed-effect meta-analysis for combining data.
If we found heterogeneity between studies sufficient to suggest
that treatment effects may differ between trials, we explored this
by sensitivity analysis. We planned to do a random-effects meta-
analysis if required, but this was not necessary.
Subgroup analysis and investigation of heterogeneity
To reduce heterogeneity between studies, we pooled the data of
GnRH agonist and GnRH antagonist cycles separately by per-
forming subgroup analyses on different treatment protocols:
• GnRH agonist in study group versus GnRH agonist in
control group
• GnRH antagonist in study group versus GnRH antagonist
in control group
• GnRH antagonist in study group versus GnRH agonist in
control group
• GnRH agonist in study group versus GnRH antagonist in
control group
Furthermore, we did subgroup analysis on low responder patients.
Unfortunately, we could only include one trial in each subgroup
which made pooling impossible.
Furthermore, we planned to do subgroup analyses on women’s
age; poor response; agonist long, short and ultra-short protocol;
and the duration of pre-treatment. However, due to the small
number of included studies per comparison, we were not able to
do subgroup analyses on these aspects.
Sensitivity analysis
Weplanned touse a sensitivity analysis to explorewhether the find-
ings from the meta-analysis were dependent on aspects within in-
dividual studies deemed eligible for inclusion. Aspects we planned
to do a sensitivity analysis on, were random sequence generation,
allocation concealment and the overall assessment of risk of bias.
Due to the small number of studies in each subgroup, we were
unable to do any sensitivity analyses.
R E S U L T S
Description of studies
See: Characteristics of included studies; Characteristics of
excluded studies; Characteristics of studies awaiting classification;
Characteristics of ongoing studies.
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Results of the search
After searching the electronic databases, we found a total of 1049
studies: 492 studies in theMDSG specialised register of controlled
trials, 123 studies in CENTRAL, 350 studies in MEDLINE, 61
studies in EMBASE, 3 studies in CINAHL and 20 studies in
PsycINFO. After removing the duplicates and searching other re-
sources, there were approximately 900 studies left. Around 200
studies seemed eligible for inclusion, after the first screening of
titles and abstracts and we were able to include 23 studies in this
review.
Included studies
The following is a summary of the methods, participants, inter-
ventions and outcomes of all the included studies. Full details of
these domains (for each study separately) can be found in the ta-
bles of Characteristics of included studies.
Methods in included studies
The main analyses were based on 23 trials, which involved a total
of 2596 women randomised to treatment.
The three largest trials included in this review were Kolibianakis
2006 (504 women), Rombauts 2006 (351 women) and Huirne
2006a (182 women). The smallest trial was Fanchin 2001 with
fourteen women randomised. Four trials used a cross-over design,
of which only two reported pre-cross-over data (Daly 2002;Wang
2008). The other two studies can not be used in our analysis since
only post-cross-over data is available (Cédrin-Durnerin 1996;
Fanchin 2001). The other nineteen trials used a parallel design.
Four studies were conducted inmultiple centres, according to their
articles (Cédrin-Durnerin 2007; Huirne 2006a; Huirne 2006b;
Rombauts 2006).
The trials took place in (or authors came from): France (six trials:
Cédrin-Durnerin 1996; Cédrin-Durnerin 2007; Fanchin 2001;
Fanchin 2003a; Hugues 1994; Salat-Baroux 1988); United King-
dom (two trials: Aston 1995; Shaker 1995); Canada (two trials:
Biljan 1998a;Tan2001);UnitedKingdomandCanada (Engmann
1999); United States of America (two trials: Daly 2002; Ditkoff
1996); Austria (Obruca 2001); Belgium (Kolibianakis 2006);
Brazil (Franco Jr 2003); China (Wang 2008); Iran (Raoofi 2008);
South Korea (Kim 2005); Taiwan (Hwang 2004); Australia, Den-
mark, Jordan and Norway (Rombauts 2006); The Netherlands
and Belgium (Huirne 2006b); and The Netherlands, Belgium,
France and Austria (Huirne 2006a).
Of the 23 included studies, ten performed and adhered a power
calculation (Aston 1995; Biljan 1998a; Engmann 1999; Fanchin
2003a; Huirne 2006a; Huirne 2006b; Hwang 2004; Kim 2005;
Kolibianakis 2006; Rombauts 2006). Seven studies did not adhere
a power calculation (Cédrin-Durnerin 1996; Cédrin-Durnerin
2007; Ditkoff 1996; Franco Jr 2003; Raoofi 2008; Salat-Baroux
1988; Shaker 1995) and of five studies this is unclear, because there
was only an abstract available (Daly 2002; Fanchin 2001; Hugues
1994;Obruca2001;Tan 2001).Of one trial it was unclear, because
we only have the article in a foreign language of which only the
most important sections were translated (Wang 2008).
Only one of the included trials seems to have used a true intention-
to-treat analysis (Kim 2005), which means that all outcomes of all
the randomised women are used in the final analysis.
Of the other included trials it seems that this was not done. Nine
trials analysed data of all randomised women for a few of the out-
comes, but not for all (for example, the table of baseline charac-
teristics is usually constructed by analysing data of all randomised
women, but the number of oocytes retrieved is calculated from
data of only women that reached oocyte retrieval).
Six trials used no intention-to-treat analysis for any of their out-
comes (Aston 1995; Engmann 1999; Fanchin 2003a; Franco Jr
2003; Kolibianakis 2006; Rombauts 2006) and of the other seven
trials it is unclear whether they used an intention-to-treat analy-
sis because there is not enough information available (Daly 2002;
Fanchin 2001; Hugues 1994; Obruca 2001; Raoofi 2008; Shaker
1995; Tan 2001).
Participants in included studies
Inclusion criteria
Of the 23 studies, 18 studies included women with a regular IVF/
ICSI indication, five trials only included women who had a spe-
cial indication for IVF. Two trials only included women who are
poor responders (Kim 2005;Wang 2008). One trial only included
women with limited ovarian reserve (Daly 2002). Another trial
only included women with polycystic ovary syndrome (Hwang
2004) and the last trial only included women if they had an ovar-
ian cyst of over 5 mm in diameter or an endometrial thickness
of over 5 mm and serum E2 concentration > 100 pmol/L after
fourteen days of GnRH agonist treatment (Shaker 1995).
Thirteen of the studies mentioned an age limit as an inclusion
criteria. Four studies only includedwomen less than 38 years of age
(Cédrin-Durnerin 2007; Franco Jr 2003; Huirne 2006b; Salat-
Baroux 1988). Five studies only includedwomen less than 39 years
of age (Fanchin 2003a; Huirne 2006a; Hwang 2004; Kolibianakis
2006; Rombauts 2006). The other four studies used age limits
above 40 years of age: one study used an upper limit of 41 years
of age (Daly 2002), two studies an upper limit of 42 years of
age (Cédrin-Durnerin 1996; Kim 2005) and one study used an
upper limit of 44 years of age (Engmann 1999). Lower limits were
defined in five of these 13 studies: four studies used a lower limit
of 18 years of age (Engmann 1999; Huirne 2006a; Huirne 2006b;
Rombauts 2006), and for one study the lower age limit was 28
years of age (Kim 2005). Ten studies did not mention an age limit
in their description of the women.
Other common inclusion criteria were the presence of regular
menstrual cycles (Cédrin-Durnerin 2007; Fanchin 2003a; Huirne
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2006b; Rombauts 2006) and a BMI of less than 29 or 30
kg/m2 (Cédrin-Durnerin 2007; Fanchin 2003a; Huirne 2006b;
Kolibianakis 2006; Rombauts 2006).
Exclusion criteria
Five studies excluded women with an evidence of poor response.
Two studies defined this as any previous ART cycles with less than
three oocytes (Huirne 2006a; Huirne 2006b), the first study also
excluded women if they had a history of three or more consecutive
ART cycles without a clinical pregnancy. Another study defined
this as less than five oocytes in a previous IVF attempt or less than
five follicles in a spontaneous cycle (Cédrin-Durnerin 2007), and
one study defined this as more than three unsuccessful controlled
ovarian stimulation cycles or a history of lowor noovarian response
during FSH/hMG (Rombauts 2006). One study did not mention
how they defined poor response to ovarian stimulation in their
trial (Kolibianakis 2006).
Other common exclusion criteria were: a high baseline serum
FSH level (Cédrin-Durnerin 2007; Ditkoff 1996; Engmann
1999; Huirne 2006b; Hwang 2004; Kolibianakis 2006), the evi-
dence of ovarian cysts or endometrioma (Aston 1995; Engmann
1999; Kolibianakis 2006) and polycystic ovary syndrome (Huirne
2006b; Rombauts 2006).
Interventions in included studies
Three of the 23 studies have more than two study arms and can be
used in more than one comparison (Cédrin-Durnerin 2007; Kim
2005; Rombauts 2006).
Combined OCP versus placebo or no pre-treatment
In eleven trials (with a total of thirteen comparisons) the study
group was given a pre-treatment with a combined OCP, while
the control group received no pre-treatment. None of these
studies used a placebo in the control group. Seven trials used
ethinyl estradiol as the oestrogen component in a daily dose of
30 µg (Cédrin-Durnerin 2007; Huirne 2006a; Huirne 2006b;
Kolibianakis 2006; Obruca 2001; Raoofi 2008; Rombauts 2006).
Five trials used 150 µg desogestrel daily (Cédrin-Durnerin 2007;
Kolibianakis 2006; Obruca 2001; Raoofi 2008; Rombauts 2006)
and two trials used 150 µg levonorgestrel daily as the progestogen
component (Huirne 2006a; Huirne 2006b). One study used Di-
ane-35, which contains 35 µg ethinyl estradiol and 2 mg cypro-
terone acetate (Hwang 2004). From three studies there are not
enough data available on the type of combined OCP used (Biljan
1998a; Kim 2005; Wang 2008).
The starting days of pre-treatment in all eleven trials varied from
cycle day one to five. Five studies started the combined OCP
pre-treatment on cycle day one (Biljan 1998a; Kolibianakis 2006;
Obruca 2001; Raoofi 2008; Rombauts 2006). Two studies started
the pre-treatment on cycle day two or three (Cédrin-Durnerin
2007; Huirne 2006b). One study started the pre-treatment on a
variable cycle day from one to five (Huirne 2006a). Another study
started the pre-treatment on cycle day five (Hwang 2004). From
two studies there are not enough data available on the start day of
pre-treatment (Kim 2005; Wang 2008).
The duration of pre-treatment in all eleven trials varied from
fourteen days to three consecutive cycles. Three studies used a
fixed duration of fourteen days of pre-treatment (Biljan 1998a;
Kolibianakis 2006; Raoofi 2008). Two studies used a variable du-
ration of pre-treatment of 14 to 28 days (Huirne 2006b; Rombauts
2006). Three other studies used a variable duration of around
two or three weeks minimum to around four weeks maximum
(Cédrin-Durnerin 2007, 15 to 21 days; Obruca 2001, 18 to 28
days; Huirne 2006a, 21 to 28 days). The longest pre-treatment
duration of three consecutive cycles was used by Hwang 2004.
From two studies there are not enough data available on the du-
ration of pre-treatment (Kim 2005; Wang 2008).
Two studies used agonists in both treatment groups. One study
used buserelin acetate (long protocol) (Biljan 1998a) and the other
used a depot of triptorelin acetate (Raoofi 2008).
Six studies used antagonists in both treatment groups. Three
of these studies used ganirelix acetate (Cédrin-Durnerin 2007;
Kolibianakis 2006; Rombauts 2006), one study used cetrorelix
acetate (Obruca 2001), one used antide (Huirne 2006b) and the
other one did not mention which GnRH antagonist was used
(Kim 2005).
Four trials used an antagonist in the study group and an agonist
in the control group. Two used cetrorelix acetate as antagonist and
buserelin acetate as agonist (Huirne 2006a; Hwang 2004). One
used ganirelix acetate as antagonist and nafarelin acetate as agonist
(Rombauts 2006). The other study did notmention whichGnRH
analogues were used (Kim 2005).
One trial used an agonist in the study group and an antagonist in
the control group, but did not mention which GnRH analogues
were used (Wang 2008).
Progestogen versus placebo or no pre-treatment
In eight trials the study groupwas given a pre-treatmentwith a pro-
gestogen, while the control group received placebo (Aston 1995)
or no pre-treatment. Five studies used norethisterone 10 mg daily
(Cédrin-Durnerin 1996; Cédrin-Durnerin 2007; Ditkoff 1996;
Engmann 1999; Hugues 1994), one study used medroxyproges-
terone acetate 10mgdaily (Aston 1995) and one study used ethyn-
odiol acetate 4 mg daily (Salat-Baroux 1988). Another study used
a single injection of 100 mg, but did not mention what type of
progestogen they used (Shaker 1995).
The starting days of pre-treatment in all eight trials varied from cy-
cle day one to nineteen. Two studies started the pre-treatment with
progestogen on cycle day one (Ditkoff 1996; Engmann 1999).
Three other studies started the pre-treatment on cycle day fifteen
(Cédrin-Durnerin 1996; Cédrin-Durnerin 2007; Salat-Baroux
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1988). One study started the pre-treatment on cycle day sixteen or
seventeen (Shaker 1995) and another study on cycle day nineteen
(Aston 1995). From one study there are not enough data available
on the start day of pre-treatment (Hugues 1994).
The duration of progestogen pre-treatment varied from one day
to twenty days. In one study the women received one single injec-
tion (Shaker 1995). One study used a duration of pre-treatment
of five days (Engmann 1999). Another study used a duration of
seven days (Aston 1995) and one study of eight days (Ditkoff
1996). Two trials used a variable duration of ten to fifteen days
(Cédrin-Durnerin 2007; Hugues 1994) and one trial had a vari-
able duration of eleven to seventeen days (Salat-Baroux 1988). At
last, there was one study that used a variable duration of twelve to
twenty days (Cédrin-Durnerin 1996).
Six trials used an agonist in both treatment groups. Three stud-
ies used buserelin acetate (Aston 1995; Engmann 1999; Shaker
1995), one study used triptorelin (Cédrin-Durnerin 1996), one
study used leuprolide acetate (Ditkoff 1996) and another study
used dTRP6-LHRH (Hugues 1994).
One trial used an antagonist (ganirelix acetate) in both treatment
groups (Cédrin-Durnerin 2007).
One trial did not use GnRH analogues for pituitary desensitiza-
tion. Women that participated in this study only received pure
FSH and hMG (Salat-Baroux 1988).
Estrogen versus placebo or no pre-treatment
In three trials the study group was given a pre-treatment with
oestrogen, while the control group received no pre-treatment. Two
studies usedmicronized 17-βE2 (Cédrin-Durnerin 2007; Fanchin
2003a) and one study used estradiol valerate (Franco Jr 2003). All
these studies used a dosage of 4 mg daily.
The starting days of pre-treatment in all three trials varied from
cycle day 15 to 21. One study started the pre-treatment on cycle
day 20 (Fanchin 2003a) and one on cycle day 21 (Franco Jr 2003).
The other study started the pre-treatment ten days before the
presumed menses (Cédrin-Durnerin 2007).
The duration of pre-treatment in all three trials varied from ten
to seventeen days. In one study the duration varied from ten to
fifteen days (Cédrin-Durnerin 2007). The other two studies used
a fixed duration of pre-treatment of eleven days (Fanchin 2003a)
and fourteen days (Franco Jr 2003).
Two trials used an antagonist in both treatment groups, one trial
used ganirelix acetate (Cédrin-Durnerin 2007) and the other used
cetrorelix acetate (Fanchin 2003a).
One trial used an antagonist (ganirelix acetate) in the study group
and an agonist (nafarelin acetate) in the control group (Franco Jr
2003).
Combined OCP versus progestogen
There was only one study that compared a combined OCP with
progestogen (Cédrin-Durnerin 2007). The women in the com-
bined OCP group received ethinyl estradiol 30µg and desogestrel
150 µg daily and the women in the progestogen group received
norethisterone 10 mg daily. This study started the combined OCP
pre-treatment on cycle day two or three with a duration of 15 to
21 days. The progestogen pre-treatment was started on cycle day
fifteen with a duration of ten to fifteen days. Both groups received
a GnRH antagonist (ganirelix acetate).
Combined OCP versus oestrogen
In two trials a pre-treatment of combinedOCPwas comparedwith
a pre-treatment of oestrogen.One trial used ethinyl estradiol 30µg
and desogestrel 150 µg daily as a combined OCP and micronized
17-βE2 4 mg daily as oestrogen pre-treatment (Cédrin-Durnerin
2007). The combined OCP pre-treatment started on cycle day
two or three with a duration of 15 to 21 days. The oestrogen
pre-treatment started ten days before the presumed menses with a
duration of ten to fifteen days and both groups received theGnRH
antagonist ganirelix acetate .
The other study did not mention which combined OCPwas used,
but used two mg ethinyl estradiol as an oestrogen pre-treatment
(Daly 2002). This study only described that the oestrogen pre-
treatment was administered in the luteal phase of the preparation
cycle, but did not report about exact starting days and durations
of pre-treatment. The combined OCP group received a GnRH
agonist (leuprolide acetate) and the oestrogen group received a
GnRH antagonist (ganirelix acetate).
Progestogen versus oestrogen
There was only one study that compared progestogen with oe-
strogen (Cédrin-Durnerin 2007). The women in the progestogen
group received norethisterone ten mg daily and the women in
the oestrogen group received micronized 17-βE2 4 mg daily. This
study started the progestogen pre-treatment on cycle day fifteen
with a duration of ten to fifteen days. The oestrogen pre-treatment
started ten days before the presumed menses with also a duration
of ten to fifteen days. Both groups received a GnRH antagonist
(ganirelix acetate).
Outcomes in included studies
Primary outcome
The number of live births was reported in seven studies (Cédrin-
Durnerin 1996; Cédrin-Durnerin 2007; Ditkoff 1996; Engmann
1999; Franco Jr 2003; Huirne 2006a; Kim 2005).
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Secondary outcomes
The number of ongoing pregnancies was reported in eight studies.
This was defined as a positive heart activity at a gestational age
of twelve weeks by three studies (Huirne 2006a; Huirne 2006b;
Kim 2005). One study used the same definition but did not men-
tion when they performed the ultrasound scan (Ditkoff 1996).
Two studies defined this as a pregnancy developing beyond twelve
weeks (Cédrin-Durnerin 2007; Kolibianakis 2006) and one study
defined this as a pregnancy assessed by ultrasound at twelve to
sixteen weeks or later (Rombauts 2006). The last study defined
ongoing pregnancy as a viable pregnancy and did not mention
how they assessed this (Daly 2002).
The number of clinical pregnancies was reported in eighteen stud-
ies. Five studies defined clinical pregnancy as the presence of one
or more fetal hearts confirmed with ultrasound (US), performed
at least four weeks after embryo transfer (Biljan 1998a; Fanchin
2003a, US after six weeks; Franco Jr 2003; Kim 2005; Raoofi
2008). Two other studies used the same definition, but one of these
also included the fetal sacs without heart activity (Huirne 2006a)
and the other performed the US scan at seven weeks after embryo
transfer (Hwang 2004). One study defined clinical pregnancy as
the presence of one or more intrauterine sacs confirmed with US,
at a gestational age of six weeks (Huirne 2006b). Of one study
we used a positive pregnancy test with evidence of a gestational
sac to define clinical pregnancy, because no clinical or ongoing
pregnancy rate was available (Engmann 1999). Another study de-
fined clinical pregnancy as the evidence of a clinical gestational
sac (Ditkoff 1996). Of the other eight studies it was not clear how
they defined this outcome (Aston 1995; Cédrin-Durnerin 1996;
Cédrin-Durnerin 2007; Daly 2002; Obruca 2001; Salat-Baroux
1988; Shaker 1995; Wang 2008). If no clinical pregnancy rates
were reported, we used the ongoing pregnancy rates (if available)
for our analysis.
The number of oocytes retrieved was reported in fourteen studies
(Biljan 1998a; Cédrin-Durnerin 2007; Ditkoff 1996; Franco Jr
2003; Huirne 2006a; Huirne 2006b; Hwang 2004; Kim 2005;
Obruca 2001; Raoofi 2008; Rombauts 2006; Salat-Baroux 1988;
Shaker 1995;Wang 2008).One study onlymentioned the number
of cumulus-oocyte complexes (Kolibianakis 2006) and three stud-
ies the number of mature oocytes or follicles (Cédrin-Durnerin
1996; Engmann 1999; Fanchin 2003a), but we assumed that this
means the same as the number of oocytes retrieved and therefore
we pooled the data of these studies.
The number of days of gonadotrophin treatment was reported
in twelve studies (Biljan 1998a; Ditkoff 1996; Engmann 1999;
Franco Jr 2003; Huirne 2006a; Huirne 2006b;Hwang 2004; Kim
2005; Kolibianakis 2006; Rombauts 2006; Shaker 1995; Wang
2008).
The amount of gonadotrophins administered in IU was reported
by eight studies (Cédrin-Durnerin 2007; Fanchin 2003a; Franco
Jr 2003; Huirne 2006a; Huirne 2006b; Kim 2005; Kolibianakis
2006; Rombauts 2006). Another seven studies reported the
amount of gonadotrophins administered in the number of am-
poules used, but we can not use these data in our analysis (Biljan
1998a; Cédrin-Durnerin 1996; Ditkoff 1996; Engmann 1999;
Hwang 2004; Shaker 1995; Wang 2008).
Adverse outcomes
The number of pregnancy losses was reported by eight studies.
One study described this as the proportionof patients with initially
positive hCG in whom pregnancy failed to develop before 12
weeks of gestation (Kolibianakis 2006). The other seven studies
did not describe a definition (Daly 2002; Engmann 1999; Franco
Jr 2003; Hwang 2004; Kim 2005; Rombauts 2006; Salat-Baroux
1988).
The number of women with ovarian cysts was reported by eight
studies. Of one study we used the number of functional ovarian
cysts with a diameter of 10 mm or more, measured after one
week of GnRH agonist treatment (Engmann 1999). Four studies
defined anovarian cyst as an intraovarian sonolucent structurewith
amean diameter of 14mmormore, measured after seven to twelve
days of pituitary suppression (Aston 1995, after twelve days; Biljan
1998a, after seven days; Ditkoff 1996, after eight days; Franco
Jr 2003, not reported). One study reported ovarian cysts when
they reached a diameter of more than 28 mm, measured seven
and fourteen days after pituitary suppression (Raoofi 2008). One
study did not mention how they defined ovarian cyst formation
and when they measured this (Huirne 2006b).
One study only reported cyst formation as reason for cycle can-
cellation, but it is unclear if there were more cysts formed that did
not lead to cycle cancellation (Salat-Baroux 1988).We did not use
these data in our analysis.
The number of multiple pregnancies was reported by five studies.
One study defined this as multiple clinical pregnancies (Huirne
2006a). Another study described the number of ongoing or live
born twin pregnancies (Hwang 2004). Three studies did not de-
scribe when the number of multiple pregnancies was measured
(Cédrin-Durnerin 2007; Franco Jr 2003; Kim 2005).
The number of OHS syndrome was reported by three studies.
One study used the WHO classification criteria to diagnose OHS
syndrome and divided the women in categories of mild (grade
I), moderate (grade II) or severe (grade III) (Rombauts 2006),
the other two studies did not mention how they diagnosed OHS
syndrome (Franco Jr 2003; Hwang 2004).
Excluded studies
We referred to a total of 67 studies that describe pre-treatments
with combined OCPs, progestogens or estrogens, but which were
not eligible for inclusion for various reasons. Some of the follow-
ing studies had multiple reasons for exclusion, but we only men-
tioned the reason we thought was most important. Full details of
reasons for exclusion can be found in the table of Characteristics
of excluded studies.
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Nineteen studies were excluded because they did not describe ran-
domised controlled trials, for themain reason that they did not ran-
domise their participants (Benadiva 1988;Cédrin-Durnerin 1995;
Cohen 1987; Copperman 2003; Couzinet 1995; Ditkoff 1997;
Forman 1991; Frydman 1986; Galera 2004; Godin 2003; Gonen
1990; Lindheim 1996; Neal 1993; Palomba 2008; Schoolcraft
1997; Surrey 1989; Tarlatzis 1993; Weisman 1989; Yokota 2006).
Twenty-three studies were also no randomised controlled trials,
for the main reason that their design was retrospective (al-Mizyen
2000; Bellver 2007; Bendikson 2006; Biljan 1998b; Chung
2006; Damario 1997; Dickey 2001; Duvan 2008; Frederick
2004; Gonzalez 1995; Keltz 2007; Kovacs 2001; Leondires 1999;
Loutradis 2003; Min 2005; Mirkin 2003; Pados 1995; Pinkas
2008; Ramsewak 2005; Talebian 2004; Talebian 2007; Yoshida
2005; Zhao 2008). Another five studies were no randomised con-
trolled trials, for the main reason that the women served as their
own controls in previous cycles (Branigan 1998; Fanchin 2003b;
Fisch 1996; Mulangi 1997; Surrey 1998). At last there were seven
studies that were no randomised controlled trials because they had
a single arm study design (Brodt 1993; De Ziegler 1999; Gerli
1989; Hugues 1992; Meldrum 2002; Meldrum 2008; Sanghvi
2002).
Six studies were excluded because they compared two (or more)
different dosages, timings or ways of administration of the same
pre-treatment (Davy 2004; Gomez 2000; Karande 2004; Lewin
2002; Mashiach 1989; Russell 1997).
Three studies were excluded because the women only received
ovarian stimulation, but no embryo transfer was performed as
part of an ART cycle (Anderson 1990; Letterie 2000; Steinkampf
1991).
Two studies were excluded because the women were oocyte donors
(Doody 2001;Martinez 2006) andone studywas excludedbecause
the women had premature ovarian failure (Tartagni 2007).
At last, there was one study that we excluded because the oestrogen
pre-treatment was not stopped before oocyte retrieval, but contin-
ued to be used as luteal phase support (Jung 2000).
Ongoing studies
One study might be eligible for inclusion in this review, but is
still ongoing. We contacted the researchers, which replied that the
trial is expected to be finished in June 2009 and that they are not
able to share data with us until that date. More information on
this trial can be found in the table of Characteristics of ongoing
studies.
Risk of bias in included studies
A complete overview of classification of risk of bias domains can
be found in the tables of Characteristics of included studies and
in Figure 1 and Figure 2.
Allocation
All 23 included trials were claimed to be randomised, but in twelve
trials the method of randomisation was not reported. Seven tri-
als used computer generated random numbers to randomise the
women (Biljan 1998a; Engmann 1999; Fanchin 2003a; Huirne
2006a; Huirne 2006b; Hwang 2004; Kolibianakis 2006). Three
studies used a table of random numbers (Cédrin-Durnerin 2007;
Franco Jr 2003; Shaker 1995) and one study accomplished the
randomisation by tossing a coin (Ditkoff 1996).
If randomisation is not done properly, there might be a difference
in baseline characteristics between the women in the treatment
groups. This may influence the outcomes measured in the trial.
Therefore it is important that the method of randomisation is
reported. Due to the high number of included studies that did not
report the method of randomisation (twelve out of 23 studies),
there might be a higher risk of bias.
Ten studies were classified as ’yes’ with regard to allocation con-
cealment. Four studies used sealed envelopes to conceal the alloca-
tion (Biljan 1998a; Cédrin-Durnerin 2007; Hwang 2004; Shaker
1995). In five studies the randomisation was done by a third party
(Aston 1995, hospital pharmacy and numbered bottles; Engmann
1999, clinic nurses and sealed envelopes; Fanchin 2003a, inde-
pendent person; Huirne 2006b, independent person from inde-
pendent monitoring company; Rombauts 2006, central remote
allocation). Another study centralised the randomisation process
(Ditkoff 1996).
Two studies were classified as ’no’ with regard to allocation con-
cealment, because they reported that the sequence of allocation
was not concealed (Franco Jr 2003; Kolibianakis 2006).One study
reported that allocation was concealed, but not how this was done
(Huirne 2006a), therefore we classified this as ’unclear’.The other
ten studies did not report any information about allocation con-
cealment, and were also classified as ’unclear’.
Because nearly all outcomes of this review are not subjective, a
poorly designed allocation concealment method of studies is not
likely to have a big influence on these outcomes. For example,
the number of live births is not likely to be influenced by the
clinician if he or she knows which treatment the woman receives.
However, OHS syndrome is diagnosed on clinical symptoms and
so there might be a bigger risk of bias when the clinician is aware
of the treatment assigned to each woman. Nevertheless, even not
subjective outcomes may be influenced indirectly if allocation is
not concealed.
Blinding
Three trials used blinding. One study used a placebo in the control
group and reported that the study was double blind (Aston 1995).
Another study used no placebo, so women could guess their treat-
ment status, but the clinicians were blinded (Engmann 1999). The
last study reported that the laboratory staff was blinded (Hwang
2004).
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Nine trials reported that the study was open labelled or not blind (
Cédrin-Durnerin 2007;Daly 2002;Ditkoff 1996; Fanchin 2003a;
Franco Jr 2003; Huirne 2006b; Kim 2005; Kolibianakis 2006;
Rombauts 2006). The other eleven studies did not report whether
the women, outcome assessors or investigators were blinded.
As with allocation concealment, poor blinding is less likely to
influence the objective outcomes such as live birth, but it might
have a bigger influence on the diagnosis of OHS syndrome.
Incomplete outcome data
Of the 23 studies, eleven addressed incomplete outcome data (
Aston 1995; Cédrin-Durnerin 1996; Ditkoff 1996; Engmann
1999; Franco Jr 2003; Huirne 2006a; Huirne 2006b; Hwang
2004; Kolibianakis 2006; Salat-Baroux 1988; Shaker 1995). In
these trials the numbers and reasons for withdrawals are reported.
We noticed a few imbalances in reasons for withdrawal between
the study group and control group in the following studies. One
study reported six withdrawals due to endometrioma, of which
five were in the control group and only one in the study group
(Aston 1995). Another study reported five withdrawals due to
inadequate response, of which four were in the control group and
only one in the study group (Salat-Baroux 1988). The third study
reported three withdrawals due to risk of severe OHS syndrome
in the control group and none in the study group (Hwang 2004).
The last study also reported more withdrawals due to risk of OHS
syndrome in the control group (n=2) than in the study group (n=
0) (Shaker 1995).
Five studies were classified as ’no’, because the journal article did
not report the numbers and reasons for withdrawals (in each
treatment group) (Biljan 1998a; Cédrin-Durnerin 2007; Fanchin
2003a; Raoofi 2008; Rombauts 2006). We classified the other six
studies as ’unclear’, because there was only an abstract available
that did not report any information on the numbers and reasons
for withdrawal.
Incomplete outcome data can bias the results of our review, es-
pecially with regard to adverse outcomes. For example, a study
might have withdrawals due to OHS syndrome that they do not
report. Also imbalances in reasons for withdrawal can occur be-
cause of differences in interventions between the study group and
control group. For example, when there are more withdrawals due
to OHS syndrome in the control group, this can be in favour of
the intervention used in the study group. The risk of bias might
increase if authors do not report on this.
Selective reporting
Althoughwe didnot retrieve any of the protocols or rawdata of any
trial, we classified six studies as free of selective reporting, because
these trials reported data on all the outcomes mentioned in the
’Methods’ section of their article (Engmann 1999; Huirne 2006b;
Hwang 2004; Kolibianakis 2006; Rombauts 2006; Shaker 1995).
The other seventeen studies did not report in their ’Methods’
section which outcomes they were going to measure.
Because we do not know if the authors of the included studies
reported all the data they retrieved in their trial, we are not able to
provide a judgement about this domain.
Other potential sources of bias
Four studies were classified as ’yes’, because there were no dif-
ferences in baseline characteristics between the treatment groups
and the number of women randomised per group was reported
(Engmann 1999; Huirne 2006a; Huirne 2006b; Kolibianakis
2006).
We classified thirteen studies as ’no’ with regard to other potential
sources of bias. Eight studies reported no data on baseline char-
acteristics or mentioned only one or two in the text of their arti-
cles (Cédrin-Durnerin 1996; Cédrin-Durnerin 2007; Daly 2002;
Ditkoff 1996; Franco Jr 2003; Hugues 1994; Kim 2005; Obruca
2001). Two studies only reported the number of cycles in the
study group and control group and did not report the number
of women in each group (Biljan 1998a; Shaker 1995). Two tri-
als did not report the number of women or cycles randomised to
each group (Fanchin 2001; Raoofi 2008), and one did report the
number of women analysed in each group, but not the number of
women randomised to each group (Fanchin 2003a). The other six
studies were classified as ’unclear’, because there were not enough
data on baseline characteristics available. Of these six studies, one
also used a slightly different treatment protocol in both groups
(Salat-Baroux 1988).
Although we classified four studies as ’yes’, it is difficult to know
if a study is truly free of other bias, because there are so many
different potential sources of bias. It is impossible to provide a
judgement about this domain based on the limited data available
for us.
Effects of interventions
Combined OCP versus no pre-treatment
Live births Analysis 1.1
COCP +Antagonist versus Antagonist (five studies included) -Only
one study in this subgroup reported the number of live births and
found three live births in the study group (n = 21) and seven in
the control group (n = 24), Peto OR 95% CI 0.43 (0.11 to 1.74);
P= 0.24 (Cédrin-Durnerin 2007).
COCP + Antagonist versus Agonist (three studies included) - There
was only one study that reported the number of live births in this
subgroup. This study found a number of seventeen live births in
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both the study (n = 91) and control group (n = 91), Peto OR 95%
CI 1.00 (0.48 to 2.10); P= 1.0 (Huirne 2006a).
COCP + Antagonist versus Antagonist, low response (one study in-
cluded) - This study found that there were eight live births in the
study group (n = 27) and five in the control group (n = 27), Peto
OR 95% CI 1.82 (0.53 to 6.25); P= 0.34 (Kim 2005).
COCP + Antagonist versus Agonist, low response (one study in-
cluded) - This study found that there were eight live births in the
study group (n = 27) and six in the control group (n = 28), Peto
OR 95% CI 1.53 (0.46 to 5.09); P= 0.49 (Kim 2005).
Ongoing pregnancies Analysis 1.2
COCP + Antagonist versus Antagonist (five studies included) - The
results of four studies, with a total of 847women, have been pooled
in this subgroup. No statistically significant difference was found
,Peto OR 0.74; 95% CI 0.53 to 1.03, P = 0.07.
COCP + Antagonist versus Agonist (three studies included) - The
results of two studies, with a total of 416 women, have been pooled
in this subgroup. No statistically significant difference was found,
Peto OR 0.76; 95% CI 0.47 to 1.23, P = 0.27.
COCP + Antagonist versus Antagonist, low response (one study in-
cluded) -This study found an ongoing pregnancy rate of eight in
the study group (n = 27) and five in the control group (n = 27),
Peto OR 95% CI 0.1.82 (0.53 to 6.25); P= 0.34 (Kim 2005).
COCP + Antagonist versus Agonist, low response (one study in-
cluded) - This study found an ongoing pregnancy rate of eight in
the study group (n = 27) and six in the control group (n = 28),
Peto OR 95% CI 1.53 (0.46 to 5.09); P= 0.49 (Kim 2005).
See Figure 3 for the graph and details of this outcome.
Figure 3. Forest plot of comparison: 1 Combined OCP versus no Rx, outcome: 1.2 Ongoing pregnancies.
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Clinical/ongoing pregnancies Analysis 1.3
COCP+Agonist versus Agonist (two studies included) - Both studies
reported the number of clinical pregnancies, but due to a lack
of data we can not pool these results. The first study reported a
clinical pregnancy rate per cycle started of 37.2% in the study
group and 33.3% in the control group, which comes down to
19 clinical pregnancies out of 51 cycles in the combined OCP
group and 17 clinical pregnancies out of 51 cycles in the control
group (Biljan 1998a). The other study reported a pregnancy rate
of 9% in the study group and 11% in the control group, but did
not report the number of women per group (Raoofi 2008). Both
studies found that their results were not statically significant. Peto
OR 1.19; 95% CI 0.53 to 2.66, P = 0.27
COCP + Antagonist versus Antagonist (five studies included) - Four
RCTs have been pooled in this subgroup, with a total of 847
women. Of two of these studies we used the number of ongoing
pregnancies, since no data on clinical pregnancy rate were avail-
able. There was a statistically significant difference in the rates
of clinical/ongoing pregnancies with fewer clinical/ongoing preg-
nancies occurring in the group pre-treated with a combined OCP
(Peto OR 0.69; 95% CI 0.50 to 0.96, P = 0.03). Of one study the
clinical pregnancy rate per embryo transfer is known, but not the
number of embryo transfers performed (Obruca 2001). The clin-
ical pregnancy rate was 29.7% in the study group and 41.2% in
the control group, this result did not reach significance according
to the authors.
COCP + Antagonist versus Agonist (three studies included) - Three
studies have been pooled in this subgroup, with a total of 472
women. Of one of these studies we used the number of ongoing
pregnancies, since nodata on clinical pregnancy ratewere available.
No statistically significant result was found (Peto OR 0.82; 95%
CI 0.53 to 1.26, P = 0.36).
COCP + Antagonist versus Antagonist, low response (one study in-
cluded) - This study found a clinical pregnancy rate of nine in the
study group (n = 27) and six in the control group (n = 27), Peto
OR 1.72; 95% CI 0.53 to 5.60, P = 0.37 (Kim 2005).
COCP + Antagonist versus Agonist, low response (one study in-
cluded) - This study found a clinical pregnancy rate of eight in the
study group (n = 27) and seven in the control group (n = 28),Peto
OR 1.49; 95% CI 0.47 to 4.71, P = 0.50 (Kim 2005).
COCP + Agonist versus Antagonist, low response (one study in-
cluded) - This trial found that the number of clinical pregnancies
was 22 in the study group (n = 63) and 18 in the control group
(n = 58), Peto OR 1.19; 95% CI 0.56 to 2.53,with a P value of
0.65 (Wang 2008).
See Figure 4 for the graph and details of this outcome.
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Figure 4. Forest plot of comparison: 1 Combined OCP versus no Rx, outcome: 1.3 Clinical/ongoing
pregnancies.
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Oocytes retrieved Analysis 1.4
COCP+Agonist versus Agonist (two studies included) -Both studies
looked at the number of oocytes retrieved, but we were not able
to pool or analyse these data. The first study reported a median of
eleven oocytes retrieved (range seven to 19) in the study group (n
= 51 cycles) and a median of ten oocytes retrieved (range 7 to 15)
in the control group (n = 51 cycles) (Biljan 1998a). Because of the
statistical method used in this study, we can not analyse these data.
The other study reported a mean number of oocytes retrieved of
5.0 (± 2.8) in the study group and 5.4 (± 5.7) in the control group
(Raoofi 2008). This study did not report the number of women
or cycles in each treatment group, and therefore we can not use
these data in our analysis.
COCP + Antagonist versus Antagonist (five studies included) - Re-
sults of all five included trials have been pooled, with a total of 891
women. No statistically significant difference was found for this
outcome (MD 0.23; 95% CI -0.55 to 1.01, P = 0.56). However,
we found a substantial amount of heterogeneity; the I2 statistic is
64%. No obvious reasons were identified for the heterogeneity in
this comparison. An overview of characteristics of the studies for
this subgroup are reported in Table 1.
COCP + Antagonist versus Agonist (three studies included) - The
results of three RCTs have been pooled in this subgroup, with a
total of 440 women. No statistically significant result was found
(MD -0.01; 95% CI -1.54 to 1.53, P = 0.99).
COCP + Antagonist versus Antagonist, low response (one study in-
cluded) - This study found a mean number of 4.8 (± 2.0) oocytes
retrieved in the study group (n=27) and a mean number of 4.4
(± 1.8) oocytes retrieved in the control group (n = 27), Peto OR
0.27; 95% CI -0.61 to 1.41, P = 0.44 (Kim 2005).
COCP + Antagonist versus Agonist, low response (one study in-
cluded) - This study found a mean number of 4.8 (± 2.0) oocytes
retrieved in the study group (n = 27) and a mean number of 4.7
(± 2.1) oocytes retrieved in the control group (n = 28),Peto OR
0.10; 95% CI -0.98 to 1.18, P = 0.86 (Kim 2005).
COCP + Agonist versus Antagonist, low response (one study in-
cluded) - This study found a mean number of 4.40 (± 2.1) oocytes
retrieved in the study group (n = 59) and 5.41 (± 2.65) in the
control group (n = 51), Peto OR -1.01; 95% CI -1.91 to 0.11, P
=0.03 (Wang 2008).
See Figure 5 for the graph and details of this outcome.
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Figure 5. Forest plot of comparison: 1 Combined OCP versus no Rx, outcome: 1.4 Oocytes retrieved.
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Days of gonadotrophin treatment Analysis 1.5
COCP + Agonist versus Agonist (two studies included) - Only one
study reported on the number of days of gonadotrophin treatment
(Biljan 1998a). This study found a median of ten days (range 9 to
11) in the study group (n = 51 cycles) and a median of twelve days
(range 11 to 12) in the control group (n = 51 cycles). Because of
the statistical method used in this study, we can not analyse these
data.
COCP+Antagonist versus Antagonist (five studies included) -Three
RCTs have been pooled in this subgroup for this outcome, with a
total of 689 women. There was a significant difference, with fewer
days of gonadotrophin treatment in the group that did not receive
pre-treatment with a combined OCP (MD 1.44; 95% CI 1.15 to
1.72, P < 0.00001). Heterogeneity in this meta-analysis was high,
with an I2 statistic of 95%. A possible explanation for the high
heterogeneity might be that Kolibianakis 2006 uses a shorter du-
ration of pre-treatment than the other studies. We did a sensitiv-
ity analysis to explore this heterogeneity and found that removing
Kolibianakis 2006 from this meta-analysis reduced heterogeneity
to 22%. This did not change the results substantially. An overview
of characteristics of the studies for this subgroup are reported in
Table 1.
COCP + Antagonist versus Agonist (three studies included) - Also,
three RCTs have been pooled in this subgroup, with a total of 434
women. There was a significant difference in this outcome, with
fewer days of gonadotrophin treatment in the group that did not
receive pre-treatment with a combined OCP (MD 0.51; 95% CI
0.17 to 0.84, P = 0.003). The heterogeneity was high, with an I2
statistic of 92%. The only substantial difference that we noticed
was that Rombauts 2006 used a different type of GnRH antago-
nist and agonist and had a higher starting dose of gonadotrophins
than the other studies. We did a sensitivity analysis on the out-
come number of days of gonadotrophin therapy and found that
removing Rombauts 2006 from this meta-analysis reduced het-
erogeneity to 9%. An overview of characteristics of the studies for
this subgroup are reported in Table 2.
COCP + Antagonist versus Antagonist, low response (one study in-
cluded) - This study found a mean number of 10.0 (± 1.4) days of
gonadotrophin treatment in the study group (n = 27) and a mean
number of 9.7 (± 1.4) days in the control group (n = 27), MD
0.30; 95% CI -0.45 to 1.05, P = 0.43 (Kim 2005).
COCP + Antagonist versus Agonist, low response - This study found
a mean number of 10.0 (± 1.4) days of gonadotrophin treatment
in the study group (n = 27) and a mean number of 11.6 (± 1.7)
days in the control group (n = 28), MD -1.60; 95% CI -2.42 to
0.78, P = 0.0001 (Kim 2005) .
COCP + Agonist versus Antagonist, low response (one study in-
cluded) - This study found that themean length of gonadotrophin
therapy was 9.60 (± 1.90) days in the study group (n = 59) and
9.65 (± 1.60) in the control group (n = 51), MD -0.50; 95% CI
-0.70 to 0.60, P = 0.88 (Wang 2008).
See Figure 6 for the graph and details of this outcome.
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Figure 6. Forest plot of comparison: 1 Combined OCP versus no Rx, outcome: 1.5 Days of gonadotrophin
treatment.
Amount of gonadotrophins administered Analysis 1.6
COCP + Antagonist versus Antagonist (five studies included) - The
results of four studies have been pooled in this subgroup and for
this outcome, with a total of 734 women. There was a statistically
significant difference, with fewer gonadotrophins administered in
the group that did not receive pre-treatment with a combined
OCP (MD 231.14; 95% CI 161.50 to 300.78, P < 0.00001).
Heterogeneity in this meta-analysis was high with an I2 statistic of
93%.We did a sensitivity analysis to explore this heterogeneity and
found that a possible explanation could be that Kolibianakis 2006
uses a shorter duration of pre-treatment than the other studies. By
removing Kolibianakis 2006 from themeta-analysis heterogeneity
was reduced to 43%. This did not change the results substantially.
An overview of characteristics of the studies for this subgroup are
reported in Table 1.
COCP + Antagonist versus Agonist (three studies included) - Two
RCTs have been pooled for this outcome, with a total of 385
women.Therewas a significant difference favouring the group that
did not receive pre-treatmentwith a combinedOCP (MD209.52;
95% CI 61.16 to 357.87, P = 0.006). The heterogeneity in this
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subgroup was also high, with an I2 statistic of 90%. We were not
able to perform a sensitivity analysis, because there were only two
studies that reported the amount of gonadotrophins administered
in this subgroup. Anoverviewof characteristics of these two studies
are reported in Table 2.
COCP + Antagonist versus Antagonist, low response (one study in-
cluded) - This study reported a mean amount of 2963.9 (± 433.1)
IU gonadotrophins administered in the study group (n = 27) and
a mean of 2931.5 (± 464.1) IU in the control group (n = 27), MD
32.40; 95% CI -207.04 to 271.84, P = 0.79 (Kim 2005).
COCP + Antagonist versus Agonist, low response (one study in-
cluded) - This study reported a mean amount of 2963.9 (± 433.1)
IU gonadotrophins administered in the study group (n = 27) and
a mean of 3390.2 (± 443.2) IU in the control group (n = 28), MD
-426.30; 95% CI -657.90 to -194.70, P = 0.0003, which makes
this difference statistically significant (Kim 2005).
See Figure 7 for the graph and details of this outcome.
Figure 7. Forest plot of comparison: 1 Combined OCP versus no Rx, outcome: 1.6 Amount of
gonadotrophins administered.
Pregnancy losses Analysis 1.7
COCP + Antagonist versus Antagonist (five studies included) - The
results of four trials have been pooled in this subgroup, with a total
of 847 women. The number of pregnancy losses did not differ
statistically significantly between groups (Peto OR 1.26; 95% CI
0.76 to 2.12, P = 0.37).
COCP + Antagonist versus Agonist (three studies included) - The
results of three trials have been pooled, with a total of 472 women.
There was no statistically significant result (Peto OR 0.52; 95%
CI 0.24 to 1.10, P = 0.09).
COCP + Antagonist versus Antagonist, low response (one study in-
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cluded) - This study found that there was one pregnancy loss in
both the study (n = 27) and the control group (n = 27)OR 1.0;
95% CI 0.06 to 16.42 (Kim 2005).
COCP + Antagonist versus Agonist, low response (one study in-
cluded) -This study found that there was one pregnancy loss in
both the study (n = 27) and the control group (n = 28), OR 1.04;
95% CI 0.06 to 17.04, P =0.98 (Kim 2005).
See Figure 8 for the graph and details of this outcome.
Figure 8. Forest plot of comparison: 1 Combined OCP versus no Rx, outcome: 1.7 Pregnancy losses.
Ovarian cyst formation Analysis 1.8
COCP + Agonist versus Agonist (two studies included) - Two stud-
ies reported on cyst formation, but results could not be pooled
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or analysed because the number of women in each study or con-
trol group is unknown. The first study found that the number of
women in which cyst formation occurred was none in the study
group (n = 51 cycles) and 27 in the control group (n = 51 cycles)
(Biljan 1998a). This result was statistically significant according to
the authors OR 0.O7; 95% CI 0.03 to 0.16, (P < 0.0001). Raoofi
2008 reported no women with cyst formation in both the study
group and the control group.
COCP + Antagonist versus Antagonist (five studies included) - In
this subgroup, the number of women with ovarian cysts was re-
ported by one study, that found two women with ovarian cysts in
the study group (n = 32) and four women in the control group (n
= 32), OR 0.48; 95% CI 0.09 to 2.57, P = 0.39 (Huirne 2006b).
Multiple pregnancies Analysis 1.9
COCP +Antagonist versus Antagonist (five studies included) - Only
one study in this subgroup reported this outcome and found two
multiple pregnancies in the study group (n = 21) and one in the
control group (n = 24), withOR 2.32; 95% CI 0.23 to 23.65 P
value of 0.48 (Cédrin-Durnerin 2007).
COCP + Antagonist versus Agonist (three studies included) - Two
of the trials included in this subgroup reported on this outcome,
with a total of 238 women. The pooling of these results showed no
statistically significant difference between treatment groups (Peto
OR 1.02; 95% CI 0.37 to 2.82, P = 0.96).
COCP + Antagonist versus Antagonist, low response (one study in-
cluded) - The only study in this subgroup (Kim 2005) found two
multiple pregnancies in the study group (n = 27) and one in the
control group (n = 27), OR 2.00; 95%CI 0.20 to 20.08 ,P= 0.56.
CP + Antagonist versus Agonist, low response (one study included) -
The only study in this subgroup (Kim 2005) found two multiple
pregnancies in the study group (n = 27) and one in the control
group (n = 28), OR 2.08; 95% CI 0.21 to 20.84,P= 0.53.
See Figure 9 for the graph and details of this outcome.
Figure 9. Forest plot of comparison: 1 Combined OCP versus no Rx, outcome: 1.9 Multiple pregnancies.
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OHS syndrome Analysis 1.10
COCP +Antagonist versus Antagonist (five studies included) - Only
one study in this subgroup reported on this outcome and found
three women with OHS syndrome in the study group (n = 117)
and two women with OHS syndrome in the control group (n =
117), OR 1.50; 95% CI 0.26 to 8.80, P = 0.65 (Rombauts 2006).
COCP + Antagonist versus Agonist (three studies included) - Two
studies, with a total of 290 women, reported on this outcome.
The pooling showed no statistically significant difference between
treatment groups (Peto OR 0.63; 95% CI 0.21 to 1.92, P = 0.42).
See Figure 10 for the graph and details of this outcome.
Figure 10. Forest plot of comparison: 1 Combined OCP versus no Rx, outcome: 1.10 OHS syndrome.
Progestogen versus placebo or no pre-treatment
Live births Analysis 2.1
Progestogen + Agonist versus Agonist (six studies included) - Two
of the studies in this subgroup reported on the live birth rate,
with a total of 222 women. There was no statistically significant
difference found between the study group and the control group
(Peto OR 1.35; 95% CI 0.69 to 2.62, P = 0.38).
Progestogen + Antagonist versus Antagonist (one study included) -
Only one study could be included in this subgroup and this study
found a number of five live births in the study group (n = 23) and
seven live births in the control group (n = 24), Peto OR 0.68; 95%
CI 0.19 to 2.50, P = 0.56 (Cédrin-Durnerin 2007).
See Figure 11 for the graph and details of this outcome.
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Figure 11. Forest plot of comparison: 2 Progestogen versus placebo/ no Rx, outcome: 2.1 Live births.
Ongoing pregnancies Analysis 2.2
Progestogen + Agonist versus Agonist (six studies included) - Only
one study in this subgroup reported ongoing pregnancy rate (
Ditkoff 1996). The number of ongoing pregnancies was found to
be eleven in the study group (n = 47) and twelve in the control
group (n = 58), Peto OR 1.17; 95% CI 0.46 to 2.95, P = 0.74.
Progestogen + Antagonist versus Antagonist (one study included) -
The only study in this subgroup reported five ongoing pregnancies
in the study group (n = 23) and seven in the control group (n = 24),
Peto OR 0.68; 95% CI 0.19 to 2.50, P = 0.56 (Cédrin-Durnerin
2007).
Progestogen + Gonadotrophins versus Gonadotrophins (one study in-
cluded) - This study found two ongoing pregnancies in the study
group (n = 21) and three in the control group (n = 21), Peto OR
0.64; 95% CI 0.10 to 4.06, P = 0.64 (Salat-Baroux 1988).
Clinical/ongoing pregnancies Analysis 2.3
Progestogen + Agonist versus Agonist (six studies included) - Results
of three of the studies in this subgroup could be pooled with a
total of 374 women. Of one of these studies we used the number
of positive pregnancy tests, because no data on clinical pregnancy
rate were available. A statistically significant result was found, with
more clinical pregnancies obtained in the group pre-treated with
a progestogen (Peto OR 1.95; 95% CI 1.20 to 3.17, P = 0.007).
Another study in this subgroup reported on this outcome (Shaker
1995), but because only the number of cycles per groupwas known
and not the number of women, data have not been pooled. In
this study the number of clinical pregnancies was seven in the
study group (n = 22 cycles) and four in the control group (n = 29
cycles). This result was not statistically significant according to the
authors.
Progestogen + Antagonist versus Antagonist (one study included) -
The only study in this subgroup (Cédrin-Durnerin 2007) found
a number of seven clinical pregnancies in the study group (n = 23)
and twelve in the control group (n = 24), Peto OR 0.53; 95% CI
0.17to 1.69, P = 0.28.
Progestogen + Gonadotrophins versus Gonadotrophins (one study in-
cluded) - The only study in this subgroup (Salat-Baroux 1988)
found a number of three clinical pregnancies in the study group
(n = 21) and four in the control group (n = 21), Peto OR 0.72;
95% CI 0.14 to 3.56, P = 0.68.
See Figure 12 for the graph and details of this outcome.
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Figure 12. Forest plot of comparison: 2 Progestogen versus placebo/ no Rx, outcome: 2.3 Clinical
pregnancies.
Oocytes retrieved Analysis 2.4
Progestogen + Agonist versus Agonist (six studies included) - Results
of two of the studies in this subgroup have been pooled, with a
total of 210 women. No statistically significant result was found
(MD -0.56; 95% CI -2.13 to 1.01, P = 0.48) There was one
other study in this subgroup that reported the mean number of
oocytes retrieved, but because this was analysed per cycle (in stead
of per woman randomised), we have not pooled the data of this
study (Shaker 1995). The mean number of oocytes retrieved was
9.82 (± 1.09) in the study group (n = 22) and 9.1 (± 1.09) in
the control group (n = 29) and this result was not statistically
significant according to the authors, but no P values were given.
Progestogen + Antagonist versus Antagonist (one study included)
- Only one study could be included in this subgroup (Cédrin-
Durnerin 2007). This study found that the mean number of
oocytes retrieved was 12.6 (± 7.3) in the study group (n = 23) and
9.9 (± 5.4) in the control group (n = 24), Peto OR 2.70; 95% CI
-0.98 to 6.38, P = 0.15.
Progestogen + Gonadotrophins versus Gonadotrophins (one study in-
cluded) - The only study in this subgroup (Salat-Baroux 1988)
found that the mean number of oocytes retrieved was 4.9 (± 0.9)
in the study group (n = 13) and 4.9 (± 0.6) in the control group
(n = 16), Peto OR 0.00; 95% CI -0.57 to 0.57, P = 1.00.
See Figure 13 for the graph and details of this outcome.
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Figure 13. Forest plot of comparison: 2 Progestogen versus placebo/ no Rx, outcome: 2.4 Oocytes retrieved.
Days of gonadotrophin treatment Analysis 2.5
Progestogen + Agonist versus Agonist (six studies included) - Results
of two RCTs in this subgroup have been pooled, with a total of
210 women. No statistically significant difference was found (MD
0.08; 95% CI -0.35 to 0.50, P = 0.73) . Another study in this sub-
group only reported the mean number of days of gonadotrophin
therapy per cycle (in stead of per woman randomised) and found
that this was 11.8 (± 0.51) in the study group (n = 22) and 11.48
(± 0.37) in the control group (n = 29) (Shaker 1995). This result
did not reach statistical significance according to the authors.
See Figure 14 for the graph and details of this outcome.
Figure 14. Forest plot of comparison: 2 Progestogen versus placebo/ no Rx, outcome: 2.5 Days of
gonadotrophin treatment.
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Amount of gonadotrophins administered Analysis 2.6
Progestogen + Antagonist versus Antagonist (one study included) -
Only one trial reported on this outcome (Cédrin-Durnerin 2007)
and found that themean amount of gonadotrophins administered
was 2,010 (± 670) IU in the study group (n = 23) and 1,734 (±
551) IU in the control group (n = 24), Peto OR 2.76.00; 95% CI
0.-75.53 to 672.53, P = 0.12.
Pregnancy losses Analysis 2.7
Progestogen + Agonist versus Agonist (six studies included) - Results
of two trials of this subgroup have been pooled, with a total of
222 women. There was no statistically significant difference found
between the study group and the control group (Peto OR 2.17;
95% CI 0.71 to 6.69, P = 0.18).
Progestogen + Antagonist versus Antagonist (one study included) -
The only study in this subgroup (Cédrin-Durnerin 2007) did not
report on the number of pregnancy losses, but we calculated this
number by subtracting the number of live births from the number
of clinical pregnancies. Through this we found two pregnancy
losses in the study group (n = 23) and five in the control group (n
= 24), Peto OR 0.39; 95% CI 0.08 to 1.92, P = 0.25.
Progestogen + Gonadotrophins versus Gonadotrophins (one study in-
cluded) - The only trial included in this subgroup found one preg-
nancy loss in each treatment group (n = 21 in each group), but we
are not sure if the follow up was long enough to detect all preg-
nancy losses (Salat-Baroux 1988) .
See Figure 15 for the graph and details of this outcome.
Figure 15. Forest plot of comparison: 2 Progestogen versus placebo/ no Rx, outcome: 2.7 Pregnancy losses.
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Ovarian cyst formation Analysis 2.8
Progestogen + Agonist versus Agonist (six studies included) - Three
of the studies in this subgroup, with a total of 374 women, re-
ported on this outcome and data have been pooled.We found that
there was a statistically significant difference, with less ovarian cyst
formation in the group pre-treated with a progestogen (Peto OR
0.21; 95% CI 0.12 to 0.35, P < 0.00001).
See Figure 16 for the graph and details of this outcome.
Figure 16. Forest plot of comparison: 2 Progestogen versus placebo/ no Rx, outcome: 2.8 Ovarian cyst
formation.
Multiple pregnancies Analysis 2.9
Progestogen + Antagonist versus Antagonist (one study included)
- The only trial included in this subgroup found one multiple
pregnancy in both the study group (n = 23) and control group (n
= 24), Peto OR 1.04; 95% CI 0.06 to 17.23, P = 0.98 (Cédrin-
Durnerin 2007).
OHS syndrome
None of the studies in which the study group was administered
a progestogen pre-treatment reported on the number of women
with OHS syndrome.
Estrogen versus no pre-treatment
Live births Analysis 3.1
Estrogen + Antagonist versus Antagonist (two studies included) -
Only one study in this subgroup reported on this outcome and
found three live births in the study group (n = 25) and seven in
the control group (n = 24), Peto OR 0.36; 95% CI 0.0.09 to 1.41,
P = 0.14 (Cédrin-Durnerin 2007).
Estrogen + Antagonist versus Agonist (one study included) - Only
one study was included in this subgroup, and this study found five
live births in the study group (n = 16) and two in the control group
(n = 6), Peto OR 0.91; 95% CI 0.13 to 6.53, P = 0.93 (Franco Jr
2003).
Ongoing pregnancies Analysis 3.2
Estrogen + Antagonist versus Antagonist (two studies included) -
Only one study in this subgroup reported on this outcome and
found three ongoing pregnancies in the study group (n = 25) and
seven in the control group (n = 24), Peto OR 0.36; 95% CI 0.09
to 1.41 P = 0.14 (Cédrin-Durnerin 2007).
Estrogen + Antagonist versus Agonist (one study included) - This
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study found five ongoing pregnancies in the study group (n = 16)
and two in the control group (n = 6), Peto OR 0.91; 95% CI 0.13
to 6.53, P = 0.93 (Franco Jr 2003).
Clinical/ongoing pregnancies Analysis 3.3
Estrogen + Antagonist versus Antagonist (two studies included) -
Both studies in this subgroup, with a total 139 women, reported
on the number of clinical pregnancies and data have been pooled.
No statistically significant difference was found (Peto OR 0.79;
95% CI 0.38 to 1.62, P = 0.52).
Estrogen + Antagonist versus Agonist (one study included) - The
only study in this subgroup found five clinical pregnancies in the
study group (n = 16) and two in the control group (n = 6), Peto
OR 1.35; 95% CI 0.13 to 6.53, P = 0.93 (Franco Jr 2003).
See Figure 17 for the graph and details of this outcome.
Figure 17. Forest plot of comparison: 3 Estrogen versus no Rx, outcome: 3.3 Clinical pregnancies.
Oocytes retrieved Analysis 3.4
Estrogen + Antagonist versus Antagonist (two studies included) -
Both studies in this subgroup, with a total of 136 women, reported
on the number of oocytes retrieved and data have been pooled.
A statistically significant difference was found, with more oocytes
retrieved in the group pre-treated with oestrogen (MD 2.01; 95%
CI 1.76 to 2.25, P < 0.00001).
Estrogen + Antagonist versus Agonist (one study included) - This
study found a mean number of oocytes retrieved of 10.5 (± 6.5) in
the study group (n = 14) and of 10.1 (± 4.6) in the control group
(n = 6), Peto OR -2.50; 95% CI -4.61 to 5.41, P = 0.88 (Franco
Jr 2003).
See Figure 18 for the graph and details of this outcome.
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Figure 18. Forest plot of comparison: 3 Estrogen versus no Rx, outcome: 3.4 Oocytes retrieved.
Days of gonadotrophin treatment Analysis 3.5
Estrogen + Antagonist versus Agonist (one study included) - Only
one study was included in this subgroup, and this study found
that the mean number of days of gonadotrophin therapy was 10.3
(± 1.6) in the study group (n = 14) and 12.8 (± 1.7) in the control
group (n = 6), with a P value of 0.002 (Franco Jr 2003).
Amount of gonadotrophins administered Analysis 3.6
Estrogen + Antagonist versus Antagonist (two studies included) -
Both studies in this subgroup, with a total of 136 women, reported
on this outcome and results have been pooled. A statistically sig-
nificant difference was found with fewer gonadotrophins admin-
istered in the group that did not receive pre-treatment with oe-
strogen (MD 207.08; 95% CI 167.77 to 246.39, P < 0.00001). A
moderate amount of heterogeneity was found, with an I2 statistic
of 57%. We could not perform a sensitivity analysis, because there
were only two studies that reported the outcome in this subgroup.
An overview of characteristics of the studies for this subgroup are
reported in Table 3.
Estrogen + Antagonist versus Agonist (one study included) - This
study found that the mean amount of gonadotrophins adminis-
tered was 2,500 IU (± 484) in the study group (n = 14) and 2,516
IU (± 484) in the control group (n = 6), Peto OR -16.0; 95% CI
-478.88 to 446.88, P = 0.95 (Franco Jr 2003).
See Figure 19 for the graph and details of this outcome.
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Figure 19. Forest plot of comparison: 3 Estrogen versus no Rx, outcome: 3.6 Amount of gonadotrophins
administered.
Pregnancy losses Analysis 3.7
Estrogen + Antagonist versus Antagonist (two studies included) -
Only one study reported on this outcome and found one preg-
nancy loss in the study group (n = 25) and five pregnancy losses in
the control group (n = 24), Peto OR 0.22; 95% CI 0.04 to 1.17,
P = 0.08 (Cédrin-Durnerin 2007).
Estrogen + Antagonist versus Agonist - The only study included in
this subgroup found no pregnancy losses in both treatment groups
(study group n = 16; control group n = 6).
Ovarian cyst formation Analysis 3.8
Estrogen +Antagonist versus Agonist (one study included) - The only
study included in this subgroup found no ovarian cyst formation
in both treatment groups (study group n = 16; control group n =
6).
Multiple pregnancies Analysis 3.9
Estrogen + Antagonist versus Antagonist (two studies included) -
Only one study reported on this outcome and found no multiple
pregnancies in the study group (n = 25) and one in the control
group (n = 24), Peto OR 0.13; 95% CI 0.00 to 6.55, P = 0.31
(Cédrin-Durnerin 2007).
Estrogen + Antagonist versus Agonist (one study included) - Only
one trial could be included in this subgroup (Franco Jr 2003). The
number of multiple pregnancies was two in the study group (n =
14) and none in the control group (n = 6), Peto OR 4.52; 95%
CI 0.20 to 101.00, P = 0.34.
OHS syndrome Analysis 3.10
Estrogen + Antagonist versus Agonist (two studies included) - The
only study included in this subgroup found no women with OHS
syndrome in both treatment groups (study group n = 16; control
group n = 6).
Combined OCP versus Progestogen
Only one trial could be included in this intervention (Cédrin-
Durnerin 2007). This trial used a GnRH antagonist in both treat-
ment groups. None of the results of this trial were found to be
statistically significant.
Live births Analysis 4.1
The number of live births was found to be three in the combined
OCP group (n = 21) and five in the progestogen group (n = 23),
Peto OR 0.61; 95% CI 0.13 to 2.79, P = 0.53.
Ongoing pregnancies Analysis 4.2
The number of ongoing pregnancies was also found to be three
in the combined OCP group (n = 21) and five in the progestogen
group (n = 23), Peto OR 0.61; 95% CI 0.13 to 2.79, P = 0.53..
Clinical/ongoing pregnancies Analysis 4.3
The number of clinical pregnancies was five in the combined OCP
group (n = 21) and seven in the progestogen group (n = 23), Peto
OR 0.72; 95% CI 0.19 to 2.68, P = 0.63.
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Oocytes retrieved Analysis 4.4
The mean number of oocytes retrieved was 14 (± 8.3) in the com-
bined OCP group (n = 21) and 12.6 (± 7.3) in the progestogen
group (n = 23), Peto OR 1.40; 95% CI -3.24 to 6.04, P = 0.55.
Days of gonadotrophin treatment Analysis 4.5
This outcome was not reported by this study.
Amount of gonadotrophins administered
The mean amount of gonadotrophins administered was 2,174 IU
(± 723) in the combined OCP group (n = 21) and 2,010 IU (±
670) in the progestogen group (n = 23), Peto OR 164.00; 95%
CI -249.03 to 577.03, P = 0.44.
Pregnancy losses Analysis 4.6
The number of pregnancy losses in both treatment groups was two
(study group n = 21; control group n = 23), Peto OR1.10; 95%
CI 0.14 to 8.43, P = 0.92.
Ovarian cyst formation
This outcome was not reported by this study.
Multiple pregnancies Analysis 4.7
There were twomultiple pregnancies in the combinedOCP group
(n = 21) and one in the progestogen group (n = 23), Peto OR
2.22; 95% CI 0.22 to 22.56, P = 0.50.
OHS syndrome
This outcome was not reported by this study.
Combined OCP versus Estrogen
Live births Analysis 5.1
COCP + Antagonist versus Estrogen + Antagonist (one study in-
cluded) - The number of live births was found to be three in
the combined OCP group (n = 21) and three in the oestrogen
group (n = 25), Peto OR 1.22; 95% CI 0.22 to 6.69, P = 0.82
(Cédrin-Durnerin 2007).
Ongoing pregnancies Analysis 5.2
COCP + Antagonist versus Estrogen + Antagonist (one study in-
cluded) - The number of ongoing pregnancies was also found to
be three in the combined OCP group (n = 21) and three in the
oestrogen group (n = 25), Peto OR 1.22; 95% CI 0.22 to 6.69, P
= 0.82 (Cédrin-Durnerin 2007).
COCP + Agonist versus Estrogen + Antagonist (one study included)
- The number of ongoing pregnancies was one in the combined
OCP group (n = 12) and seven in the oestrogen group (n = 13).
This is a statistically significant difference Peto OR 0.13; 95% CI
0.03 to 0.70, P =0.02 (Daly 2002).
Clinical/ongoing pregnancies Analysis 5.3
COCP + Antagonist versus Estrogen + Antagonist (one study in-
cluded) - The number of clinical pregnancies was five in the com-
bined OCP group (n = 21) and four in the oestrogen group
(n = 25), Peto OR 1.62; 95% CI 0.38 to 6.90, P = 0.51
(Cédrin-Durnerin 2007).
COCP + Agonist versus Estrogen + Antagonist (one study included)
- The number of clinical pregnancies was two in the combined
OCP group (n = 12) and eight in the oestrogen group (n = 13).
This is a statistically significant difference , Peto OR 0.17; 95%
CI 0.03 to 0.80, P =0.02 (Daly 2002).
Oocytes retrieved Analysis 5.4
COCP + Antagonist versus Estrogen + Antagonist (one study in-
cluded) - The mean number of oocytes retrieved was 14 ± 8.3 in
the combined OCP group (n = 21) and 13.1 ± 7 in the oestrogen
group (n = 22), Peto OR 0.90; 95% CI -3.70 to 5.50, P = 0.70
(Cédrin-Durnerin 2007).
Days of gonadotrophin treatment
This outcome was not reported by these studies.
Amount of gonadotrophins administered Analysis 5.5
COCP + Antagonist versus Estrogen + Antagonist (one study in-
cluded) - The mean amount of gonadotrophins administered was
2,174 IU (± 723) in the combined OCP group (n = 21) and 1,700
IU (± 524) in the oestrogen group (n = 22). This is a statistically
significant difference, with Peto OR 474.00; 95% CI 95.10 to
852.90, P = 0.01 (Cédrin-Durnerin 2007).
Pregnancy losses Analysis 5.6
COCP + Antagonist versus Estrogen + Antagonist (one study in-
cluded) - The number of pregnancy losses in the combined OCP
group was two (n = 21) and in the oestrogen group the number
was one (n = 25), Peto OR 2.43; 95% CI 0.24 to 24.79, P =0.45
(Cédrin-Durnerin 2007).
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COCP + Agonist versus Estrogen + Antagonist (one study included)
- In each group there was one pregnancy loss (study group n = 12;
control group n = 13), Peto OR 1.09; 95% CI 0.06 to 18.49, P =
0.95 (Daly 2002).
Ovarian cyst formation
This outcome was not reported by these studies.
Multiple pregnancies Analysis 5.7
COCP + Antagonist versus Estrogen + Antagonist (one study in-
cluded) - There were two multiple pregnancies in the combined
OCP group (n = 21) and none in the oestrogen group (n = 25),
PetoOR9.40; 95%CI0.56 to 156.66, P =0.12 (Cédrin-Durnerin
2007).
OHS syndrome
This outcome was not reported by these studies.
Progestogen versus Estrogen
Only one trial could be included in this subgroup (Cédrin-
Durnerin 2007). This trial used a GnRH antagonist in both treat-
ment groups. None of the results of this trial were found to be
statistically significant.
Live births Analysis 6.1
The number of live births was found to be five in the progestogen
group (n = 23) and three in the oestrogen group (n = 25), Peto
OR 1.99; 95% CI 0.44 to 8.94, P = 0.37.
Ongoing pregnancies Analysis 6.2
The number of ongoing pregnancies was also found to be five in
the progestogen group (n = 23) and three in the oestrogen group
(n = 25), with Peto OR 1.99; 95% CI 0.44 to 8.94, P = 0.37.
Clinical/ongoing pregnancies Analysis 6.3
The number of clinical pregnancies was seven in the progestogen
group (n = 23) and four in the oestrogen group (n = 25), with a P
value of 0.24.
Oocytes retrieved Analysis 6.4
The mean number of oocytes retrieved was 12.6 (± 7.3) in the
progestogen group (n = 23) and 13.1 (± 7) in the oestrogen group
(n = 22), with Peto OR 2.23; 95% CI 0.59 to 8.44, P = 0.81.
Days of gonadotrophin treatment
This outcome was not reported by this study.
Amount of gonadotrophins administered Analysis 6.5
The mean amount of gonadotrophins administered was 2,010 IU
(± 670) in the progestogen group (n = 23) and 1,700 IU (± 524)
in the oestrogen group (n = 22), Peto OR -0.50; 95% CI -4.68 to
3.68, P = 0.08.
Pregnancy losses Analysis 6.6
There were two pregnancy losses in the progestogen group (n =
23) and one in the oestrogen group (n = 25), Peto OR 310.00;
95% CI -40.60 to 660.60, P = 0.51.
Ovarian cyst formation
This outcome was not reported by this study.
Multiple pregnancies Analysis 6.7
There was one multiple pregnancy in the progestogen group (n
= 23) and none in the oestrogen group (n = 25), Peto OR 8.06;
95% CI 0.16 to 407.60, P = 0.30.
OHS syndrome
This outcome was not reported by this study.
D I S C U S S I O N
Summary of main results
This systematic review on the role of pre-treatment with the com-
bined OCP, a progestogen or an oestrogen prior to ART cycles,
has pooled the results of studies for three of the six interventions.
For the other interventions, we have not been able to pool any
results, since only one study could be included in the subgroups
of these interventions.
No statistically significant results were found for the primary out-
come of live births. We were able to pool results of two trials that
used progestogen as a pre-treatment and compared this with no
pre-treatment or placebo. This showed no evidence for a differ-
ence in the number of live births. For the other interventions, we
have not been able to pool results of two or more studies, so no
sound conclusion can be given.
For the outcome of ongoing pregnancies, we have been able to
pool results of two or more studies that compared a pre-treatment
with the combined OCP with no pre-treatment. None of these
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showed evidence for a treatment effect. We have not been able to
pool results for the other interventions.
With regard to the outcome clinical pregnancy rate, we found a
statistically significant result in two subgroups of two different in-
terventions. In comparison 1.3.2 (COCP plus antagonist versus
antagonist) this difference was in favour of the group not pre-
treated with the combined OCP, with fewer clinical pregnancies
being achieved in the study group. In comparison 1.3.3 (COCP
plus antagonist versus agonist), we pooled the results of three stud-
ies and found no statistically significant difference. However, in
comparison 2.3.1 (progestogen plus agonist versus agonist) there
was a statistically significant difference in favour of the group pre-
treated with the progestogen. In this comparison, the number of
clinical pregnancies was increased in the study group. For the other
interventions and subgroups, we have not been able to pool results
of two or more studies.
For the outcome of the number of oocytes retrieved we have been
able to pool results of four subgroups in three different interven-
tions and only one of these showed a statistically significant dif-
ference. This difference was found in comparison 3.4.1 (oestro-
gen plus antagonist versus antagonist), with more oocytes being
retrieved after pre-treatment with an oestrogen.
Two other outcomes that showed statistically significant differ-
ences were the number of days of gonadotrophin therapy and the
amount of gonadotrophins administered. These differences were
found in the comparisons 1.5.1 and 1.6.1 (COCP plus antagonist
versus antagonist) and comparisons 1.5.2 and 1.6.2 (COCP plus
antagonist versus agonist). All these differences were in favour of
the groups that did not receive pre-treatment, with fewer days of
gonadotrophin therapy and a smaller amount of gonadotrophins
administered in the control group. A statistically significant differ-
ence with regard to the amount of gonadotrophins administered
was also found in the comparison 3.6.1 (oestrogen plus antago-
nist versus antagonist). This difference was also in favour of the
control group. Furthermore we have been able to pool the results
of two studies in comparison 2.6.1 (progestogen plus agonist ver-
sus agonist), with regard to the number of days of gonadotrophin
treatment and we found no evidence for a treatment effect. For
the other interventions and subgroups we have not been able to
pool any data.
These results are mainly important with regard to the financial
aspects of the IVF/ICSI treatment andmight be explained because
of a longer duration of ovarian suppression. Instead of suppression
with only a GnRH analogue as in the control group, the ovaria
were also suppressed with a combined OCP or oestrogen in the
pre-treatment group. However, this might result in less need for
GnRH analogue administration as suggested by Griesinger 2008,
but we did not address this outcome in our review.
With regard to the number of pregnancy losses, we have been able
to pool the results for three subgroups in two interventions, but
we found no evidence for a treatment effect.
The only adverse outcome that showed a statistically significant
difference was found in comparison 2.8.1 (progestogen plus ag-
onist versus agonist). The number of ovarian cysts was shown to
be increased in the control group that did not receive hormonal
pretreatment. This is clinically important, because a frequent rea-
son for cycle cancellation is the occurrence of ovarian cysts. It is
unclear whether the formation of ovarian cysts in the studies of
this comparison has lead to cycle cancellation, because this was not
reported. The lower incidence of ovarian cysts in progestogen pre-
treated cycles, might explain the higher clinical pregnancy rates
because fewer cycles have to be cancelled. This was also suggested
in another review on combined OCP pre-treatment (Griesinger
2008).
For the outcome of multiple pregnancies and OHS syndrome we
have been able to pool results for one subgroup in the interven-
tion that compared a combined OCP pre-treatment with no pre-
treatment, but this showed no statistically significant difference.
For the other interventions or subgroups we were not able to pool
any results with regard to these outcomes.
Overall completeness and applicability of
evidence
Although we were able to include 23 studies across 6 comparisons,
there were insufficient data to report on the primary outcome of
live births. Using subgroups of different GnRH antagonist and
agonist protocols also limited the ability to pool data. There were
also limited data for many of the secondary outcomes and almost
all of the adverse outcomes.
This review did include women with polycystic ovary syndrome
(PCOS), but there was only one study of 56 randomised women
that only included a diagnosis of PCOS. Five other studies have
used PCOS or ovarian cysts as an exclusion criteria. These studies
have randomised a total of 1118 women, so almost half of all the
women in this review were not diagnosed with PCOS. Because
of the small proportion of women with PCOS included in this
review, results might not be relevant for these women.
Also, we planned on doing subgroup analysis on poor responders
and there were two included randomised trials that used poor re-
sponse to ovarian stimulation as an inclusion criteria. These stud-
ies randomised a total of 203 women. However, we have not been
able to pool results of these two studies, since they used a different
ovarian stimulation protocol. Therefore, although a relatively large
number of poor responder patients is included, this review might
not be applicable to women who have a history of poor response.
An outcome that we did not address was the number of days
of GnRH analogue treatment. This could be considered in the
update as pre-treatment with a combined OCP, progestogen or
oestrogen, may result in a reduction in the amount of GnRH
analogues administered. This is mainly important with regard to
the financial aspect of the treatment.
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Quality of the evidence
Because of the few studies in each subgroup (with a maximum
of six studies), a solid conclusion regarding the objective of this
review is not possible.
In this review we included 23 studies with a total of 2596 women.
These 23 studies were distributed to six comparisons and thirteen
subgroups. Three of the studies were used in more than one sub-
group, due to the existence of three or four study arms.
A possible methodological limitation of the included studies is
that an intention-to-treat (ITT) analysis was not carried out on all
the outcomes that the studies reported. Most of the studies used
an ITT analysis to describe baseline characteristics of the women,
but did not analyse the (continuous) data according to a true ITT
definition, which describes that all randomised women should be
included in the final analyses. Blinding was only used in 13% of
the studies but this was not considered a major problem because
women in the placebo arm would have been able to recognise
which treatment they were receiving because of bleeding patterns.
Other smaller concerns were the inconsistency of the outcomes
reported.Definitions of oocytes retrieved, cyst formation and clin-
ical pregnancy, differed between studies. Also, different units were
used to describe gonadotrophin usage.
Potential biases in the review process
A strength of this review is the grouping of the studies into sub-
groups regarding the type of down regulation used (agonist or an-
tagonist). Nonetheless, there is still some substantial heterogene-
ity in a few of the statistically significant outcomes, such as the
number of days of gonadotrophin administration, but this may be
explained by differences in treatment protocols between studies.
The major limitation of this review is the poor reporting of all
outcomes that are important to clinicians prior to making changes
to treatment protocols. In particular, the outcomes of live birth
rate but also pregnancy losses, cyst formation, cycle cancellation,
multiple pregnancies andwomenwithOHS syndrome aremissing
from the majority of the studies.
Furthermore, we were not able to construct a funnel plot, due to
the small number of studies in each subgroup. Therefore we could
not examine if publication bias was present.
Agreements and disagreements with other
studies or reviews
To our knowledge, there is one systematic review on combined
OCP pre-treatment available (Griesinger 2008). This review in-
vestigates the effect of a combined OCP pre-treatment in a GnRH
antagonist cycle versus no pre-treatment, and included four stud-
ies (Cédrin-Durnerin 2007; Huirne 2006b; Kolibianakis 2006;
Rombauts 2006). All of these studies are also included in our re-
view, but we have included twomore studies in this subgroup (Kim
2005; Obruca 2001). Due to a lack of data, despite contacting the
author, or differences in treatment protocols we were not able to
pool their results. Because the systematic review of Dr Griesinger
included the same studies and investigated almost the same out-
comes, it is not surprising that we reach the same conclusions. In
his review, Dr Griesinger found no significant effects on ongoing
pregnancies. Also, he found a significant difference in favour of
the control group with regard to the number of days and amount
of gonadotrophin administration.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
It is not possible to make recommendations for clinical practice
on the basis of this review. Although we did find some signifi-
cant differences in a few outcomes for three comparisons, more
studies are required before major changes should be made to ART
protocols. Besides this, there are a few other important aspects to
consider when deciding if a pre-treatment with a combined OCP,
a progestogen or an oestrogen should be given. First of all, a pre-
treatment with one of these drugs results in a longer duration and
a higher amount of gonadotrophin treatment, which is expensive.
Secondly, the pre-treatment with one of these drugs means the
need for a longer duration of the IVF/ICSI cycle and this is a
burden to the woman. And last, if pre-treatment with combined
OCP, progestogen or oestrogen will be given, this should be clearly
explained to the woman, because the need for oral contraceptive
drugs might be hard to understand when you are trying to get
pregnant.
The positive effect of a pre-treatment with progestogen on the rate
of clinical pregnancies found in this review is surprising, since a
pre-treatment with a combined OCP seems to yield lower clinical
pregnancy rates. In our review we also found that a pre-treatment
with progestogen results in the formation of fewer ovarian cysts.
This is important, since ovarian cysts have a negative effect on the
number of pregnancies, because ART cycles have to be cancelled.
However, only one study that used a combined OCP pre-treat-
ment reported on the number of ovarian cyst formation and this
study also found a statistically significant difference in favour of
the combined OCP group. Unless more research is done on the
underlying mechanism that could explain these effects, no impli-
cations for practice can be made.
If pre-treatment with progestogens seems to result in a better IVF/
ICSI outcome, this could be clinically and financially important.
The administration of progestogen is easy, appears to be safe for the
woman and it is less expensive than combinedOCPpre-treatment.
Implications for research
More and largerRCTs are needed that randomise subfertile women
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with regular IVF/ICSI indications, undergoing a pre-treatment
with a combined OCP, progestogen or oestrogen in GnRH ana-
logue plus gonadotrophin cycles. Especially pre-treatments with
the combined OCP or a progestogen are of interest for further
research. The most important outcome that should be addressed is
the number of live births. Other outcomes that are important are
the formation of ovarian cysts, pregnancy losses and the number
of women with OHS syndrome. Furthermore, research on poor
responder patients is necessary, because we were unable to include
many trials with poor responder patients.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Aston 1995
Methods Parallel group study
Number of women randomised: 152 (75 in control group, 77 in study group)
Number of withdrawals: 8 (7 in control group: 5 due to endometrioma or cysts and 2
chose not to proceed; 1 in study group due to endometrioma)
Number of women analysed:144
Participants Country: authors are from the United Kingdom
Inclusion criteria: women planning to have an IVF cycle on the Southampton IVF
programme.
Exclusion criteria: an endometrioma or an ovarian cyst seen on vaginal ultrasound scan
on day 19 of the menstrual cycle (after recruitment)
Mean age and SD
Study group: 33.8 ± 4.1
Control group: 33.5 ± 3.5
Interventions 1)Medroxyprogesterone acetate 10mg/day on cycle days 19-25 +GnRHagonist (busere-
lin acetate, nasal administration) 200 µg 3 times daily from cycle day 21 + hMG 4
ampoules/day (75 IU FSH and 75 IU LH per ampoule) from day 4 of ensuing menses
2) Placebo on cycle days 19-25 + GnRH agonist (buserelin acetate, nasal administration)
200 µg 3 times daily from cycle day 21 + hMG 4 ampoules/day (75 IU FSH and 75 IU
LH per ampoule) from day 4 of ensuing menses
Both hMG and GnRH agonist are continued until hCG injection (10,000 IU, IM),
administered when the leading 3 follicles reach a diameter of ≥ 18 mm and the serum
oestradiol level is > 300 pmol/L for every follicle > 14 mm in diameter
Outcomes Cyst development; intraovarian sonolucent structure with a mean diameter of > 14 mm,
measured after 12 days of pituitary suppression
Clinical pregnancy rates; not defined
Notes Power calculation performed: yes
Intention-to-treat analysis performed: no
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Quote: ’The hospital pharmacy ran-
domised to contain placebo or progesto-
gen.’
Method of randomisation not reported.
Allocation concealment? Yes Quote: ’The hospital pharmacy provided a
series of consecutively numbered bottles’
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Women in control group received a
placebo.
Incomplete outcome data addressed?
All outcomes
Yes Reasons for withdrawals reported. With-
drawals due to endometrioma slightly im-
balanced: 5 in control group, 1 in study
group
Free of selective reporting? Unclear Planned outcomes not reported.
Free of other bias? Unclear Quote: ’Nodifferencewas seenbetween the
study group and control group in the indi-
cation of IVF and age.’ No P values given
in table.
Only baseline data available of women
analysed, but not of all the women ran-
domised
Biljan 1998a
Methods Academic centre, parallel group study
Number of women randomised: 83 women undergoing 102 cycles (51 cycles in control
group, 51 cycles in study group; number of women per group not reported)
Number of withdrawals: not reported
Number of women analysed: only number of cycles analysed reported (n=102)
Participants Country: authors are from Canada
Inclusion criteria: patients who were receiving a long protocol of pituitary suppression
in the early follicular phase as a part of IVF-ET treatment.
Exclusion criteria: not reported
Median age and range:
Study group: 35.2 (32.5-39.1)
Control group: 33.7 (31.6-38.3)
Interventions 1) CombinedOCP on cycle days 1-14 +GnRH agonist (buserelin acetate, long protocol)
500 µg/day start on cycle day 14 + hMG (75 IU FSH and 75 IU LH) or pure FSH (75
IU) start after achievement of pituitary suppression.
2) GnRH agonist (buserelin acetate, long protocol) 500 µg/day start on cycle day 2
+ hMG (75 IU FSH and 75 IU LH) or pure FSH (75 IU) start after achievement of
pituitary suppression
If no pituitary suppression (serum E2 concentration < 40 pg/mL) is achieved after 14
days of GnRH agonist administration, the dosage of buserelin acetate is increased to 500
µg twice daily + administration of an IM injection of progesterone 100 mg
Both hMG/FSH and GnRH agonist are continued until hCG injection, administered
when ≥ 3 follicles reach a mean diameter of ≥ 18 mm
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Biljan 1998a (Continued)
Outcomes Clinical pregnancy rate per cycle started; presence of one or more fetal hearts confirmed
with US performed at least 4 weeks after embryo transfer
Number of patients with a cyst; intraovarian sonolucent structure with a mean diameter
of > 14 mm, measured after 7 days of pituitary suppression
Number of days of GnRH-a treatment
Number of days of gonadotrophin treatment
Total quantity of gonadotrophin administered; measured in ampoules
Number of follicles and
Number of oocytes collected/fertilised
Number of embryos replaced
Implantation rate
Notes Power calculation performed: yes
Intention-to-treat analysis performed: no
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Quote: ’They were randomised in two
groups by drawing sealed envelopes that
contained randomly generated numbers.’




Incomplete outcome data addressed?
All outcomes
No Numbers and reasons for withdrawals not
reported.
Free of selective reporting? Unclear Planned outcomes not reported.
Free of other bias? No Only number of cycles per treatment group
known, number of women per group not
reported.
No significant difference in baseline char-
acteristics between groups with regard to
age, cause of infertility, number of previous
attempts, and E2, FSH or LH level.
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Cédrin-Durnerin 1996
Methods Cross-over study, no pre-crossover data available.
Number of women randomised: 68 (35 cycles in control group, 34 cycles in study group;
1 patient was randomised twice after cancellation for an ovarian cyst).
Crossover design: 18 patients in the control group crossed over to the study group, 3
patients in the study group crossed over to the control group.
Number of withdrawals: 9 (6 in control group: 1 due to high serum progesterone value
on day 6, 4 due to inadequate or poor response to stimulation, 1 due to personal reasons;
3 in study group: 2 due to inadequate or poor response to stimulation, 1 due to ovarian
cyst)
Number of women analysed after crossover: 52 in study group and 38 in control group
Participants Country: authors are from France
Inclusion criteria: patients < 42 years old who were undergoing an IVF procedure for
tubal disease, male factor, endometriosis or unexplained infertility.
Exclusion criteria: not reported
Mean age and SD both groups: 32.8 ± 0.5
Interventions 1) Norethisterone 10 mg/day for 12-20 days, start on cycle day 15 + GnRH agonist
(triptorelin) 100 µg/day, start on post-treatment day 3 + hMG 140-150 IU a.m. start
on day 4/5 of GnRH agonist treatment (dose adjustments if necessary).
2) GnRH agonist (triptorelin) 100 µg/day, start on cycle day 1 + hMG 140-150 IU IM
start on cycle day 4/5 (dose adjustments if necessary)
Both hMG and GnRH agonist are continued until hCG injection (10,000 IU), admin-
istered when≥ 2 follicles reach a diameter of≥ 18 mm and serum oestradiol values were
~ 200 pg/mL per follicle > 15 mm
Outcomes Hormonal values
Day of hCG
Number of hMG vials
Number of oocytes retrieved; defined as mature oocytes or follicles
Number of embryos replaced
Number of pregnancies; not defined.
Number of ’take home babies’
Notes Power calculation performed: no
Intention-to-treat analysis performed: no
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Quote: ’Participating women were ran-
domised...’
Method not reported.
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Cédrin-Durnerin 1996 (Continued)
Incomplete outcome data addressed?
All outcomes
Yes Reasons for withdrawals reported.
Free of selective reporting? Unclear Planned outcomes not reported.
Free of other bias? No Quote: ’There was no difference in the
mean age or in the indication of IVF be-
tween the groups.’
No data on baseline characteristics re-
ported.
Cédrin-Durnerin 2007
Methods Multicentre (6 IVF centres), parallel group study
Number of women randomised: 93 (21 in OCP group, 23 in progestogen group, 25 in
oestrogen group, 24 in control group)
Number of withdrawals: 3 in oestrogen group (1 did not start any treatment, 1 due to
an ovarian cyst and one due to major protocol violation)
Number of women analysed: 90
Duration of study: 10 months of recruitment
Participants Country: authors are from France
Inclusion criteria: (i) regular normo-ovulatory cycles (28 to 35 days), (ii) age < 38 years,
(iii) BMI between 18 and 30.
Exclusion criteria: (i) high levels of baseline serum FSH or E2 values, (ii) < 5 follicles at
the antral follicular count performed on day three of a spontaneous cycle, (iii) a history
of high (> 20 oocytes) or low (< 5 oocytes) ovarian response in a previous IVF attempt
Mean age and SD:
OCP group: 30.8 ± 4.6
Progestogen group: 32.9 ± 2.5
Estrogen group: 31.8 ± 3.2
Control group: 31.2 ± 4.3
Interventions 1) Combined OCP (ethinyl 30 µg + desogestrel 150 µg) daily, start cycle day two or
three for 15 to 21 days (stop on a Sunday) + rFSH (recombinant follitropin beta) 150
to 300 IU/day, start post-treatment day five + GnRH antagonist (ganirelix acetate) 0.25
mg/day, start when leading follicle reaches 14 mm in diameter.
2) Norethisterone 10 mg/day, start cycle day 15 for 10 to 15 days (stop on a Sunday)
+ rFSH (recombinant follitropin beta) 150-300 IU/day, start post-treatment day five +
GnRH antagonist (ganirelix acetate) 0.25 mg/day, start when leading follicle reaches 14
mm in diameter.
3)Micronized 17-βE2 2 mg twice daily, 10 to 15 days, start 10 days before the presumed
menses (stop on a Sunday) + rFSH (recombinant follitropin beta) 150 to 300 IU/day,
start post-treatment day five + GnRH antagonist (ganirelix acetate) 0.25 mg/day, start
when leading follicle reaches 14 mm in diameter.
4) rFSH (recombinant follitropin beta) 150 to 300 IU/day, start day three after spon-
taneous menses + GnRH antagonist (ganirelix acetate) 0.25 mg/day, start when leading
follicle reaches 14 mm in diameter
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Cédrin-Durnerin 2007 (Continued)
rFSH dose according to age, BMI and previous responses to stimulation; after five days
of treatment dose adjustment according to ovarian response
Both rFSH and GnRH antagonist are continued until hCG injection (10,000 IU),
administered when ≥ three mature (≥ 17 mm) follicles were obtained
Outcomes Number of live births
Number of positive pregnancy tests
Clinical pregnancy rate; not defined
Ongoing pregnancy rate; a pregnancy developing beyond 12 weeks
Multiple pregnancy rate; not defined







Notes Power calculation performed: no
Intention-to-treat analysis performed: no (not for oestrogen group)
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Quote: ’Random allocation sequence was
generated from a table of randomnumbers.
.. Randomization was stratified by centre..
.’
Allocation concealment? Yes Quote: ’Random allocation sequence was





No Quote: ’This study was not blind.’
Incomplete outcome data addressed?
All outcomes
No The reason for one withdrawal in the oe-
strogen group is unclear (quote: ’did not
start any treatment’)
Free of selective reporting? Unclear Hormonal values planned and (incom-
pletely) reported in abstract and also (com-
pletely) reported in journal article.
Other planned outcomes not reported.
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Cédrin-Durnerin 2007 (Continued)
Free of other bias? No No significant baseline imbalance with re-




Number of women randomised: 25 (13 study group, 12 in control group)
Number of withdrawals: not reported
Number of women analysed: unclear
Participants Country: authors are from United States of Amerika
Inclusion criteria: women, < 41 years of age, whowere anticipated to have limited ovarian
reserve (LOR) based on transvaginal ultrasound showing limited follicles on cycle day
2-3 or hormonal values (inhibin B, FSH, E2)
Exclusion criteria: not reported
Mean age and SD: not reported
Poor response: yes (’limited ovarian reserve’)
Interventions 1) Estradiol 2 mg in the luteal phase of the preparation cycle + FSH 300 IU, start cycle
day 2 + GnRH antagonist (ganirelix acetate) start in late follicular phase + hMG (375
IU FSH + 150 IU LH), timing not reported.
2) Combined OCP + GnRH agonist (leuprolide acetate, microdose) + hMG (300 IU
FSH + 75 IU LH). Timing of administration of combined OCP, hMG and GnRH
agonist not reported
Outcomes Ongoing pregnancy; a viable pregnancy, method of assessment is not reported
Clinical pregnancy; not defined
Number of mature oocytes
Number of good embryos
Implantation rate
Cancellation rate
Notes Power calculation performed: unclear
Intention-to-treat analysis performed: unclear
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear ’Randomized’, method not reported.
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Daly 2002 (Continued)
Incomplete outcome data addressed?
All outcomes
Unclear Only abstract available. Numbers and rea-
sons for withdrawals not reported
Free of selective reporting? Unclear Data on all planned outcomes reported.
Pre-crossover data on primary outcome re-
ported, but on some secondary outcomes
(implantation rate, mature oocytes, good
embryos) only post-cross-over data is re-
ported
Free of other bias? No No data on baseline characteristics re-
ported.
Ditkoff 1996
Methods Parallel group study
Number of women randomised: 105 (58 in control group and 47 in study group)
Number of withdrawals: 0
Number of women analysed: 105
Length of follow up: until end of treatment cycle.
Participants Country: United States of America
Inclusion criteria: day 3 FSH values < 15 mIU/mL
Exclusion criteria: not reported
Mean age and SD:
Study group: 36.7 ± 4.8
Control group: 35.8 ± 4.57
Interventions 1) Norethindrone acetate (NETA, oral) 10 mg/day on cycle days one to eight + GnRH
agonist (leuprolide acetate, s.c.) 1 mg/day, start cycle day one + hMG 225 IU/day (IM
administration), start when serum oestradiol level was < 30 pg/ml.
2) GnRH agonist (leuprolide acetate, s.c.) 1 mg/day, start cycle day 1 + hMG 225 IU/
day (IM), start when serum oestradiol level was < 30 pg/mL
Both hMG and GnRH agonist are continued until hCG injection (10,000 IU, IM),
administered when the leading follicles reaches a diameter of ≥ 18 mm
Outcomes Number of deliveries/ongoing pregnancies; positive heart activity on US.
Number of clinical pregnancies; evidence of a clinical gestational sac.
Days until suppression
Number of cysts cycles; intraovarian sonolucent structure with a mean diameter of > 14
mm, measured after 8 days of pituitary suppression
Number of oocytes retrieved
Days of ovarian stimulation
Number of ampoules of hMG
Notes Power calculation performed: no
Intention-to-treat analysis performed: no
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Ditkoff 1996 (Continued)
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Quote: ’Patients were randomly assigned
by tossing a coin to one of two groups.’




Incomplete outcome data addressed?
All outcomes
Yes No withdrawals
Free of selective reporting? Unclear Planned outcomes not reported.
Free of other bias? No No table of baseline characteristics.
Quote: ’The various infertility diagnoses
were distributed equally between the con-
trol and study groups.’
Engmann 1999
Methods Parallel group study
Number of women recruited: 123
Number of women excluded: six (two due to ovarian cysts ≥ 15 mm, two due to raised
early follicular phase serum FSH, two did not undergo IVF)
Number of women randomised: 117 (54 in control group, 63 in study group)
Number of withdrawals: one (in study group, due to violation of the study protocol)
Number of women analysed: 116
Duration of study: one year of recruitment
Source of funding: Schering Health Care Limited, West Sussex, United Kingdom, sup-
plied the norethindrone
Participants Country: authors are from the United Kingdom and Canada
Inclusion criteria: (i) age 18 to 44 years at time of screening, (ii) duration of infertility
≥ one year, (iii) early follicular phase serum FSH ≤ 11.0 IU/L, (iv) good physical and
mental health, (v) suitability for the long-term buserelin protocol for desensitization.
Exclusion criteria: (i) endometrioma of the ovary, (ii) ovarian cysts (≥ 15 mm) in the
early follicular phase, (iii) known contraindications to the use of progestogen, GnRH
agonists or hMG
Mean age and SD:
Study group: 35.3 ± 4.3
Control group: 33.8 ± 5.5
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Engmann 1999 (Continued)
Interventions 1) Norethindrone 10 mg on cycle day 1 and 5 mg twice daily on cycle day two to five
+ GnRH agonist (buserelin acetate, s.c., long protocol) 500 µg/day, start on cycle day
2 (dose adjustment after pituitary suppression to 200 µg/day) + hMG (Normegon, 75
IU FSH) two to five ampoules daily or rFSH, start when serum E2 ≤ 150 pmol/L.
2) GnRH agonist (buserelin acetate, s.c., long protocol) 500 µg/day start on cycle day
two (dose adjustment after pituitary suppression to 200 µg/day) + hMG (Normegon,
75 IU FSH) two to five ampoules daily or rFSH, start when serum E2 ≤ 150 pmol/L.
Pituitary suppression is achieved when there is an absence of follicular activity and
endometrial thickness < 5 mm
hMG or rFSH dose according to patient’s age, previous response, basal serum FSH levels
and PCO
Both hMG/rFSH and GnRH agonist are continued until hCG injection (10,000 IU,
IM), administered when two or three leading follicles are ≥ 18 mm in diameter
Outcomes Incidence of functional ovarian cysts (≥ 10 mm, measured after one week of GnRH
agonist)
Number of days required to achieve pituitary desensitization
Number of hospital visits before ovarian stimulation
Number of preovulatory follicles and mature oocytes
Fertilization rate
Number of good-quality embryos produced and transferred
Implantation rate
Clinical pregnancy rate; a positive pregnancy test with evidence of a gestational sac
Amount of gonadotrophins administered; measured in ampoules
Pregnancy loss
Notes Power calculation performed: yes
Intention-to-treat analysis performed: no
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Quote: ’Eligible patients were randomly as-
signed in a ratio of 1:1 by means of com-
puter-generated random numbers. To en-
sure similar distributions of age in the two
groups, separate randomization schedules
were drawn up for women < 40 years old
and women ≥ 40 years old by use of strat-
ified randomized blocks.’
Allocation concealment? Yes Quote: ’Selection into the groups (and of
administration of the appropriate treat-
ment protocol) was performed by the clinic
nurses by using a series of consecutively
numbered sealed envelopes (one for each
age group).’
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Yes Quote: ’Although the patient could guess
her treatment status, treatment allocation
was not recorded in the clinical notes, and
all clinicians were blinded to the status of
study participants until the trial was over.’
Incomplete outcome data addressed?
All outcomes
Yes Reasons for withdrawals reported.
Free of selective reporting? Yes Data on all planned outcomes reported.
Free of other bias? Yes No significant baseline imbalance between
groups with regard to age, duration of in-
fertility, previous attempts, baseline serum
FSH, polycystic ovaries and cause of infer-
tility
Fanchin 2001
Methods Cross-over study, no pre-cross-over data available.
Crossover design: ’Women randomly started the protocol by control or E2 pre-treated
cycles.’ Thereafter, all women did a second (cross-over) cycle.
Number of women randomised: 14 (all these women underwent two cycles of treatment;
one E2 pre-treated cycle and one control cycle)
Number of withdrawals: not reported
Number of women analysed: not reported
Participants Country: authors are from France
Inclusion criteria: not reported
Exclusion criteria: not reported
Mean age and SD: not reported
Interventions 1) 17β-E2 (oral) 4mg/day, start cycle day 20, stop day 2 next cycle + follicular assessment
on day three.
2) Follicular assessment on day three in two successive menstrual cycles




Notes Power calculation performed: unclear
Intention-to-treat analysis performed: unclear
Risk of bias
Item Authors’ judgement Description
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Fanchin 2001 (Continued)
Adequate sequence generation? Unclear Quote: ’Women randomly started...’
Method not reported.




Incomplete outcome data addressed?
All outcomes
Unclear Numbers and reasons for withdrawals not
reported.
Free of selective reporting? No Data on planned outcomes ’follicular de-
velopment’ and ’follicular size on day 3’ re-
ported.
No other planned outcomes reported, es-
pecially no data on pregnancy rates. (Ab-
stract)
Free of other bias? No Number ofwomenper groupnot reported.
Baseline characteristics not reported.
Fanchin 2003a
Methods Parallel group study
Number of women randomised: 100 (number of women per group not reported)
Number of withdrawals: 10 (four due to personal reasons and six due to major protocol
violation)
Number of women analysed: 90 (47 in study group and 43 in control group)
Duration of study: one IVF-ET cycle, from day 20 of the previous cycle until day of
hCG administration (information obtained from contact person)
Participants Country: authors are from France
Inclusion criteria: (i) age ≤ 38 years, (ii) regular, ovulatory menstrual cycles every 25 to
35 days, (iii) both ovaries present, (iv) no current or past diseases affecting ovaries or
gonadotrophin or sex steroid secretion, clearance or excretion, (v) BMI ranging from 18
to27kg/m2 , (vi) nohormone therapy during the past 6weeks, (vii) adequate visualization
of both ovaries in transvaginal ultrasound scans.
Exclusion criteria: not reported
Median age and range
Study group: 33 (26-38)
Control group: 33 (25-38)
Interventions 1) Micronized 17β-E2 (oral tablets) 4 mg/day, start cycle day 20 until day two of the
next cycle + rFSH 225 IU/day (s.c.) on cycle days three to seven + GnRH antagonist
(cetrorelix acetate, s.c.) three mg single dose when ≥one follicle > 13 mm in diameter.
2) rFSH 225 IU/day (s.c.) on cycle days three to seven + GnRH antagonist (cetrorelix
acetate, s.c.) three mg single dose when ≥ one follicle > 13 mm in diameter
rFSH dose adjustments according to follicle growth determined by serum E2 levels and
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Fanchin 2003a (Continued)
ultrasound monitoring.
Outcomes Days of GnRH antagonist administration
Day of hCG administration
Dose of gonadotrophins
Number of mature follicles
Number of embryos transferred
Clinical pregnancy rates per cycle; presence of a gestational sac with fetal heart activity
at 6 weeks on US scan
Notes Power calculation performed: yes
Intention-to-treat analysis performed: no
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Quote: ’Women randomly received...’,
’...according to a computer-generated,
blocked randomization list’
Allocation concealment? Yes Quote: ’Treatment allocation was decided
by an independent person.’
Blinding?
All outcomes
No No blinding, information obtained from
contact person
Incomplete outcome data addressed?
All outcomes
No Only total number of withdrawals re-
ported, not how many per group
Free of selective reporting? Unclear Planned outcomes not reported.
Free of other bias? No Number of women randomised per group
not reported, only number of women anal-
ysed per group.
No difference in baseline characteristics
with regard to age, indication for IVF-ET,
duration of infertility, rank of the current
IVF-ET attempt, menstrual cycle length,
day 3 serum FSH and E2.
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Franco Jr 2003
Methods Parallel group study
Number of women recruited: 22
Number of women randomised: 22 (16 in study group, six in control group)
Number of withdrawals: two (in study group, due to spontaneous pregnancies)
Number of women analysed: 20
Participants Country: authors are from Brazil
Inclusion criteria: patients without specific ovulatory dysfunction, aged ≤ 37 years, that
would be submitted to ovarian stimulation
Exclusion criteria: not reported
Mean age and SD:
Study group: 32.2 ± 2.1
Control group: 31.8 ± 1.9
Interventions 1) Estradiol valerate 4 mg/day for 14 days, start cycle day 21 + rFSH 150-300 IU (fixed
dose for 5 days), start post-treatment day 1 + GnRH antagonist (ganirelix acetate) 0.25
mg/day, start when follicular diameter ≥ 15 mm.
2) GnRH agonist (nafarelin acetate, nasal) 200 µg twice daily, start cycle day 21 + rFSH
150-300 IU (fixed dose for 5 days), start stimulation day 14
Both rFSH and GnRH analogues are continued until hCG injection (5,000-10,000 IU)
, administered when ≥ 2 follicles are ≥ 17 mm in diameter
Outcomes Clinical pregnancy rate; one or more fetal hearts confirmed with US, performed at least
4 weeks after embryo transfer
Ovarian cyst; intraovarian sonolucent structure with a mean diameter of > 14 mm, time
of measurement not reported
OHS syndrome; not defined
Values of LH, estradiol, progesterone
Dose of FSH
Number of collected oocytes
Number of oocytes in metaphase II
Fertilisation rate
Number of transferred embryos
Embryo implantation rate
Gestation rate per embryo transfer
Notes Power calculation performed: no
Intention-to-treat analysis performed: no
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Randomisation was done by drawing lots
after constructing a table of distribution.
2:1 randomisation (study:control)
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Allocation concealment? No After drawing lots, the clinicians and the
participants could see in the table to which




Incomplete outcome data addressed?
All outcomes
Yes No withdrawals
Free of selective reporting? Unclear Planned outcomes not reported.
Free of other bias? No No significant difference in baseline charac-
teristics with regard to age. No other base-
line characteristics reported
Hugues 1994
Methods Parallel group study
Number of women randomised: 45 (25 in control group, 20 in study group)
Number of withdrawals: not reported
Number of women analysed: not reported
Participants Country: authors are from France
Inclusion criteria: not reported
Exclusion criteria: not reported
Mean age and SD: not reported
Interventions 1) Norethisterone 10 mg/day for 10-15 days + GnRH agonist (DTRP6-LHRH) 100
µg/day.
2) GnRH agonist (DTRP6-LHRH) 100 µg/day.
Timing of treatments not reported.
Outcomes Values of estradiol and progestogen
Notes Power calculation performed: unclear
Intention-to-treat analysis performed: unclear
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear ’Randomised’, method not reported.
Allocation concealment? Unclear Not reported
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Incomplete outcome data addressed?
All outcomes
Unclear Numbers and reasons of withdrawals not
reported.
Free of selective reporting? No Planned outcomes not reported. No data
on pregnancy rates.
Free of other bias? No Baseline characteristics not reported.
Huirne 2006a
Methods Multicentre (8 IVF centres), parallel group study
Number of women recruited: 216
Number of women excluded: 34 (reasons not reported)
Number of women randomised: 182 (91 in study group, 91 in control group)
Number of withdrawals: 22 (10 in study group: one due to hepatitis B, one due to non-
compliance, one due to personal reasons, two due to insufficient follicular response, one
due to conversion to IUI, one due to absence of mature oocytes, three due to absence
of viable embryos; 12 in control group:two due to spontaneous pregnancy, three due to
failure of desensitization, one due to personal reasons, one due to stimulation failure,
three due to absence of ’mature’ oocytes, two due to failure of fertilisation)
Number of women analysed: 182
Participants Country: authors are from The Netherlands, Belgium, France and Austria
Inclusion criteria: (i) regular IVF/ICSI indication, (ii) a male partner with viable sperm
in the ejaculate, (iii) aged between 18 to 39 years.
Exclusion criteria: (i) any previous ART cycles with < three oocytes or ≥ three con-
secutive ART cycles without a clinical pregnancy, (ii) any contraindication to ART, go-
nadotrophins or OCPs, (iii) a significant systemic disease
Mean age and SD:
Study group: 32.8 ± 3.8
Control group: 32.2 ± 4.2
Interventions 1) Combined OCP (ethinyl E2 30 µg + levonorgestrel 150 µg ) daily, start within 5
days of onset of menses for 21-28 days (stop on a Sunday) + r-hFSH 150-225 IU/day,
start post-treatment day 5 (= stimulation day 1) + GnRH antagonist (cetrorelix acetate,
s.c.) 0.25 mg/day, start stimulation day six.
2) GnRH agonist (buserelin acetate, s.c.) 500 µg/day, start cycle day 18-22 (reducing
dose to 200 µg/day when down-regulation is achieved) + r-hFSH 150 to 225 IU/day,
start when down-regulation is achieved
After five days of r-hFSH-treatment, the dose can be adjusted by steps of 75 IU (maximal
dose 450 IU/day), according to the ovarian response
Both r-hFSH and GnRH analogues were continued until hCG injection, administered
when the largest follicle reaches a mean diameter of ≥ 18 mm and ≥ 2 other follicles
had a mean diameter of ≥ 16 mm
63Oral contraceptive pill, progestogen or estrogen pre-treatment for ovarian stimulation protocols for women undergoing assisted
reproductive techniques (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Huirne 2006a (Continued)
Outcomes Ongoing pregnancy rate; positive heart activity at a gestational age of 12 weeks
Clinical pregnancy rate; presence of one or more fetal sacs with or without heart activity
confirmed with US, performed at least 4 weeks after embryo transfer
Numbers of oocytes retrieved per patient
Multiple clinical pregnancies
Total number of oocyte retrievals performed on weekends or public holidays
Cancellation rate
Drug requirements
Total number of (good quality) embryos
Implantation rate
Notes Power calculation performed: yes
Intention-to-treat analysis performed: no
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Quote: ’182 were randomly allocated to...’,
’The treatment assigned to each patient was
determined according to a computer-gen-
erated concealed randomization list. Ran-
domization was performed by centre.’





Incomplete outcome data addressed?
All outcomes
Yes Reasons for withdrawals reported.
Free of selective reporting? Unclear Data on all planned outcomes reported.
Free of other bias? Yes No significant difference in baseline char-
acteristics with regard to age, race, duration
of infertility, cause of infertility, smoking
habits, primary infertility, number of previ-
ous ART attempts, number of follicles, en-
dometrial thickness, FSH levels and estra-
diol levels.
P value of BMI is 0.04.
64Oral contraceptive pill, progestogen or estrogen pre-treatment for ovarian stimulation protocols for women undergoing assisted
reproductive techniques (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Huirne 2006b
Methods Academic, Multicentre, parallel group study
Number of women randomised: 64 (32 in study group, 32 in control group)
Number of withdrawals: one (in study group, due to unwillingness to take OCP)
Number of women analysed: 63
Source of funding: Serono Geneva supplied the antide.
Participants Country: The Netherlands and Belgium
Inclusion criteria: (i) a regular IVF or ICSI indication (i.e. idiopathic infertility after six
unsuccessful IUIs, infertility based on a male or tubal factor), (ii) a spontaneous, regular
ovulatory menstrual cycle, (iii) two ovaries and a normal uterine cavity, (iv) age 18 to 38
years
Exclusion criteria: (i) FSH≥ 12 IU/L on cycle day two to four (ii) BMI > 30 kg/m2, (iii)
abnormal gynaecological bleeding, (iv) an extrauterine pregnancy within the last three
months, (v) previous ART cycles with < three oocytes or severe OHS syndrome, (vi) any
contraindication to receive gonadotrophins or OCP, (vii) PCOS
Mean age and SD:
Study group: 32.3 ± 4.0
Control group: 33.3 ± 3.8
Interventions 1) Combined OCP (ethinyl estradiol 30 µg + levonorgestrel 150 µg) for 14-28 days,
start cycle day 2 or 3 + rFSH 150-300 IU, start post-treatment day 2 or 3 (= stimulation
day 1) + GnRH antagonist (antide) 0.5 mg/mL daily, start stimulation day 6.
2) rFSH 150-300 IU, start on cycle days 2 or 3 (= stimulation day 1) + GnRH antagonist
(antide) 0.5 mg/mL daily, start on stimulation day 6
rFSH dose adjustments after 5 days of stimulation (up to a maximum of 450 IU),
according to number and size of oocytes and risk for OHS syndrome
Both rFSH and GnRH antagonist are continued until hCG injection (6,500 IU), ad-
ministered when ≥ 1 follicle reached a diameter of ≥ 18 mm + ≥ 2 follicles reached a
diameter of ≥ 16 mm
Outcomes Ongoing pregnancy rate; positive heart activity at a gestational age of 12 weeks
Clinical pregnancy rate; presence of ≥ one intrauterine sac confirmed with US at a
gestational age of six weeks.
Number of oocytes retrieved
Ovarian cysts; not defined
Number and size of follicles
Cumulative dose of rFSH





Notes Power calculation performed: yes
Intention-to-treat analysis performed: no
Risk of bias
Item Authors’ judgement Description
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Adequate sequence generation? Yes Quote: ’64 patients were randomly allo-
cated according to a computer-generated,
blocked randomization list. The randomi-
sation was stratified by centre.’
Allocation concealment? Yes Quote: ’Treatment allocation was decided





Incomplete outcome data addressed?
All outcomes
Yes Reason for withdrawal reported.
Free of selective reporting? Yes Data on all planned outcomes reported.
Free of other bias? Yes No significant differences in baseline char-
acteristics with regard to age, BMI, cycle
length, primary infertility, smoking habits,
duration of infertility, type of infertility and
antral follicle count
Hwang 2004
Methods Single centre, parallel group study
Number of women recruited: 60
Number ofwomen excluded: 4 (2 refused toparticipate, 2 did notmeet inclusion criteria)
Number of women randomised: 56 (27 in study group, 29 in control group)
Number of withdrawals: 7 (2 in study group: 1 due to poor ovarian response, 1 due to
personal reasons; 5 in control group: 2 due to inadequate ovarian response, 3 due to risk
of severe OHS syndrome)
Number of women analysed: 49
Participants Country: Taiwan
Inclusion criteria: polycystic ovary syndrome.
Exclusion criteria: (i) diagnosis of congenital adrenal hyperplasia, Cushing’s syndrome,
androgen-producing tumours, hyperprolactinaemia or thyroid dysfunction, (ii) age > 38
years, (iii) serum FSH levels > 12 mIU/mL
Mean age and SD:
Study group: 31.4 ± 3.5
Control group: 31.7 ± 3.7
Interventions 1) Combined OCP (Diane-35, oral) on cycle days five to 25 for 3 consecutive cycles +
GnRH antagonist (cetrorelix acetate, s.c.) 0.25 mg single dose on post-treatment day 3,
0.125 mg/day on post-treatment days four to nine, and 0.25mg/day start post-treatment
day 10 + hMG 150 IU/day, start post-treatment day four.
2)GnRHagonist (buserelin acetate, long protocol) 500µg/day start day three of induced
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or spontaneous menstruation, and 250 µg/day start day of ensuing pituitary down
regulation + hMG 150 IU/day for six days start when pituitary down regulation is
achieved
hMG dose can be adjusted according to patient’s follicular response
Pituitary down regulation is achieved when serum E2 levels are < 50 pg/mL and there is
an absence of ovarian cysts > 10 mm in diameter
Both GnRH analogues and hMG are continued until hCG injection (10,000 IU, IM),
administered when ≥2 follicles reached 18 mm in diameter with adequate E2 response.
Outcomes Fertilisation
Clinical pregnancy; presence of one or more fetal hearts confirmed with US, performed
7 weeks after embryo transfer
Implantation rates
Serum LH and testosterone status upon starting and during hMG administration
Total days and amount of gonadotrophins administered; measured in ampoules
Pregnancy loss
Multiple pregnancy rate; ongoing or live born
OHS syndrome; not defined
Notes Power calculation performed: yes
Intention-to-treat analysis performed: no
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Quote: ’Randomization was done by open-
ing sealed envelopes containing computer-
generated block randomization numbers
with a block size of 10.’
Allocation concealment? Yes Sealed envelopes
Blinding?
All outcomes
Yes Quote: ’The laboratory staff were blinded
to the stimulation protocol.’ Unclear if
treating physicians were blinded
Incomplete outcome data addressed?
All outcomes
Yes Reasons for withdrawals reported. Slight
imbalance in numbers of withdrawal due
to risk of severe OHS syndrome: 0 in study
group and three in control group
Free of selective reporting? Yes Data on all planned outcomes is reported.
Free of other bias? Unclear No significant difference in baseline char-
acteristics with regard to age, duration of
infertility, BMI and hormonal levels
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Methods Parallel group study
Number of women randomised: 82 (27 in ’combined OCP + GnRH antagonist’ group;
27 in GnRH antagonist group; and 28 in GnRH agonist group).
Number of withdrawals: 0
Number of women analysed: 82
Duration of study: follow up until 12th week of pregnancy (information obtained from
author)
Participants Country: authors are from South Korea
Inclusion criteria: patients who were defined as low responders (defined as patients with
repeated high basal serum levels of FSH > 8.5 IU/L and/or total basal antral follicle
count of ≤ five), aged 28 to 42 years
Exclusion criteria: not reported
Mean age and SD:
combined OCP + GnRH antagonist group: 35.0 ± 3.4
GnRH antagonist group: 34.8 ± 3.2
GnRH agonist group: 35.8 ± 3.1
Poor response: Yes
Interventions 1) Combined OCP + GnRH antagonist + rFSH
2) GnRH antagonist + rFSH
3) GnRH agonist (low dose, long protocol) + rFSH
Outcomes Live births
Clinical pregnancy rate; presence of an intrauterine gestational sac confirmed with US
performed four weeks after oocyte retrieval
Ongoing pregnancy rate; evidence of a gestational sac with fetal heart motion at 12 weeks
of later confirmed with US
Total dose and duration of rhFSH
Number of mature oocytes
Fertilisation rate
Number of grade I, II embryos
Miscarriage rate
Multiple pregnancy rate
Notes Power calculation performed: yes
Intention-to-treat analysis performed: yes
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes ’Randomized’, computerised allocation
(information obtained from author)
Allocation concealment? Unclear Not reported
Blinding?
All outcomes
No This trial was not blinded
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Incomplete outcome data addressed?
All outcomes
Unclear Number and reasons of withdrawals not re-
ported.
Free of selective reporting? Unclear Planned outcomes not reported.
Free of other bias? No Quote: ’Patient characteristics were com-
parable among three groups.’
No data on baseline characteristics avail-
able.
Kolibianakis 2006
Methods Acadamic, single centre, parallel group study
Number of women randomised: 504 (250 in study group, 254 in control group)
Number of withdrawals: 79 (36 in study group: 28 due to personal reasons, six due
to abnormal steroid levels, two due to spontaneous pregnancy; 43 in control group:
31 due to personal reasons, 10 due to abnormal steroid levels, two due to spontaneous
pregnancy)
Number of women analysed: 425
Duration of study: three years of recruitment
Source of funding: the Fund for Scientific Research Flanders
Participants Country: Belgium
Inclusion criteria: (i) age < 39 years, (ii) ≤ three previous ART attempts, (iii) BMI 18-
29 kg/m2, (iv) levels of FSH < 10 IU/L, (v) levels of LH < 10 IU/L
Exclusion criteria: (i) polycystic ovaries, (ii) endometriosis > stage II, (iii) poor response
to ovarian stimulation
Mean age and SD:
Study group: 31.2 ± 0.3
Control group: 31.5 ± 0.3
Interventions 1) Combined OCP (ethinyl estradiol 30µg + desogestrel 150 µg) for 14 days, start cycle
day one + rFSH 200 IU/day (fixed dose), start post-treatment day 5 + GnRH antagonist
(ganirelix acetate)
2) rFSH 200 IU/day (fixed dose), start cycle day 2 + GnRH antagonist (ganirelix acetate)
Timing of GnRH antagonist not reported.
Both rFSH and GnRH antagonist are continued until hCG injection (10,000 IU),
administered when ≥ 3 follicles ≥ 17 mm in diameter
Outcomes Ongoing pregnancies per started cycle; developing beyond 12 weeks
Stimulation length
Gonadotrophin consumption
Early pregnancy loss; the proportion of patients with initially positive hCG in whom
pregnancy failed to develop before 12 weeks of gestation
Notes Power calculation performed: yes
Intention-to-treat analysis performed: no
69Oral contraceptive pill, progestogen or estrogen pre-treatment for ovarian stimulation protocols for women undergoing assisted
reproductive techniques (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Kolibianakis 2006 (Continued)
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Quote: ’Randomized on the basis of a com-
puter-generated list’
Allocation concealment? No Quote: ’... randomised at the outpatient
clinic by the treating physician.’, ’The se-
quence of allocation was not concealed and
thus it was possible for the treating physi-




No Not reported, but treating physician is not
blinded as this was the person to allocate
the participants
Incomplete outcome data addressed?
All outcomes
Yes Reasons for withdrawals reported.
Free of selective reporting? Yes Data on all planned outcomes reported.
Free of other bias? Yes No significant differences in baseline char-
acteristics with regard to age, BMI, pri-
mary/secondary infertility, duration of in-
fertility, number of previous IVF trials, in-
dication for treatment
Obruca 2001
Methods Parallel group study
Number of women randomised: 150 (75 in study group, 75 in control group)
Number of withdrawals: not reported
Number of women analysed: unclear
Participants Country: authors are from Austria
Inclusion criteria: patients undergoing COS and IVF
Exclusion criteria: not reported
Mean age and SD: not reported
Interventions 1) Combined OCP (ethinyl oestradiol 30 µg + desogestrel 150 µg) daily, start cycle day
one for 18 to 28 days (stop on a Sunday) + rFSH 150 IU/day, start post-treatment day
five (= stimulation day one) + GnRH antagonist (cetrorelix acetate) 0.25 mg/day, start
stimulation day six.
2) rFSH 150 IU/day, start cycle day three (= stimulation day 1) + GnRH antagonist
(cetrorelix acetate) 0.25 mg/day, start stimulation day six
Both rFSH and GnRH antagonist are continued until final follicular maturation
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Outcomes Number of cancelled cycles
Number of oocytes
Number of transferred embryos
Clinical pregnancy rate; not defined
Number of weekend oocyte retrievals
Notes Power calculation performed: unclear
Intention-to-treat analysis performed: unclear
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear ’Randomized’, method not reported.




Incomplete outcome data addressed?
All outcomes
Unclear Number and reasons for withdrawals not
reported.
Free of selective reporting? Unclear Planned outcomes not reported.
Free of other bias? No No data on baseline characteristics re-
ported.
Raoofi 2008
Methods Academic, single centre, parallel group study.
Number of women randomised: 54 women (number of women per group not reported)
Number of withdrawals: three women were excluded due to incomplete data
Number of women analysed: 51
Duration of study: one year of recruitment
Source of funding: Yazd IVF centre, Yazd, Iran
Participants Country: Iran
Inclusion criteria: patients who were undergoing IVF and ICSI
Exclusion criteria: not reported
Mean age and SD:
Study group: 31.48 ± 5.82
Control group: 35.27 ± 4.13
Interventions 1) Combined OCP (ethinyl estradiol 30 µg + desogestrel 150 µg), on cycle days one
to 14 + GnRH agonist (triptorelin acetate depot i.m.) 3.75 mg single dose on post-
treatment day one + hMG (75 IU FSH + 75 IU LH), start post-treatment day 2
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2) GnRH agonist (triptorelin acetate depot IM) 3.75 mg single dose on cycle day one +
hMG (75 IU FSH + 75 IU LH), start cycle day one
Outcomes Cyst formation > 28 mm; measured seven and 14 days after pituitary suppression
Number of follicles
Number of oocytes retrieved
Implantation rate
Clinical pregnancy rate; presence of one or more fetal hearts confirmed with US per-
formed at least 4 weeks after embryo transfer
Notes Power calculation performed: no
Intention-to-treat analysis performed: unclear
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear ’Randomized allocation method’, method
not reported.




Incomplete outcome data addressed?
All outcomes
No Quote: ’Three patients were excluded from
the study because of incomplete data.’
Free of selective reporting? Unclear Planned outcomes not reported.
Free of other bias? No Number ofwomenper groupnot reported.
Quote: ’The etiology and duration of in-
fertility were equally distributed among the
groups.’ No table of characteristics avail-
able
Rombauts 2006
Methods Multicentre (ten IVF centres), parallel group study
Number of women randomised: 351 (117 per treatment group)
Number of withdrawals: 19 (five due to spontaneous pregnancy: two in OCP group and
three in GnRH-antagonist group). Other reasons not reported.
Number of women analysed: 332 (111 in OCP group, 110 in GnRH-antagonist group
and 111 in GnRH-agonist group)
Participants Country: Australia, Denmark, Jordan and Norway.
Inclusion criteria: (i) healthy females of infertile couples, (ii) age 18-39 years, (iii) BMI
between 18-29 kg/m2, (iv) body weight ≤ 90 kg, (v) a normal menstrual cycle with a
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range of 24-35 days and an intra-individual variation of ± 3 days
Exclusion criteria: (i) contraindications for the use of gonadotrophins, (ii) endocrine ab-
normalities (e.g. PCOS), (iii) > 3 unsuccessful controlled ovarian stimulation cycles, (iv)
history of low or no ovarian response during FSH/hMG treatment, (v) clinically relevant
abnormal laboratory values (including hormones) or medical examination findings
Mean age and SD:
OCP group: 32.7 ± 3.9
GnRH-antagonist group: 32.1 ± 3.7
GnRH-agonist group: 32.2 ± 4.0
Interventions 1) Combined OCP (ethinyl oestradiol 30 µg + desogestrel 150 µg) daily, start cycle
day one for 14-28 days (depending on the planned start of rFSH treatment) + rFSH
(follitropin beta, s.c.) 200 IU/day, start post-treatment day two (= stimulation day 1) +
GnRH antagonist (ganirelix acetate, s.c.) 0.25 mg/day, start stimulation day 5 or 6.
2) rFSH (follitropin beta, s.c.) 200 IU/day, start cycle day two or three (= stimulation
day one) + GnRH antagonist (ganirelix acetate, s.c.) 0.25 mg/day, start stimulation day
five or six.
3) GnRH agonist (nafarelin acetate, intranasal) 0.8 mg/day, start cycle day 21 to 24 +
rFSH (follitropin beta, s.c.) 200 IU/day, start when down regulation (i.e. serum estradiol
≤ 50 pg/ml) is achieved (after 2-4 weeks of GnRH agonist treatment)
After five to six days of rFSH treatment, the dose could be adjusted depending on the
ovarian response as assessed by ultrasound
rFSH and GnRH analogues are both continued until hCG injection (10,000 IU, s.c. or
IM), administered when ≥ three follicles ≥ 17 mm in diameter, or ≥ one follicle ≥ 20
mm in diameter
Outcomes Ongoing pregnancy rate; assessed by US at ≥ 12 to 16 weeks
Number of cumulus-oocyte complexes
Number of grade one or two embryos
Number and size of follicles
Serum hormone values
Duration of rFSH treatment
Total rFSH dose
Number of good quality embryos
Implantation rate
Incidences of LH rises
Pregnancy loss
OHS syndrome; according to WHO classification
Notes Power calculation performed: yes
Intention-to-treat analysis performed: no
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Quote: ’The subjects were randomly as-
signed...’ ’To improve balance, the random-
ization of subjects to treatment was strati-
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fied for type of infertility (primary or sec-
ondary), IVF or ICSI, centre, and age.’
Method not reported.




Incomplete outcome data addressed?
All outcomes
No No reasons for 14 withdrawals reported.
Also unclear how many withdrawals per
group
Free of selective reporting? Yes Data on all planned outcomes reported.
Free of other bias? Unclear No differences in baseline characteristics
with regard to age, BMI, height andweight.
Other characteristics reported in table, but
no P values given
Salat-Baroux 1988
Methods Parallel group study.
Four study arms (A1+A2 and B1+B2), of which we can only include two study arms (A2
and B2)
Number of women randomised: 42 (21 in study group (A2), 21 in control group (B2))
Number ofwithdrawals: 13 (eight in study group: three due to poorly followed treatment,
one due to inadequate response, two due to spontaneous ovulation, two due to other
reasons; five in control group: one due to ovarian cyst, four due to inadequate response)
Number of women analysed: 29
Duration of study: seven months of recruitment
Participants Country: authors are from France
Inclusion criteria: infertile patients scheduled for IVF treatment, aged < 38 years
Exclusion criteria: not reported
Mean age and SD:
Study group (A1+A2): 32.8 ± 0.7
Control group (B1+B2): 31.7 ± 0.5
Interventions 1) Progestogen (ethynodiol acetate) 2 mg twice daily for 11 to 17 days, start cycle day
15 + pure FSH four ampoules on post-treatment days six to seven and two ampoules on
post-treatment days eight to nine + hMG (75 IU FSH + 75 IU LH) two ampoules on
post-treatment days 10 to11
2) Pure FSH four ampoules on cycle days tow to three and two ampoules on cycle days
four to five + hMG (75 IU FSH + 75 IU LH) when needed
FSH and GnRH agonist are both continued until hCG injection (10,000 IU), admin-
istration depending on follicular maturity
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Outcomes Clinical pregnancy rate; not defined
Pregnancy loss
Day of hCG
Values of E2 and P on day of hCG
Number of oocytes recovered, cleaved or replaced
Notes Power calculation performed: no
Intention-to-treat analysis performed: no
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear ’Randomized’, method not reported.




Incomplete outcome data addressed?
All outcomes
Yes Reasons for 11 withdrawals reported. Rea-
sons for 2 withdrawals unclear. With-
drawals due to inadequate response slightly
imbalanced: 4 in control group, 1 in study
group
Free of selective reporting? Unclear Planned outcomes not reported.
Free of other bias? Unclear Baseline characteristics reported in table,
but no P values given. Data only reported
on the total number of women in group A
and the total in group B
Slight differences in treatment proto-
col. Control group received hMG when
needed, study group received hMG (2 am-
poules) on day 10 and 11. In study group
hCG was injected on day 12, in control
group this day was variable
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Methods Parallel group study.
Number of women randomised: 49 (number of women per group not reported; 22 cycles
in study group, 29 cycles in control group)
Number of withdrawals: 11 cycles (eight in control group: three due to conversion to
IUI, one due to poor response, two due to failed fertilisation, two due to risk of OHS
syndrome; three in study group: two due to poor response, one due to failure of embryo
cleavage)
Number of women analysed: unclear
Duration of study: eight months of recruitment
Participants Country: authors are from the United Kingdom
Inclusion criteria: patients who underwent IVF treatment cycles and had an ovarian cyst
> 15 mm in diameter or an endometrial thickness > 5 mm and serum E2 concentration
> 100 pmol/L after 14 days of GnRH agonist (buserelin acetate) treatment.
Exclusion criteria: relevant uterine or ovarian pathology
Mean age and SEM:
Study group: 36.0 ± 0.86
Control group: 35.72 ± 0.69
Interventions 1) GnRH agonist (buserelin acetate) 500 µg daily start cycle day two or three + P (IM
injection) 100 mg single dose on cycle day 16 or 17 + hMG, start when serum E2
concentration ≤ 100 pmol/L
2) GnRH agonist (buserelin acetate) 500 µg daily, start cycle day 2 or 3 + hMG, start
when serum E2 concentration ≤ 100 pmol/L
hMG start dose according to women’s age, baseline serum FSH level, response to stim-
ulation in previous treatment cycles
hMG and GnRH agonist are both continued until hCG injection (10,000 IU), admin-
istered when 3 follicles ≥ 18 mm in diameter
Outcomes Clinical pregnancy rate; not defined
Serum E2 levels on day of recruitment
Number of days of hMG administration
Number of days of GnRH agonist
Endometrial thickness
Mean diameter of ovarian cyst on day of recruitment and 6 days later
Total number of hMG ampoules
Number of follicles
Number of oocytes retrieved
Number of embryos transferred
Notes Power calculation performed: no
Intention-to-treat analysis performed: unclear
Risk of bias
Item Authors’ judgement Description
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Adequate sequence generation? Yes Quote: ’Randomization was done by draw-
ing sequentially labelled sealed envelops,
each containing a number obtained from a
table of random numbers.’




Incomplete outcome data addressed?
All outcomes
Yes Reasons for withdrawals reported.
two women in control were excluded due
to risk of OHS syndrome, none in study
group
Free of selective reporting? Yes Data on all planned outcomes reported.
Free of other bias? No Only number of cycles per treatment group
known, number of women per group not
reported.
No significant differences in baseline char-
acteristics between groups with regard to
age, length of infertility, number of previ-
ous IVF cycles and cause of infertility. Data
only reported on the number of cycles per
group, not on the number of women
Tan 2001
Methods Parallel group study.
Number of women randomised: 117 (number of women per group not reported)
Number of withdrawals: not reported
Number of women analysed: unclear
Participants Country: authors are from Canada
Inclusion criteria: not reported
Exclusion criteria: not reported
Mean age and SD: not reported
Interventions 1) Progestogen (norethindrone) for five days, start cycle day one + GnRH agonist, start
cycle day two.
2) GnRH agonist. Timing of treatment not reported.
Outcomes Cyst formation
Time required to achieve pituitary suppression
Implantation rate
Pregnancy rate
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Tan 2001 (Continued)
Notes Power calculation performed: unclear
Intention-to-treat analysis used: unclear
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Method not reported




Incomplete outcome data addressed?
All outcomes
Unclear No data reported
Free of selective reporting? No No data reported, especially no data on
pregnancy rates.
Free of other bias? Unclear Unclear
Wang 2008
Methods Academic, single centre, cross-over study.
Crossover design: 20 women were treated with GnRH antagonist in the first cycle and
with OCP + GnRH agonist in a second cycle.
Number of women randomised: 121 (58 in study group, 63 in control group)
Number of withdrawals: unclear
Number of women analysed: unclear
Participants Country: authors are from China
Inclusion criteria: not reported
Exclusion criteria: not reported
Mean age and SD:
Study group: 35.27 ± 4.76
Control group: 35.53 ± 4.21
Poor response: yes
Interventions 1) Combined OCP + GnRH agonist
2) GnRH antagonist
Timing and dosage of treatments unclear.
Outcomes Clinical pregnancy rate per embryo transfer; not defined
Ampoules of gonadotrophins
Time of Gn
Number of oocytes retrieved
Number of embryos transferred
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Wang 2008 (Continued)
Notes Power calculation performed: unclear
Intention-to-treat analysis performed: unclear
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Method not reported




Incomplete outcome data addressed?
All outcomes
Unclear No data reported
Free of selective reporting? Unclear No data reported
Free of other bias? Unclear Unclear
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
al-Mizyen 2000 No randomised controlled trial. Retrospective study.
Anderson 1990 No randomised controlled trial. The women only received controlled ovarian stimulation, but no embryo
transfer as part of an ART cycle
Bellver 2007 No randomised controlled trial. Retrospective study.
Benadiva 1988 No randomised controlled trial.
Bendikson 2006 No randomised controlled trial. Retrospective study.
Biljan 1998b No randomised controlled trial. Retrospective study. Each patient served as her own control
Branigan 1998 No randomised controlled trial. Each woman served as her own control
Brodt 1993 No randomised controlled trial. Single arm study.
Chung 2006 No randomised controlled trial. Retrospective study.
Monophasic OCP versus triphasic OCP.
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Cohen 1987 No randomised controlled trial.
Copperman 2003 No randomised controlled trial.
Couzinet 1995 No randomised controlled trial. Naltrexon used in treatment protocol
Cédrin-Durnerin 1995 No randomised controlled trial.
Damario 1997 No randomised controlled trial. Retrospective study.
Davy 2004 Compares different durations of combined OCP pre-treatment.
De Ziegler 1999 No randomised controlled trial. Open single-arm study.
Dickey 2001 No randomised controlled trial. Retrospective study.
Ditkoff 1997 No randomised controlled trial.
Doody 2001 No randomised controlled trial. The women in the study are oocyte donors. Compares different durations
of combined OCP pre-treatment
Duvan 2008 No randomised controlled trial. Retrospective study.
Fanchin 2003b No randomised controlled trial. Eachwoman served as her own control. Thewomenonly received controlled
ovarian stimulation, but no embryo transfer as part of an ART cycle
Fisch 1996 No randomised controlled trial. Each woman served as her own control
Forman 1991 No randomised controlled trial.
Frederick 2004 No randomised controlled trial. Retrospective study.
Frydman 1986 No randomised controlled trial.
Galera 2004 No randomised controlled trial.
Gerli 1989 No randomised controlled trial. Single-arm study.
Godin 2003 No randomised controlled trial.
Gomez 2000 Compares two different ways of administration of oestrogen.
Gonen 1990 No randomised controlled trial. Clomiphene citrate used in treatment protocol
Gonzalez 1995 No randomised controlled trial. Retrospective study.
Hugues 1992 No randomised controlled trial. Single-arm study.
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Jung 2000 Estrogen pre-treatment was not stopped before oocyte retrieval, but was also used as luteal phase support
Karande 2004 Compares two different ways of administration of a combined contraceptive (Nuvaring versus oral Desogen)
Keltz 2007 No randomised controlled trial. Retrospective study.
Kovacs 2001 No randomised controlled trial. Retrospective study.
Leondires 1999 No randomised controlled trial. Retrospective study.
Letterie 2000 Women only received a combination of an oestrogen and a progestogen, but no gonadotrophins or GnRH
analogues as part of an ART cycle. Compares two different timings of administration
Lewin 2002 Compares two different doses of oestrogen treatment for endometrial preparation
Lindheim 1996 No randomised controlled trial.
Loutradis 2003 No randomised controlled trial. Retrospective study.
Martinez 2006 The women in the study are oocyte donors.
Mashiach 1989 Compares different durations of combined OCP pre-treatment.
Meldrum 2002 No randomised controlled trial. Open-label single-arm study.
Meldrum 2008 No randomised controlled trial. Open-label single-arm study.
Min 2005 No randomised controlled trial. Retrospective study.
Mirkin 2003 No randomised controlled trial. Retrospective study.
Mulangi 1997 No randomised controlled trial. Each patient served as her own control
Neal 1993 No randomised controlled trial.
Pados 1995 No randomised controlled trial. Retrospective study.
Pednisolon used in treatment protocol.
Palomba 2008 No randomised controlled trial.
Pinkas 2008 No randomised controlled trial. Retrospective study.
Ramsewak 2005 No randomised controlled trial. Retrospective study.
Russell 1997 Compares different doses and timings of oestrogen pre-treatments
Sanghvi 2002 No randomised controlled trial. Retrospective study. Single-arm study
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Schoolcraft 1997 No randomised controlled trial.
Steinkampf 1991 Women only received ovulation induction, no embryo transfer as part of an ART cycle
Surrey 1989 No randomised controlled trial.
Surrey 1998 No randomised controlled trial. Each woman served as her own control
Talebian 2004 No randomised controlled trial. Retrospective study.
Talebian 2007 No randomised controlled trial. Retrospective study.
Tarlatzis 1993 No randomised controlled trial.
Tartagni 2007 The patients in the study are women with premature ovarian failure
Weisman 1989 No randomised controlled trial.
Yokota 2006 No randomised controlled trial.
Yoshida 2005 No randomised controlled trial. Retrospective study.
Zhao 2008 No randomised controlled trial. Retrospective study.




Interventions Two armed study either pre treatment or not with 200IU recFSH in a GnRH antagonist protocol
Outcomes Ongoing pregnancy
Notes
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Characteristics of ongoing studies [ordered by study ID]
Organon 2008
Trial name or title A randomised, open-label clinical trial to identify predictive factors for controlled ovarian stimulation using a
fixed daily dose of 200 IU recombinant FSH in GnRH antagonist regimen with or without oral contraceptive
scheduling
Methods Randomised controlled trial
Participants Inclusion criteria: (i) females of couples with an indication for IVF and/or ICSI scheduled for their first COS
treatment cycle; (ii) >18 and≤ 39 years of age at the time of signing informed consent; (iii) BMI≤ 32 kg/m2;
(iv) normal menstrual cycle length of 24 to 35 days; and (v) availability of ejaculatory sperm (use of donated
and/or cryopreserved sperm is allowed).
Exclusion criteria: (i) (history of ) endocrine abnormality; (ii) < two ovaries or any other ovarian abnormality (e.
g. > 10 mm endometrioma); (iii) presence of unilateral or bilateral hydrosalpinx; (iv) presence of any clinically
relevant pathology affecting the uterine cavity or fibroids ≥ five cm; (v) history of ≥ three miscarriages; (vi)
FSH or LH > 12 IU/L during the early
follicular phase; (vii) any clinically relevant abnormal laboratory value (FSH, LH, E2, P, total T, prolactin,
TSH, blood biochemistry, hematology and urinalysis) based on a sample during the
screening phase; (viii) contraindications for the use of gonadotrophins (tumours, pregnancy, lactation,
undiagnosed vaginal bleeding, hypersensitivity, ovarian cysts); (ix) contraindications for the use of oral contra-
ceptive pills (thromboembolism, breast cancer, undiagnosed vaginal bleeding); (x) (recent history of ) epilepsy,
HIV infection, diabetes, cardiovascular, gastrointestinal, hepatic, renal or pulmonary disease; (xi) abnormal
karyotyping of the patient or her partner (if karyotyping is performed); (xii) (history of ) alcohol or drug
abuse within 12 months of signing the consent; (xiii) use of hormonal preparations within one month prior
to randomization; (xiv) hypersensitivity to any of the concomitant medication; and (xv) administration of
investigational drugs within three months prior to signing the informed consent
Interventions 1) combined OCP (Desogen) for one month + ovarian stimulation
2) ovarian stimulation
Outcomes Primary: total number of oocytes
Secondary: number of mature oocytes, number of follicles on stimulation day 8, number of follicles on day
of hCG, number of fertilised (2PN) oocytes, number of good quality embryos, cycle cancellation rate
Starting date October 2006
Contact information Dr. Z. Rosenwaks
Notes Sponsored by Organon/Schering Plough
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D A T A A N D A N A L Y S E S
Comparison 1. Combined OCP versus no Rx




participants Statistical method Effect size
1 Live births 3 Peto Odds Ratio (Peto, Fixed, 95% CI) Subtotals only
1.1 COCP + Ant vs Ant 1 45 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.43 [0.11, 1.74]
1.2 COCP + Ant vs Ag 1 182 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.0 [0.48, 2.10]
1.3 COCP + Ant vs Ant, low
response
1 54 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.82 [0.53, 6.25]
1.4 COCP + Ant vs Ag, low
response
1 55 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.53 [0.46, 5.09]
2 Ongoing pregnancies 6 Peto Odds Ratio (Peto, Fixed, 95% CI) Subtotals only
2.1 COCP + Ant vs Ant 4 847 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.74 [0.53, 1.03]
2.2 COCP + Ant vs Ag 2 416 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.76 [0.47, 1.23]
2.3 COCP + Ant vs Ant, low
response
1 54 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.82 [0.53, 6.25]
2.4 COCP + Ant vs Ag, low
response
1 55 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.53 [0.46, 5.09]
3 Clinical/ongoing pregnancies 9 Peto Odds Ratio (Peto, Fixed, 95% CI) Subtotals only
3.1 COCP + Ag vs Ag 1 102 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.19 [0.53, 2.66]
3.2 COCP + Ant vs Ant 4 847 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.69 [0.50, 0.96]
3.3 COCP + Ant vs Ag 3 472 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.82 [0.53, 1.26]
3.4 COCP + Ant vs Ant, low
response
1 54 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.72 [0.53, 5.60]
3.5 COCP + Ant vs Ag, low
response
1 55 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.49 [0.47, 4.71]
3.6 COCP + Ag vs Ant, low
response
1 121 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.19 [0.56, 2.53]
4 Oocytes retrieved 9 Mean Difference (IV, Fixed, 95% CI) Subtotals only
4.1 COCP + Ant vs Ant 5 891 Mean Difference (IV, Fixed, 95% CI) 0.23 [-0.55, 1.01]
4.2 COCP + Ant vs Ag 3 440 Mean Difference (IV, Fixed, 95% CI) -0.01 [-1.54, 1.53]
4.3 COCP + Ant vs Ant, low
response
1 54 Mean Difference (IV, Fixed, 95% CI) 0.40 [-0.61, 1.41]
4.4 COCP + Ant vs Ag, low
response
1 55 Mean Difference (IV, Fixed, 95% CI) 0.10 [-0.98, 1.18]
4.5 COCP + Ag vs Ant, low
response
1 110 Mean Difference (IV, Fixed, 95% CI) -1.01 [-1.91, -0.11]
5 Days of gonadotrophin
treatment
7 Mean Difference (IV, Fixed, 95% CI) Subtotals only
5.1 COCP + Ant vs Ant 3 689 Mean Difference (IV, Fixed, 95% CI) 1.44 [1.15, 1.72]
5.2 COCP + Ant vs Ag 3 434 Mean Difference (IV, Fixed, 95% CI) 0.51 [0.17, 0.84]
5.3 COCP + Ant vs Ant, low
response
1 54 Mean Difference (IV, Fixed, 95% CI) 0.30 [-0.45, 1.05]
5.4 COCP + Ant vs Ag, low
response
1 55 Mean Difference (IV, Fixed, 95% CI) -1.60 [-2.42, -0.78]
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5.5 COCP + Ag vs Ant, low
response
1 110 Mean Difference (IV, Fixed, 95% CI) -0.05 [-0.70, 0.60]
6 Amount of gonadotrophins
administered
6 Mean Difference (IV, Fixed, 95% CI) Subtotals only
6.1 COCP + Ant vs Ant 4 734 Mean Difference (IV, Fixed, 95% CI) 231.14 [161.50,
300.78]
6.2 COCP + Ant vs Ag 2 385 Mean Difference (IV, Fixed, 95% CI) 209.52 [61.16, 357.
87]
6.3 COCP + Ant vs Ant, low
response
1 54 Mean Difference (IV, Fixed, 95% CI) 32.40 [-207.04, 271.
84]
6.4 COCP + Ant vs Ag, low
response
1 55 Mean Difference (IV, Fixed, 95% CI) -426.30 [-657.90, -
194.70]
7 Pregnancy losses 7 Peto Odds Ratio (Peto, Fixed, 95% CI) Subtotals only
7.1 COCP + Ant vs Ant 4 847 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.26 [0.76, 2.12]
7.2 COCP + Ant vs Ag 3 472 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.52 [0.24, 1.10]
7.3 COCP + Ant vs Ant, low
response
1 54 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.0 [0.06, 16.42]
7.4 COCP + Ant vs Ag, low
response
1 55 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.04 [0.06, 17.04]
8 Ovarian cyst formation 2 Peto Odds Ratio (Peto, Fixed, 95% CI) Subtotals only
8.1 COCP + Ag vs Ag 1 102 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.07 [0.03, 0.16]
8.2 COCP + Ant vs Ant 1 64 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.48 [0.09, 2.57]
9 Multiple pregnancies 4 Peto Odds Ratio (Peto, Fixed, 95% CI) Subtotals only
9.1 COCP + Ant vs Ant 1 45 Peto Odds Ratio (Peto, Fixed, 95% CI) 2.32 [0.23, 23.65]
9.2 COCP + Ant vs Ag 2 238 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.02 [0.37, 2.82]
9.3 COCP + Ant vs Ant, low
response
1 54 Peto Odds Ratio (Peto, Fixed, 95% CI) 2.00 [0.20, 20.08]
9.4 COCP + Ant vs Ag, low
response
1 55 Peto Odds Ratio (Peto, Fixed, 95% CI) 2.08 [0.21, 20.84]
10 OHS syndrome 2 Peto Odds Ratio (Peto, Fixed, 95% CI) Subtotals only
10.1 COCP + Ant vs Ant 1 234 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.50 [0.26, 8.80]
10.2 COCP + Ant vs Ag 2 290 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.63 [0.21, 1.92]
Comparison 2. Progestogen versus placebo/ no Rx




participants Statistical method Effect size
1 Live births 3 Peto Odds Ratio (Peto, Fixed, 95% CI) Subtotals only
1.1 Prog + Ag vs Ag 2 222 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.35 [0.69, 2.62]
1.2 Prog + Ant vs Ant 1 47 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.68 [0.19, 2.50]
2 Ongoing pregnancies 3 Peto Odds Ratio (Peto, Fixed, 95% CI) Subtotals only
2.1 Prog + Ag vs Ag 1 105 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.17 [0.46, 2.95]
2.2 Prog + Ant vs Ant 1 47 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.68 [0.19, 2.50]
2.3 Prog + Gon vs Gon 1 42 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.64 [0.10, 4.06]
3 Clinical pregnancies 5 Peto Odds Ratio (Peto, Fixed, 95% CI) Subtotals only
3.1 Prog + Ag vs Ag 3 374 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.95 [1.20, 3.17]
3.2 Prog + Ant vs Ant 1 47 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.53 [0.17, 1.69]
3.3 Prog + Gon vs Gon 1 42 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.72 [0.14, 3.56]
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4 Oocytes retrieved 4 Mean Difference (IV, Fixed, 95% CI) Subtotals only
4.1 Prog + Ag vs Ag 2 210 Mean Difference (IV, Fixed, 95% CI) -0.56 [-2.13, 1.01]
4.2 Prog + Ant vs Ant 1 47 Mean Difference (IV, Fixed, 95% CI) 2.70 [-0.98, 6.38]
4.3 Prog + Gon vs Gon 1 29 Mean Difference (IV, Fixed, 95% CI) Not estimable
5 Days of gonadotrophin
treatment
2 Mean Difference (IV, Fixed, 95% CI) Subtotals only
5.1 Prog + Ag vs Ag 2 210 Mean Difference (IV, Fixed, 95% CI) 0.08 [-0.35, 0.50]
6 Amount of gonadotrophins
administered
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
6.1 Prog + Ant vs Ant 1 47 Mean Difference (IV, Fixed, 95% CI) 276.0 [-75.53, 627.
53]
7 Pregnancy losses 4 Peto Odds Ratio (Peto, Fixed, 95% CI) Subtotals only
7.1 Prog + Ag vs Ag 2 222 Peto Odds Ratio (Peto, Fixed, 95% CI) 2.17 [0.71, 6.69]
7.2 Prog + Ant vs Ant 1 47 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.39 [0.08, 1.92]
7.3 Prog + Gon vs Gon 1 42 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.0 [0.06, 16.55]
8 Ovarian cyst formation 3 Peto Odds Ratio (Peto, Fixed, 95% CI) Subtotals only
8.1 Prog + Ag vs Ag 3 374 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.21 [0.12, 0.35]
9 Multiple pregnancies 1 Peto Odds Ratio (Peto, Fixed, 95% CI) Subtotals only
9.1 Prog + Ant vs Ant 1 47 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.04 [0.06, 17.23]
Comparison 3. Estrogen versus no Rx




participants Statistical method Effect size
1 Live births 2 Peto Odds Ratio (Peto, Fixed, 95% CI) Subtotals only
1.1 Estr + Ant vs Ant 1 49 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.36 [0.09, 1.41]
1.2 Estr + Ant vs Ag 1 22 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.91 [0.13, 6.53]
2 Ongoing pregnancies 2 Peto Odds Ratio (Peto, Fixed, 95% CI) Subtotals only
2.1 Estr + Ant vs Ant 1 49 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.36 [0.09, 1.41]
2.2 Estr + Ant vs Ag 1 22 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.91 [0.13, 6.53]
3 Clinical pregnancies 3 Peto Odds Ratio (Peto, Fixed, 95% CI) Subtotals only
3.1 Estr + Ant vs Ant 2 139 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.79 [0.38, 1.62]
3.2 Estr + Ant vs Ag 1 22 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.91 [0.13, 6.53]
4 Oocytes retrieved 3 Mean Difference (IV, Fixed, 95% CI) Subtotals only
4.1 Estr + Ant vs Ant 2 136 Mean Difference (IV, Fixed, 95% CI) 2.01 [1.76, 2.25]
4.2 Estr + Ant vs Ag 1 20 Mean Difference (IV, Fixed, 95% CI) 0.40 [-4.61, 5.41]
5 Days of gonadotrophin
treatment
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
5.1 Estr + Ant vs Ag 1 20 Mean Difference (IV, Fixed, 95% CI) -2.5 [-4.10, -0.90]
6 Amount of gonadotrophins
administered
3 Mean Difference (IV, Fixed, 95% CI) Subtotals only
6.1 Estr + Ant vs Ant 2 136 Mean Difference (IV, Fixed, 95% CI) 207.08 [167.77,
246.39]
6.2 Estr + Ant vs Ag 1 20 Mean Difference (IV, Fixed, 95% CI) -16.0 [-478.88, 446.
88]
7 Pregnancy losses 2 Peto Odds Ratio (Peto, Fixed, 95% CI) Subtotals only
7.1 Estr + Ant vs Ant 1 49 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.22 [0.04, 1.17]
7.2 Estr + Ant vs Ag 1 22 Peto Odds Ratio (Peto, Fixed, 95% CI) Not estimable
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8 Ovarian cyst formation 1 Peto Odds Ratio (Peto, Fixed, 95% CI) Subtotals only
8.1 Estr + Ant vs Ag 1 22 Peto Odds Ratio (Peto, Fixed, 95% CI) Not estimable
9 Multiple pregnancies 2 Peto Odds Ratio (Peto, Fixed, 95% CI) Subtotals only
9.1 Estr + Ant vs Ant 1 49 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.13 [0.00, 6.55]
9.2 Estr + Ant vs Ag 1 20 Peto Odds Ratio (Peto, Fixed, 95% CI) 4.52 [0.20, 101.00]
10 OHS syndrome 1 Peto Odds Ratio (Peto, Fixed, 95% CI) Subtotals only
10.1 Estr + Ant vs Ag 1 22 Peto Odds Ratio (Peto, Fixed, 95% CI) Not estimable
Comparison 4. Combined OCP versus progestogen




participants Statistical method Effect size
1 Live births 1 Peto Odds Ratio (Peto, Fixed, 95% CI) Subtotals only
1.1 COCP + Ant vs Prog +
Ant
1 44 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.61 [0.13, 2.79]
2 Ongoing pregnancies 1 Peto Odds Ratio (Peto, Fixed, 95% CI) Subtotals only
2.1 COCP + Ant vs Prog +
Ant
1 44 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.61 [0.13, 2.79]
3 Clinical pregnancies 1 Peto Odds Ratio (Peto, Fixed, 95% CI) Subtotals only
3.1 COCP + Ant vs Prog +
Ant
1 44 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.72 [0.19, 2.68]
4 Oocytes retrieved 1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
4.1 COCP + Ant vs Prog +
Ant
1 44 Mean Difference (IV, Fixed, 95% CI) 1.40 [-3.24, 6.04]
5 Amount of gonadotrophins
administered
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
5.1 COCP + Ant vs Prog +
Ant
1 44 Mean Difference (IV, Fixed, 95% CI) 164.0 [-249.03, 577.
03]
6 Pregnancy losses 1 Peto Odds Ratio (Peto, Fixed, 95% CI) Subtotals only
6.1 COCP + Ant vs Prog +
Ant
1 44 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.10 [0.14, 8.43]
7 Multiple pregnancies 1 Peto Odds Ratio (Peto, Fixed, 95% CI) Subtotals only
7.1 COCP + Ant vs Prog +
Ant
1 44 Peto Odds Ratio (Peto, Fixed, 95% CI) 2.22 [0.22, 22.56]
Comparison 5. Combined OCP versus estrogen




participants Statistical method Effect size
1 Live births 1 Peto Odds Ratio (Peto, Fixed, 95% CI) Subtotals only
1.1 COCP + Ant vs Estr + Ant 1 46 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.22 [0.22, 6.69]
2 Ongoing pregnancies 2 Peto Odds Ratio (Peto, Fixed, 95% CI) Subtotals only
2.1 COCP + Ant vs Estr + Ant 1 46 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.22 [0.22, 6.69]
2.2 COCP + Ag vs Estr + Ant 1 25 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.13 [0.03, 0.70]
3 Clinical pregnancies 2 Peto Odds Ratio (Peto, Fixed, 95% CI) Subtotals only
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3.1 COCP + Ant vs Estr + Ant 1 46 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.62 [0.38, 6.90]
3.2 COCP + Ag vs Estr + Ant 1 25 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.17 [0.03, 0.80]
4 Oocytes retrieved 1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
4.1 COCP + Ant vs Estr + Ant 1 43 Mean Difference (IV, Fixed, 95% CI) 0.90 [-3.70, 5.50]
5 Amount of gonadotrophins
administered
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
5.1 COCP + Ant vs Estr + Ant 1 43 Mean Difference (IV, Fixed, 95% CI) 474.0 [95.10, 852.
90]
6 Pregnancy losses 2 Peto Odds Ratio (Peto, Fixed, 95% CI) Subtotals only
6.1 COCP + Ant vs Estr + Ant 1 46 Peto Odds Ratio (Peto, Fixed, 95% CI) 2.43 [0.24, 24.79]
6.2 COCP + Ag vs Estr + Ant 1 25 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.09 [0.06, 18.49]
7 Multiple pregnancies 1 Peto Odds Ratio (Peto, Fixed, 95% CI) Subtotals only
7.1 COCP + Ant vs Estr + Ant 1 46 Peto Odds Ratio (Peto, Fixed, 95% CI) 9.40 [0.56, 156.66]
Comparison 6. Progestogen versus estrogen




participants Statistical method Effect size
1 Live births 1 Peto Odds Ratio (Peto, Fixed, 95% CI) Subtotals only
1.1 Prog + Ant vs Estr + Ant 1 48 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.99 [0.44, 8.94]
2 Ongoing pregnancies 1 Peto Odds Ratio (Peto, Fixed, 95% CI) Subtotals only
2.1 Prog + Ant vs Estr + Ant 1 48 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.99 [0.44, 8.94]
3 Clinical pregnancies 1 Peto Odds Ratio (Peto, Fixed, 95% CI) Subtotals only
3.1 Prog + Ant vs Estr + Ant 1 48 Peto Odds Ratio (Peto, Fixed, 95% CI) 2.23 [0.59, 8.44]
4 Oocytes retrieved 1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
4.1 Prog + Ant vs Estr + Ant 1 45 Mean Difference (IV, Fixed, 95% CI) -0.5 [-4.68, 3.68]
5 Amount of gonadotrophins
administered
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
5.1 Prog + Ant vs Estr + Ant 1 45 Mean Difference (IV, Fixed, 95% CI) 310.0 [-40.60, 660.
60]
6 Pregnancy losses 1 Peto Odds Ratio (Peto, Fixed, 95% CI) Subtotals only
6.1 Prog + Ant vs Estr + Ant 1 48 Peto Odds Ratio (Peto, Fixed, 95% CI) 2.19 [0.22, 22.19]
7 Multiple pregnancies 1 Peto Odds Ratio (Peto, Fixed, 95% CI) Subtotals only
7.1 Prog + Ant vs Estr + Ant 1 48 Peto Odds Ratio (Peto, Fixed, 95% CI) 8.06 [0.16, 407.60]
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Analysis 1.1. Comparison 1 Combined OCP versus no Rx, Outcome 1 Live births.
Review: Oral contraceptive pill, progestogen or estrogen pre-treatment for ovarian stimulation protocols for women undergoing assisted reproductive techniques
Comparison: 1 Combined OCP versus no Rx
Outcome: 1 Live births





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 COCP + Ant vs Ant
C drin-Durnerin 2007 (1) 3/21 7/24 100.0 % 0.43 [ 0.11, 1.74 ]
Subtotal (95% CI) 21 24 100.0 % 0.43 [ 0.11, 1.74 ]
Total events: 3 (Combined OCP), 7 (No Rx)
Heterogeneity: not applicable
Test for overall effect: Z = 1.18 (P = 0.24)
2 COCP + Ant vs Ag
Huirne 2006a 17/91 17/91 100.0 % 1.00 [ 0.48, 2.10 ]
Subtotal (95% CI) 91 91 100.0 % 1.00 [ 0.48, 2.10 ]
Total events: 17 (Combined OCP), 17 (No Rx)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
3 COCP + Ant vs Ant, low response
Kim 2005 8/27 5/27 100.0 % 1.82 [ 0.53, 6.25 ]
Subtotal (95% CI) 27 27 100.0 % 1.82 [ 0.53, 6.25 ]
Total events: 8 (Combined OCP), 5 (No Rx)
Heterogeneity: not applicable
Test for overall effect: Z = 0.95 (P = 0.34)
4 COCP + Ant vs Ag, low response
Kim 2005 8/27 6/28 100.0 % 1.53 [ 0.46, 5.09 ]
Subtotal (95% CI) 27 28 100.0 % 1.53 [ 0.46, 5.09 ]
Total events: 8 (Combined OCP), 6 (No Rx)
Heterogeneity: not applicable
Test for overall effect: Z = 0.69 (P = 0.49)
0.002 0.1 1 10 500
Favours control Favours COCP
(1) Data obtained from Dr. Griesinger.
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Analysis 1.2. Comparison 1 Combined OCP versus no Rx, Outcome 2 Ongoing pregnancies.
Review: Oral contraceptive pill, progestogen or estrogen pre-treatment for ovarian stimulation protocols for women undergoing assisted reproductive techniques
Comparison: 1 Combined OCP versus no Rx
Outcome: 2 Ongoing pregnancies





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 COCP + Ant vs Ant
C drin-Durnerin 2007 (1) 3/21 7/24 5.6 % 0.43 [ 0.11, 1.74 ]
Huirne 2006b 4/32 8/32 7.0 % 0.45 [ 0.13, 1.55 ]
Kolibianakis 2006 51/250 60/254 61.2 % 0.83 [ 0.54, 1.26 ]
Rombauts 2006 (2) 20/117 26/117 26.2 % 0.72 [ 0.38, 1.38 ]
Subtotal (95% CI) 420 427 100.0 % 0.74 [ 0.53, 1.03 ]
Total events: 78 (Combined OCP), 101 (No Rx)
Heterogeneity: Chi2 = 1.50, df = 3 (P = 0.68); I2 =0.0%
Test for overall effect: Z = 1.80 (P = 0.071)
2 COCP + Ant vs Ag
Huirne 2006a 17/91 20/91 44.4 % 0.82 [ 0.40, 1.68 ]
Rombauts 2006 (3) 20/117 26/117 55.6 % 0.72 [ 0.38, 1.38 ]
Subtotal (95% CI) 208 208 100.0 % 0.76 [ 0.47, 1.23 ]
Total events: 37 (Combined OCP), 46 (No Rx)
Heterogeneity: Chi2 = 0.06, df = 1 (P = 0.81); I2 =0.0%
Test for overall effect: Z = 1.10 (P = 0.27)
3 COCP + Ant vs Ant, low response
Kim 2005 8/27 5/27 100.0 % 1.82 [ 0.53, 6.25 ]
Subtotal (95% CI) 27 27 100.0 % 1.82 [ 0.53, 6.25 ]
Total events: 8 (Combined OCP), 5 (No Rx)
Heterogeneity: not applicable
Test for overall effect: Z = 0.95 (P = 0.34)
4 COCP + Ant vs Ag, low response
Kim 2005 8/27 6/28 100.0 % 1.53 [ 0.46, 5.09 ]
Subtotal (95% CI) 27 28 100.0 % 1.53 [ 0.46, 5.09 ]
Total events: 8 (Combined OCP), 6 (No Rx)
Heterogeneity: not applicable
Test for overall effect: Z = 0.69 (P = 0.49)
Test for subgroup differences: Chi2 = 3.06, df = 3 (P = 0.38), I2 =2%
0.05 0.2 1 5 20
Favours control Favours COCP
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(1) Data obtained from Dr. C drin-Durnerin.
(2) Includes 2 spontaneous pregnancies in the study group and 3 in the control group.
(3) Includes 2 spontaneous pregnancies in the study group.
Analysis 1.3. Comparison 1 Combined OCP versus no Rx, Outcome 3 Clinical/ongoing pregnancies.
Review: Oral contraceptive pill, progestogen or estrogen pre-treatment for ovarian stimulation protocols for women undergoing assisted reproductive techniques
Comparison: 1 Combined OCP versus no Rx
Outcome: 3 Clinical/ongoing pregnancies





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 COCP + Ag vs Ag
Biljan 1998a (1) 19/51 17/51 100.0 % 1.19 [ 0.53, 2.66 ]
Subtotal (95% CI) 51 51 100.0 % 1.19 [ 0.53, 2.66 ]
Total events: 19 (Combined OCP), 17 (No Rx)
Heterogeneity: not applicable
Test for overall effect: Z = 0.41 (P = 0.68)
2 COCP + Ant vs Ant
C drin-Durnerin 2007 (2) 5/21 11/24 7.2 % 0.39 [ 0.12, 1.31 ]
Huirne 2006b 4/32 12/32 8.3 % 0.27 [ 0.09, 0.83 ]
Kolibianakis 2006 (3) 51/250 60/254 59.2 % 0.83 [ 0.54, 1.26 ]
Rombauts 2006 (4) 20/117 26/117 25.3 % 0.72 [ 0.38, 1.38 ]
Subtotal (95% CI) 420 427 100.0 % 0.69 [ 0.50, 0.96 ]
Total events: 80 (Combined OCP), 109 (No Rx)
Heterogeneity: Chi2 = 4.30, df = 3 (P = 0.23); I2 =30%
Test for overall effect: Z = 2.23 (P = 0.025)
3 COCP + Ant vs Ag
Huirne 2006a 19/91 22/91 38.9 % 0.83 [ 0.41, 1.66 ]
Hwang 2004 (5) 10/27 10/29 15.9 % 1.12 [ 0.38, 3.30 ]
Rombauts 2006 (6) 20/117 26/117 45.2 % 0.72 [ 0.38, 1.38 ]
Subtotal (95% CI) 235 237 100.0 % 0.82 [ 0.53, 1.26 ]
Total events: 49 (Combined OCP), 58 (No Rx)
Heterogeneity: Chi2 = 0.45, df = 2 (P = 0.80); I2 =0.0%
Test for overall effect: Z = 0.91 (P = 0.36)
0.1 0.2 0.5 1 2 5 10
Favours control Favours COCP
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n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
4 COCP + Ant vs Ant, low response
Kim 2005 9/27 6/27 100.0 % 1.72 [ 0.53, 5.60 ]
Subtotal (95% CI) 27 27 100.0 % 1.72 [ 0.53, 5.60 ]
Total events: 9 (Combined OCP), 6 (No Rx)
Heterogeneity: not applicable
Test for overall effect: Z = 0.90 (P = 0.37)
5 COCP + Ant vs Ag, low response
Kim 2005 9/27 7/28 100.0 % 1.49 [ 0.47, 4.71 ]
Subtotal (95% CI) 27 28 100.0 % 1.49 [ 0.47, 4.71 ]
Total events: 9 (Combined OCP), 7 (No Rx)
Heterogeneity: not applicable
Test for overall effect: Z = 0.67 (P = 0.50)
6 COCP + Ag vs Ant, low response
Wang 2008 22/63 18/58 100.0 % 1.19 [ 0.56, 2.53 ]
Subtotal (95% CI) 63 58 100.0 % 1.19 [ 0.56, 2.53 ]
Total events: 22 (Combined OCP), 18 (No Rx)
Heterogeneity: not applicable
Test for overall effect: Z = 0.45 (P = 0.65)
0.1 0.2 0.5 1 2 5 10
Favours control Favours COCP
(1) Numbers calculated from rates; Number of women per group unknown, only number of cycles known.
(2) Data obtained from Dr. C drin-Durnerin.
(3) Ongoing pregnancies.
(4) Ongoing pregnancies. Includes 2 spontaneous pregnancies in the study group and 3 in the control group.
(5) Calculated from rates.
(6) Ongoing pregnancies. Includes 2 spontaneous pregnancies in the study group.
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Analysis 1.4. Comparison 1 Combined OCP versus no Rx, Outcome 4 Oocytes retrieved.
Review: Oral contraceptive pill, progestogen or estrogen pre-treatment for ovarian stimulation protocols for women undergoing assisted reproductive techniques
Comparison: 1 Combined OCP versus no Rx
Outcome: 4 Oocytes retrieved





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 COCP + Ant vs Ant
C drin-Durnerin 2007 21 14 (8.3) 24 9.9 (5.4) 3.5 % 4.10 [ -0.06, 8.26 ]
Huirne 2006b (1) 31 13.5 (6.7) 32 10.2 (6) 6.2 % 3.30 [ 0.16, 6.44 ]
Kolibianakis 2006 (2) 209 12.8 (7.7) 203 13.2 (8.8) 23.9 % -0.40 [ -2.00, 1.20 ]
Obruca 2001 (3) 75 5.8 (3.4) 75 6.3 (3.4) 51.6 % -0.50 [ -1.59, 0.59 ]
Rombauts 2006 (4) 111 13.1 (7.8) 110 11.5 (7.6) 14.8 % 1.60 [ -0.43, 3.63 ]
Subtotal (95% CI) 447 444 100.0 % 0.23 [ -0.55, 1.01 ]
Heterogeneity: Chi2 = 11.07, df = 4 (P = 0.03); I2 =64%
Test for overall effect: Z = 0.58 (P = 0.56)
2 COCP + Ant vs Ag
Huirne 2006a (5) 85 11.4 (7.3) 84 10.9 (10.9) 30.1 % 0.50 [ -2.30, 3.30 ]
Hwang 2004 (6) 25 16.3 (6.4) 24 17.6 (5.9) 19.9 % -1.30 [ -4.74, 2.14 ]
Rombauts 2006 (7) 111 13.1 (7.8) 111 12.9 (8.7) 50.0 % 0.20 [ -1.97, 2.37 ]
Subtotal (95% CI) 221 219 100.0 % -0.01 [ -1.54, 1.53 ]
Heterogeneity: Chi2 = 0.70, df = 2 (P = 0.70); I2 =0.0%
Test for overall effect: Z = 0.01 (P = 0.99)
3 COCP + Ant vs Ant, low response
Kim 2005 27 4.8 (2) 27 4.4 (1.8) 100.0 % 0.40 [ -0.61, 1.41 ]
Subtotal (95% CI) 27 27 100.0 % 0.40 [ -0.61, 1.41 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.77 (P = 0.44)
4 COCP + Ant vs Ag, low response
Kim 2005 27 4.8 (2) 28 4.7 (2.1) 100.0 % 0.10 [ -0.98, 1.18 ]
Subtotal (95% CI) 27 28 100.0 % 0.10 [ -0.98, 1.18 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.18 (P = 0.86)
5 COCP + Ag vs Ant, low response
Wang 2008 (8) 59 4.4 (2.1) 51 5.41 (2.65) 100.0 % -1.01 [ -1.91, -0.11 ]
Subtotal (95% CI) 59 51 100.0 % -1.01 [ -1.91, -0.11 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.19 (P = 0.028)
-4 -2 0 2 4
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(1) No ITT in COCP group.
(2) No ITT. ’Cumulus oocyte complexes’.






Analysis 1.5. Comparison 1 Combined OCP versus no Rx, Outcome 5 Days of gonadotrophin treatment.
Review: Oral contraceptive pill, progestogen or estrogen pre-treatment for ovarian stimulation protocols for women undergoing assisted reproductive techniques
Comparison: 1 Combined OCP versus no Rx
Outcome: 5 Days of gonadotrophin treatment





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 COCP + Ant vs Ant
Huirne 2006b (1) 31 11.6 (2.1) 32 8.7 (1.6) 9.4 % 2.90 [ 1.98, 3.82 ]
Kolibianakis 2006 (2) 209 9.7 (2) 203 9.1 (2) 54.0 % 0.60 [ 0.21, 0.99 ]
Rombauts 2006 (3) 109 11.7 (1.9) 105 9.4 (1.6) 36.5 % 2.30 [ 1.83, 2.77 ]
Subtotal (95% CI) 349 340 100.0 % 1.44 [ 1.15, 1.72 ]
Heterogeneity: Chi2 = 40.62, df = 2 (P<0.00001); I2 =95%
Test for overall effect: Z = 9.92 (P < 0.00001)
2 COCP + Ant vs Ag
Huirne 2006a (4) 90 10.1 (1.8) 85 10.3 (1.6) 44.5 % -0.20 [ -0.70, 0.30 ]
Hwang 2004 (5) 25 9.9 (2.1) 24 10.8 (2.2) 7.8 % -0.90 [ -2.11, 0.31 ]
Rombauts 2006 (6) 109 11.7 (1.9) 101 10.3 (1.7) 47.7 % 1.40 [ 0.91, 1.89 ]
Subtotal (95% CI) 224 210 100.0 % 0.51 [ 0.17, 0.84 ]
Heterogeneity: Chi2 = 25.71, df = 2 (P<0.00001); I2 =92%
Test for overall effect: Z = 2.96 (P = 0.0030)
3 COCP + Ant vs Ant, low response
-4 -2 0 2 4
Favours COCP Favours control
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N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Kim 2005 27 10 (1.4) 27 9.7 (1.4) 100.0 % 0.30 [ -0.45, 1.05 ]
Subtotal (95% CI) 27 27 100.0 % 0.30 [ -0.45, 1.05 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.79 (P = 0.43)
4 COCP + Ant vs Ag, low response
Kim 2005 27 10 (1.4) 28 11.6 (1.7) 100.0 % -1.60 [ -2.42, -0.78 ]
Subtotal (95% CI) 27 28 100.0 % -1.60 [ -2.42, -0.78 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.82 (P = 0.00014)
5 COCP + Ag vs Ant, low response
Wang 2008 59 9.6 (1.9) 51 9.65 (1.6) 100.0 % -0.05 [ -0.70, 0.60 ]
Subtotal (95% CI) 59 51 100.0 % -0.05 [ -0.70, 0.60 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.15 (P = 0.88)
Test for subgroup differences: Chi2 = 63.07, df = 4 (P = 0.00), I2 =94%
-4 -2 0 2 4
Favours COCP Favours control
(1) No ITT in COCP group.
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Analysis 1.6. Comparison 1 Combined OCP versus no Rx, Outcome 6 Amount of gonadotrophins
administered.
Review: Oral contraceptive pill, progestogen or estrogen pre-treatment for ovarian stimulation protocols for women undergoing assisted reproductive techniques
Comparison: 1 Combined OCP versus no Rx
Outcome: 6 Amount of gonadotrophins administered





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 COCP + Ant vs Ant
C drin-Durnerin 2007 21 2174 (723) 24 1734 (551) 3.4 % 440.00 [ 60.24, 819.76 ]
Huirne 2006b (1) 31 2958 (1162) 32 1950 (616) 2.3 % 1008.00 [ 546.62, 1469.38 ]
Kolibianakis 2006 (2) 209 1943 (402) 203 1818 (398) 81.3 % 125.00 [ 47.75, 202.25 ]
Rombauts 2006 (3) 109 2667 (880.7) 105 1965.7 (515.5) 13.1 % 701.30 [ 508.80, 893.80 ]
Subtotal (95% CI) 370 364 100.0 % 231.14 [ 161.50, 300.78 ]
Heterogeneity: Chi2 = 42.22, df = 3 (P<0.00001); I2 =93%
Test for overall effect: Z = 6.50 (P < 0.00001)
2 COCP + Ant vs Ag
Huirne 2006a (4) 90 1919 (638) 85 1949 (773) 49.6 % -30.00 [ -240.66, 180.66 ]
Rombauts 2006 (5) 109 2667 (880.7) 101 2221.8 (655.3) 50.4 % 445.20 [ 236.23, 654.17 ]
Subtotal (95% CI) 199 186 100.0 % 209.52 [ 61.16, 357.87 ]
Heterogeneity: Chi2 = 9.85, df = 1 (P = 0.002); I2 =90%
Test for overall effect: Z = 2.77 (P = 0.0056)
3 COCP + Ant vs Ant, low response
Kim 2005 27 2963.9 (433.1) 27 2931.5 (464.1) 100.0 % 32.40 [ -207.04, 271.84 ]
Subtotal (95% CI) 27 27 100.0 % 32.40 [ -207.04, 271.84 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.27 (P = 0.79)
4 COCP + Ant vs Ag, low response
Kim 2005 27 2963.9 (433.1) 28 3390.2 (443.2) 100.0 % -426.30 [ -657.90, -194.70 ]
Subtotal (95% CI) 27 28 100.0 % -426.30 [ -657.90, -194.70 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.61 (P = 0.00031)
Test for subgroup differences: Chi2 = 29.96, df = 3 (P = 0.00), I2 =90%
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(1) No ITT in COCP group.




Analysis 1.7. Comparison 1 Combined OCP versus no Rx, Outcome 7 Pregnancy losses.
Review: Oral contraceptive pill, progestogen or estrogen pre-treatment for ovarian stimulation protocols for women undergoing assisted reproductive techniques
Comparison: 1 Combined OCP versus no Rx
Outcome: 7 Pregnancy losses





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 COCP + Ant vs Ant
C drin-Durnerin 2007 (1) 2/21 5/24 10.4 % 0.43 [ 0.09, 2.13 ]
Huirne 2006b (2) 4/32 5/32 13.5 % 0.78 [ 0.19, 3.14 ]
Kolibianakis 2006 28/250 16/254 69.3 % 1.85 [ 1.00, 3.43 ]
Rombauts 2006 1/117 3/117 6.8 % 0.36 [ 0.05, 2.61 ]
Subtotal (95% CI) 420 427 100.0 % 1.26 [ 0.76, 2.12 ]
Total events: 35 (Combined OCP), 29 (No Rx)
Heterogeneity: Chi2 = 5.20, df = 3 (P = 0.16); I2 =42%
Test for overall effect: Z = 0.89 (P = 0.37)
2 COCP + Ant vs Ag
Huirne 2006a (3) 8/91 10/91 60.5 % 0.78 [ 0.30, 2.07 ]
Hwang 2004 (4) 1/27 2/29 10.7 % 0.54 [ 0.05, 5.41 ]
Rombauts 2006 1/117 7/117 28.8 % 0.21 [ 0.05, 0.87 ]
Subtotal (95% CI) 235 237 100.0 % 0.52 [ 0.24, 1.10 ]
Total events: 10 (Combined OCP), 19 (No Rx)
Heterogeneity: Chi2 = 2.23, df = 2 (P = 0.33); I2 =10%
Test for overall effect: Z = 1.71 (P = 0.087)
3 COCP + Ant vs Ant, low response
Kim 2005 1/27 1/27 100.0 % 1.00 [ 0.06, 16.42 ]
Subtotal (95% CI) 27 27 100.0 % 1.00 [ 0.06, 16.42 ]
Total events: 1 (Combined OCP), 1 (No Rx)
0.05 0.2 1 5 20
Favours COCP Favours control
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n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
4 COCP + Ant vs Ag, low response
Kim 2005 1/27 1/28 100.0 % 1.04 [ 0.06, 17.04 ]
Subtotal (95% CI) 27 28 100.0 % 1.04 [ 0.06, 17.04 ]
Total events: 1 (Combined OCP), 1 (No Rx)
Heterogeneity: not applicable
Test for overall effect: Z = 0.03 (P = 0.98)
0.05 0.2 1 5 20
Favours COCP Favours control
(1) Calculated from the number of clinical pregnancies minus the number of live births.
(2) Calculated from the number of positive pregnancy tests minus the number of ongoing pregnancies.
(3) Calculated from the number of positive pregnancy tests minus the number of live births.
(4) Calculated from rates.
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Analysis 1.8. Comparison 1 Combined OCP versus no Rx, Outcome 8 Ovarian cyst formation.
Review: Oral contraceptive pill, progestogen or estrogen pre-treatment for ovarian stimulation protocols for women undergoing assisted reproductive techniques
Comparison: 1 Combined OCP versus no Rx
Outcome: 8 Ovarian cyst formation





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 COCP + Ag vs Ag
Biljan 1998a (1) 0/51 27/51 100.0 % 0.07 [ 0.03, 0.16 ]
Subtotal (95% CI) 51 51 100.0 % 0.07 [ 0.03, 0.16 ]
Total events: 0 (Combined OCP), 27 (No Rx)
Heterogeneity: not applicable
Test for overall effect: Z = 6.03 (P < 0.00001)
2 COCP + Ant vs Ant
Huirne 2006b 2/32 4/32 100.0 % 0.48 [ 0.09, 2.57 ]
Subtotal (95% CI) 32 32 100.0 % 0.48 [ 0.09, 2.57 ]
Total events: 2 (Combined OCP), 4 (No Rx)
Heterogeneity: not applicable
Test for overall effect: Z = 0.85 (P = 0.39)
0.001 0.01 0.1 1 10 100 1000
Favours COCP Favours control
(1) Number of women per group unknown, only number of cycles known.
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Analysis 1.9. Comparison 1 Combined OCP versus no Rx, Outcome 9 Multiple pregnancies.
Review: Oral contraceptive pill, progestogen or estrogen pre-treatment for ovarian stimulation protocols for women undergoing assisted reproductive techniques
Comparison: 1 Combined OCP versus no Rx
Outcome: 9 Multiple pregnancies





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 COCP + Ant vs Ant
C drin-Durnerin 2007 (1) 2/21 1/24 100.0 % 2.32 [ 0.23, 23.65 ]
Subtotal (95% CI) 21 24 100.0 % 2.32 [ 0.23, 23.65 ]
Total events: 2 (Combined OCP), 1 (No Rx)
Heterogeneity: not applicable
Test for overall effect: Z = 0.71 (P = 0.48)
2 COCP + Ant vs Ag
Huirne 2006a (2) 6/91 5/91 69.2 % 1.21 [ 0.36, 4.09 ]
Hwang 2004 (3) 2/27 3/29 30.8 % 0.70 [ 0.11, 4.34 ]
Subtotal (95% CI) 118 120 100.0 % 1.02 [ 0.37, 2.82 ]
Total events: 8 (Combined OCP), 8 (No Rx)
Heterogeneity: Chi2 = 0.24, df = 1 (P = 0.62); I2 =0.0%
Test for overall effect: Z = 0.05 (P = 0.96)
3 COCP + Ant vs Ant, low response
Kim 2005 2/27 1/27 100.0 % 2.00 [ 0.20, 20.08 ]
Subtotal (95% CI) 27 27 100.0 % 2.00 [ 0.20, 20.08 ]
Total events: 2 (Combined OCP), 1 (No Rx)
Heterogeneity: not applicable
Test for overall effect: Z = 0.59 (P = 0.56)
4 COCP + Ant vs Ag, low response
Kim 2005 2/27 1/28 100.0 % 2.08 [ 0.21, 20.84 ]
Subtotal (95% CI) 27 28 100.0 % 2.08 [ 0.21, 20.84 ]
Total events: 2 (Combined OCP), 1 (No Rx)
Heterogeneity: not applicable
Test for overall effect: Z = 0.62 (P = 0.53)
0.01 0.1 1 10 100
Favours COCP Favours control
(1) Data obtained from Dr. Griesinger.
(2) ’Multiple clinical pregnancies’.
(3) Data obtained from text. In the study group 2 ongoing. In the control group 1 live birth and 2 ongoing.
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Analysis 1.10. Comparison 1 Combined OCP versus no Rx, Outcome 10 OHS syndrome.
Review: Oral contraceptive pill, progestogen or estrogen pre-treatment for ovarian stimulation protocols for women undergoing assisted reproductive techniques
Comparison: 1 Combined OCP versus no Rx
Outcome: 10 OHS syndrome





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 COCP + Ant vs Ant
Rombauts 2006 3/117 2/117 100.0 % 1.50 [ 0.26, 8.80 ]
Subtotal (95% CI) 117 117 100.0 % 1.50 [ 0.26, 8.80 ]
Total events: 3 (Combined OCP), 2 (No Rx)
Heterogeneity: not applicable
Test for overall effect: Z = 0.45 (P = 0.65)
2 COCP + Ant vs Ag
Hwang 2004 (1) 2/27 2/29 30.3 % 1.08 [ 0.14, 8.11 ]
Rombauts 2006 3/117 6/117 69.7 % 0.50 [ 0.13, 1.90 ]
Subtotal (95% CI) 144 146 100.0 % 0.63 [ 0.21, 1.92 ]
Total events: 5 (Combined OCP), 8 (No Rx)
Heterogeneity: Chi2 = 0.39, df = 1 (P = 0.53); I2 =0.0%
Test for overall effect: Z = 0.81 (P = 0.42)
0.01 0.1 1 10 100
Favours COCP Favours control
(1) Calculated from rates.
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Analysis 2.1. Comparison 2 Progestogen versus placebo/ no Rx, Outcome 1 Live births.
Review: Oral contraceptive pill, progestogen or estrogen pre-treatment for ovarian stimulation protocols for women undergoing assisted reproductive techniques
Comparison: 2 Progestogen versus placebo/ no Rx
Outcome: 1 Live births





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 Prog + Ag vs Ag
Ditkoff 1996 8/47 11/58 44.8 % 0.88 [ 0.32, 2.37 ]
Engmann 1999 16/63 8/54 55.2 % 1.90 [ 0.78, 4.66 ]
Subtotal (95% CI) 110 112 100.0 % 1.35 [ 0.69, 2.62 ]
Total events: 24 (Progestogen), 19 (Placebo/ no Rx)
Heterogeneity: Chi2 = 1.28, df = 1 (P = 0.26); I2 =22%
Test for overall effect: Z = 0.87 (P = 0.38)
2 Prog + Ant vs Ant
C drin-Durnerin 2007 (1) 5/23 7/24 100.0 % 0.68 [ 0.19, 2.50 ]
Subtotal (95% CI) 23 24 100.0 % 0.68 [ 0.19, 2.50 ]
Total events: 5 (Progestogen), 7 (Placebo/ no Rx)
Heterogeneity: not applicable
Test for overall effect: Z = 0.58 (P = 0.56)
0.02 0.1 1 10 50
Favours control Favours progestogen
(1) Data obtained from Dr. Griesinger.
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Analysis 2.2. Comparison 2 Progestogen versus placebo/ no Rx, Outcome 2 Ongoing pregnancies.
Review: Oral contraceptive pill, progestogen or estrogen pre-treatment for ovarian stimulation protocols for women undergoing assisted reproductive techniques
Comparison: 2 Progestogen versus placebo/ no Rx
Outcome: 2 Ongoing pregnancies





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 Prog + Ag vs Ag
Ditkoff 1996 (1) 11/47 12/58 100.0 % 1.17 [ 0.46, 2.95 ]
Subtotal (95% CI) 47 58 100.0 % 1.17 [ 0.46, 2.95 ]
Total events: 11 (Progestogen), 12 (Placebo/ no Rx)
Heterogeneity: not applicable
Test for overall effect: Z = 0.33 (P = 0.74)
2 Prog + Ant vs Ant
C drin-Durnerin 2007 5/23 7/24 100.0 % 0.68 [ 0.19, 2.50 ]
Subtotal (95% CI) 23 24 100.0 % 0.68 [ 0.19, 2.50 ]
Total events: 5 (Progestogen), 7 (Placebo/ no Rx)
Heterogeneity: not applicable
Test for overall effect: Z = 0.58 (P = 0.56)
3 Prog + Gon vs Gon
Salat-Baroux 1988 (2) 2/21 3/21 100.0 % 0.64 [ 0.10, 4.06 ]
Subtotal (95% CI) 21 21 100.0 % 0.64 [ 0.10, 4.06 ]
Total events: 2 (Progestogen), 3 (Placebo/ no Rx)
Heterogeneity: not applicable
Test for overall effect: Z = 0.47 (P = 0.64)
0.02 0.1 1 10 50
Favours control Favours progestogen
(1) Data obtained from Dr. Ditkoff.
(2) Data obtained from text.
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Analysis 2.3. Comparison 2 Progestogen versus placebo/ no Rx, Outcome 3 Clinical pregnancies.
Review: Oral contraceptive pill, progestogen or estrogen pre-treatment for ovarian stimulation protocols for women undergoing assisted reproductive techniques
Comparison: 2 Progestogen versus placebo/ no Rx
Outcome: 3 Clinical pregnancies





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 Prog + Ag vs Ag
Aston 1995 (1) 22/77 10/75 39.0 % 2.49 [ 1.14, 5.41 ]
Ditkoff 1996 11/47 12/58 27.5 % 1.17 [ 0.46, 2.95 ]
Engmann 1999 (2) 20/63 9/54 33.5 % 2.23 [ 0.96, 5.16 ]
Subtotal (95% CI) 187 187 100.0 % 1.95 [ 1.20, 3.17 ]
Total events: 53 (Progestogen), 31 (Placebo/ no Rx)
Heterogeneity: Chi2 = 1.64, df = 2 (P = 0.44); I2 =0.0%
Test for overall effect: Z = 2.69 (P = 0.0071)
2 Prog + Ant vs Ant
C drin-Durnerin 2007 (3) 7/23 11/24 100.0 % 0.53 [ 0.17, 1.69 ]
Subtotal (95% CI) 23 24 100.0 % 0.53 [ 0.17, 1.69 ]
Total events: 7 (Progestogen), 11 (Placebo/ no Rx)
Heterogeneity: not applicable
Test for overall effect: Z = 1.07 (P = 0.28)
3 Prog + Gon vs Gon
Salat-Baroux 1988 3/21 4/21 100.0 % 0.72 [ 0.14, 3.56 ]
Subtotal (95% CI) 21 21 100.0 % 0.72 [ 0.14, 3.56 ]
Total events: 3 (Progestogen), 4 (Placebo/ no Rx)
Heterogeneity: not applicable
Test for overall effect: Z = 0.41 (P = 0.68)
0.05 0.2 1 5 20
Favours control Favours progestogen
(1) Numbers calculated from rates.
(2) Positive pregnancy test.
(3) Data obtained from Dr. C drin-Durnerin.
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Analysis 2.4. Comparison 2 Progestogen versus placebo/ no Rx, Outcome 4 Oocytes retrieved.
Review: Oral contraceptive pill, progestogen or estrogen pre-treatment for ovarian stimulation protocols for women undergoing assisted reproductive techniques
Comparison: 2 Progestogen versus placebo/ no Rx
Outcome: 4 Oocytes retrieved





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Prog + Ag vs Ag
Ditkoff 1996 (1) 41 13.8 (7.6) 53 12.8 (8.9) 22.0 % 1.00 [ -2.34, 4.34 ]
Engmann 1999 (2) 62 8.4 (4.7) 54 9.4 (5) 78.0 % -1.00 [ -2.77, 0.77 ]
Subtotal (95% CI) 103 107 100.0 % -0.56 [ -2.13, 1.01 ]
Heterogeneity: Chi2 = 1.07, df = 1 (P = 0.30); I2 =7%
Test for overall effect: Z = 0.70 (P = 0.48)
2 Prog + Ant vs Ant
C drin-Durnerin 2007 23 12.6 (7.3) 24 9.9 (5.4) 100.0 % 2.70 [ -0.98, 6.38 ]
Subtotal (95% CI) 23 24 100.0 % 2.70 [ -0.98, 6.38 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.44 (P = 0.15)
3 Prog + Gon vs Gon
Salat-Baroux 1988 (3) 13 4.9 (0.9) 16 4.9 (0.6) 100.0 % 0.0 [ -0.57, 0.57 ]
Subtotal (95% CI) 13 16 100.0 % 0.0 [ -0.57, 0.57 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Test for subgroup differences: Chi2 = 2.55, df = 2 (P = 0.28), I2 =22%
-10 -5 0 5 10
Favours control Favours progestogen
(1) No ITT.
(2) No ITT in progestogen group. ’Mature oocytes’.
(3) No ITT.
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Analysis 2.5. Comparison 2 Progestogen versus placebo/ no Rx, Outcome 5 Days of gonadotrophin
treatment.
Review: Oral contraceptive pill, progestogen or estrogen pre-treatment for ovarian stimulation protocols for women undergoing assisted reproductive techniques
Comparison: 2 Progestogen versus placebo/ no Rx
Outcome: 5 Days of gonadotrophin treatment





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Prog + Ag vs Ag
Ditkoff 1996 (1) 41 11.8 (1.5) 53 11.1 (1.5) 48.0 % 0.70 [ 0.09, 1.31 ]
Engmann 1999 (2) 62 11.2 (1.5) 54 11.7 (1.7) 52.0 % -0.50 [ -1.09, 0.09 ]
Subtotal (95% CI) 103 107 100.0 % 0.08 [ -0.35, 0.50 ]
Heterogeneity: Chi2 = 7.69, df = 1 (P = 0.01); I2 =87%
Test for overall effect: Z = 0.35 (P = 0.73)
Test for subgroup differences: Not applicable
-1 -0.5 0 0.5 1
Favours progestogen Favours control
(1) No ITT.
(2) No ITT in progestogen group.
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Analysis 2.6. Comparison 2 Progestogen versus placebo/ no Rx, Outcome 6 Amount of gonadotrophins
administered.
Review: Oral contraceptive pill, progestogen or estrogen pre-treatment for ovarian stimulation protocols for women undergoing assisted reproductive techniques
Comparison: 2 Progestogen versus placebo/ no Rx
Outcome: 6 Amount of gonadotrophins administered





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Prog + Ant vs Ant
C drin-Durnerin 2007 23 2010 (670) 24 1734 (551) 100.0 % 276.00 [ -75.53, 627.53 ]
Subtotal (95% CI) 23 24 100.0 % 276.00 [ -75.53, 627.53 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.54 (P = 0.12)
-1000 -500 0 500 1000
Favours progestogen Favours control
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Analysis 2.7. Comparison 2 Progestogen versus placebo/ no Rx, Outcome 7 Pregnancy losses.
Review: Oral contraceptive pill, progestogen or estrogen pre-treatment for ovarian stimulation protocols for women undergoing assisted reproductive techniques
Comparison: 2 Progestogen versus placebo/ no Rx
Outcome: 7 Pregnancy losses





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 Prog + Ag vs Ag
Ditkoff 1996 (1) 3/47 1/58 31.6 % 3.52 [ 0.48, 26.03 ]
Engmann 1999 6/63 3/54 68.4 % 1.74 [ 0.45, 6.77 ]
Subtotal (95% CI) 110 112 100.0 % 2.17 [ 0.71, 6.69 ]
Total events: 9 (Progestogen), 4 (Placebo/ no Rx)
Heterogeneity: Chi2 = 0.33, df = 1 (P = 0.57); I2 =0.0%
Test for overall effect: Z = 1.35 (P = 0.18)
2 Prog + Ant vs Ant
C drin-Durnerin 2007 (2) 2/23 5/24 100.0 % 0.39 [ 0.08, 1.92 ]
Subtotal (95% CI) 23 24 100.0 % 0.39 [ 0.08, 1.92 ]
Total events: 2 (Progestogen), 5 (Placebo/ no Rx)
Heterogeneity: not applicable
Test for overall effect: Z = 1.16 (P = 0.25)
3 Prog + Gon vs Gon
Salat-Baroux 1988 (3) 1/21 1/21 100.0 % 1.00 [ 0.06, 16.55 ]
Subtotal (95% CI) 21 21 100.0 % 1.00 [ 0.06, 16.55 ]
Total events: 1 (Progestogen), 1 (Placebo/ no Rx)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
0.01 0.1 1 10 100
Favours progestogen Favours control
(1) Calculated from the number of clinical pregnancies minus the number of live births.
(2) Calculated from the number of clinical pregnancies minus the number of live births.
(3) Data obtained from text, not sure whether follow up was long enough.
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Analysis 2.8. Comparison 2 Progestogen versus placebo/ no Rx, Outcome 8 Ovarian cyst formation.
Review: Oral contraceptive pill, progestogen or estrogen pre-treatment for ovarian stimulation protocols for women undergoing assisted reproductive techniques
Comparison: 2 Progestogen versus placebo/ no Rx
Outcome: 8 Ovarian cyst formation





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 Prog + Ag vs Ag
Aston 1995 (1) 5/77 16/75 34.9 % 0.29 [ 0.12, 0.73 ]
Ditkoff 1996 (2) 3/47 15/58 28.5 % 0.26 [ 0.09, 0.71 ]
Engmann 1999 (3) 3/63 21/54 36.6 % 0.13 [ 0.05, 0.31 ]
Subtotal (95% CI) 187 187 100.0 % 0.21 [ 0.12, 0.35 ]
Total events: 11 (Progestogen), 52 (Placebo/ no Rx)
Heterogeneity: Chi2 = 1.89, df = 2 (P = 0.39); I2 =0.0%
Test for overall effect: Z = 5.71 (P < 0.00001)
0.01 0.1 1 10 100
Favours progestogen Favours control
(1) Measured after 12 days of pituitary suppression.
(2) Measured after 8 days of pituitary suppression.
(3) Measured after 7 days of pituitary suppression.
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Analysis 2.9. Comparison 2 Progestogen versus placebo/ no Rx, Outcome 9 Multiple pregnancies.
Review: Oral contraceptive pill, progestogen or estrogen pre-treatment for ovarian stimulation protocols for women undergoing assisted reproductive techniques
Comparison: 2 Progestogen versus placebo/ no Rx
Outcome: 9 Multiple pregnancies





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 Prog + Ant vs Ant
C drin-Durnerin 2007 1/23 1/24 100.0 % 1.04 [ 0.06, 17.23 ]
Subtotal (95% CI) 23 24 100.0 % 1.04 [ 0.06, 17.23 ]
Total events: 1 (Progestogen), 1 (Placebo/ no Rx)
Heterogeneity: not applicable
Test for overall effect: Z = 0.03 (P = 0.98)
Test for subgroup differences: Not applicable
0.02 0.1 1 10 50
Favours progestogen Favours control
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Analysis 3.1. Comparison 3 Estrogen versus no Rx, Outcome 1 Live births.
Review: Oral contraceptive pill, progestogen or estrogen pre-treatment for ovarian stimulation protocols for women undergoing assisted reproductive techniques
Comparison: 3 Estrogen versus no Rx
Outcome: 1 Live births





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 Estr + Ant vs Ant
C drin-Durnerin 2007 (1) 3/25 7/24 100.0 % 0.36 [ 0.09, 1.41 ]
Subtotal (95% CI) 25 24 100.0 % 0.36 [ 0.09, 1.41 ]
Total events: 3 (Estrogen), 7 (No Rx)
Heterogeneity: not applicable
Test for overall effect: Z = 1.48 (P = 0.14)
2 Estr + Ant vs Ag
Franco Jr 2003 (2) 5/16 2/6 100.0 % 0.91 [ 0.13, 6.53 ]
Subtotal (95% CI) 16 6 100.0 % 0.91 [ 0.13, 6.53 ]
Total events: 5 (Estrogen), 2 (No Rx)
Heterogeneity: not applicable
Test for overall effect: Z = 0.09 (P = 0.93)
0.005 0.1 1 10 200
Favours control Favours estrogen
(1) Data obtained from Dr. Griesinger.
(2) Includes 2 spontaneous pregnancies in the study group. Data obtained from Dr. Franco Jr.
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Analysis 3.2. Comparison 3 Estrogen versus no Rx, Outcome 2 Ongoing pregnancies.
Review: Oral contraceptive pill, progestogen or estrogen pre-treatment for ovarian stimulation protocols for women undergoing assisted reproductive techniques
Comparison: 3 Estrogen versus no Rx
Outcome: 2 Ongoing pregnancies





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 Estr + Ant vs Ant
C drin-Durnerin 2007 (1) 3/25 7/24 100.0 % 0.36 [ 0.09, 1.41 ]
Subtotal (95% CI) 25 24 100.0 % 0.36 [ 0.09, 1.41 ]
Total events: 3 (Estrogen), 7 (No Rx)
Heterogeneity: not applicable
Test for overall effect: Z = 1.48 (P = 0.14)
2 Estr + Ant vs Ag
Franco Jr 2003 (2) 5/16 2/6 100.0 % 0.91 [ 0.13, 6.53 ]
Subtotal (95% CI) 16 6 100.0 % 0.91 [ 0.13, 6.53 ]
Total events: 5 (Estrogen), 2 (No Rx)
Heterogeneity: not applicable
Test for overall effect: Z = 0.09 (P = 0.93)
0.01 0.1 1 10 100
Favours control Favours estrogen
(1) Data obtained from Dr. C drin-Durnerin.
(2) Includes 2 spontaneous pregnancies in the study group.
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Analysis 3.3. Comparison 3 Estrogen versus no Rx, Outcome 3 Clinical pregnancies.
Review: Oral contraceptive pill, progestogen or estrogen pre-treatment for ovarian stimulation protocols for women undergoing assisted reproductive techniques
Comparison: 3 Estrogen versus no Rx
Outcome: 3 Clinical pregnancies





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 Estr + Ant vs Ant
C drin-Durnerin 2007 (1) 4/25 11/24 35.8 % 0.25 [ 0.08, 0.84 ]
Fanchin 2003a (2) 16/47 11/43 64.2 % 1.49 [ 0.61, 3.65 ]
Subtotal (95% CI) 72 67 100.0 % 0.79 [ 0.38, 1.62 ]
Total events: 20 (Estrogen), 22 (No Rx)
Heterogeneity: Chi2 = 5.37, df = 1 (P = 0.02); I2 =81%
Test for overall effect: Z = 0.64 (P = 0.52)
2 Estr + Ant vs Ag
Franco Jr 2003 (3) 5/16 2/6 100.0 % 0.91 [ 0.13, 6.53 ]
Subtotal (95% CI) 16 6 100.0 % 0.91 [ 0.13, 6.53 ]
Total events: 5 (Estrogen), 2 (No Rx)
Heterogeneity: not applicable
Test for overall effect: Z = 0.09 (P = 0.93)
0.005 0.1 1 10 200
Favours control Favours estrogen
(1) Data obtained from Dr. C drin-Durnerin.
(2) No ITT. Calculated from rates.
(3) Includes 2 spontaneous pregnancies in the study group.
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Analysis 3.4. Comparison 3 Estrogen versus no Rx, Outcome 4 Oocytes retrieved.
Review: Oral contraceptive pill, progestogen or estrogen pre-treatment for ovarian stimulation protocols for women undergoing assisted reproductive techniques
Comparison: 3 Estrogen versus no Rx
Outcome: 4 Oocytes retrieved





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Estr + Ant vs Ant
C drin-Durnerin 2007 (1) 22 13.1 (7) 24 9.9 (5.4) 0.5 % 3.20 [ -0.44, 6.84 ]
Fanchin 2003a (2) 47 9.3 (0.7) 43 7.3 (0.5) 99.5 % 2.00 [ 1.75, 2.25 ]
Subtotal (95% CI) 69 67 100.0 % 2.01 [ 1.76, 2.25 ]
Heterogeneity: Chi2 = 0.42, df = 1 (P = 0.52); I2 =0.0%
Test for overall effect: Z = 15.78 (P < 0.00001)
2 Estr + Ant vs Ag
Franco Jr 2003 (3) 14 10.5 (6.5) 6 10.1 (4.6) 100.0 % 0.40 [ -4.61, 5.41 ]
Subtotal (95% CI) 14 6 100.0 % 0.40 [ -4.61, 5.41 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.16 (P = 0.88)
Test for subgroup differences: Chi2 = 0.39, df = 1 (P = 0.53), I2 =0.0%
-4 -2 0 2 4
Favours control Favours estrogen
(1) No ITT in estrogen group.
(2) No ITT. ’Mature follicles’.
(3) No ITT.
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Analysis 3.5. Comparison 3 Estrogen versus no Rx, Outcome 5 Days of gonadotrophin treatment.
Review: Oral contraceptive pill, progestogen or estrogen pre-treatment for ovarian stimulation protocols for women undergoing assisted reproductive techniques
Comparison: 3 Estrogen versus no Rx
Outcome: 5 Days of gonadotrophin treatment





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Estr + Ant vs Ag
Franco Jr 2003 (1) 14 10.3 (1.6) 6 12.8 (1.7) 100.0 % -2.50 [ -4.10, -0.90 ]
Subtotal (95% CI) 14 6 100.0 % -2.50 [ -4.10, -0.90 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.07 (P = 0.0022)
-100 -50 0 50 100
Favours estrogen Favours control
(1) No ITT. Data obtained from Dr. Franco Jr.
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Analysis 3.6. Comparison 3 Estrogen versus no Rx, Outcome 6 Amount of gonadotrophins administered.
Review: Oral contraceptive pill, progestogen or estrogen pre-treatment for ovarian stimulation protocols for women undergoing assisted reproductive techniques
Comparison: 3 Estrogen versus no Rx
Outcome: 6 Amount of gonadotrophins administered





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Estr + Ant vs Ant
C drin-Durnerin 2007 (1) 22 1700 (524) 24 1734 (551) 1.6 % -34.00 [ -344.71, 276.71 ]
Fanchin 2003a (2) 47 2674 (91) 43 2463 (100) 98.4 % 211.00 [ 171.37, 250.63 ]
Subtotal (95% CI) 69 67 100.0 % 207.08 [ 167.77, 246.39 ]
Heterogeneity: Chi2 = 2.35, df = 1 (P = 0.13); I2 =57%
Test for overall effect: Z = 10.33 (P < 0.00001)
2 Estr + Ant vs Ag
Franco Jr 2003 (3) 14 2500 (484) 6 2516 (484) 100.0 % -16.00 [ -478.88, 446.88 ]
Subtotal (95% CI) 14 6 100.0 % -16.00 [ -478.88, 446.88 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.07 (P = 0.95)
Test for subgroup differences: Chi2 = 0.89, df = 1 (P = 0.35), I2 =0.0%
-1000 -500 0 500 1000
Favours estrogen Favours control
(1) No ITT in estrogen group.
(2) No ITT.
(3) No ITT.
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Analysis 3.7. Comparison 3 Estrogen versus no Rx, Outcome 7 Pregnancy losses.
Review: Oral contraceptive pill, progestogen or estrogen pre-treatment for ovarian stimulation protocols for women undergoing assisted reproductive techniques
Comparison: 3 Estrogen versus no Rx
Outcome: 7 Pregnancy losses





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 Estr + Ant vs Ant
C drin-Durnerin 2007 (1) 1/25 5/24 0.22 [ 0.04, 1.17 ]
Subtotal (95% CI) 25 24 0.22 [ 0.04, 1.17 ]
Total events: 1 (Estrogen), 5 (No Rx)
Heterogeneity: not applicable
Test for overall effect: Z = 1.78 (P = 0.075)
2 Estr + Ant vs Ag
Franco Jr 2003 0/16 0/6 0.0 [ 0.0, 0.0 ]
Subtotal (95% CI) 16 6 0.0 [ 0.0, 0.0 ]
Total events: 0 (Estrogen), 0 (No Rx)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
0.01 0.1 1 10 100
Favours estrogen Favours control
(1) Calculated from the number of clinical pregnancies minus the number of live births.
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Analysis 3.8. Comparison 3 Estrogen versus no Rx, Outcome 8 Ovarian cyst formation.
Review: Oral contraceptive pill, progestogen or estrogen pre-treatment for ovarian stimulation protocols for women undergoing assisted reproductive techniques
Comparison: 3 Estrogen versus no Rx
Outcome: 8 Ovarian cyst formation





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 Estr + Ant vs Ag
Franco Jr 2003 (1) 0/16 0/6 0.0 [ 0.0, 0.0 ]
Subtotal (95% CI) 16 6 0.0 [ 0.0, 0.0 ]
Total events: 0 (Estrogen), 0 (No Rx)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
0.01 0.1 1 10 100
Favours estrogen Favours control
(1) Data obtained from Dr. Franco Jr.
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Analysis 3.9. Comparison 3 Estrogen versus no Rx, Outcome 9 Multiple pregnancies.
Review: Oral contraceptive pill, progestogen or estrogen pre-treatment for ovarian stimulation protocols for women undergoing assisted reproductive techniques
Comparison: 3 Estrogen versus no Rx
Outcome: 9 Multiple pregnancies





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 Estr + Ant vs Ant
C drin-Durnerin 2007 0/25 1/24 100.0 % 0.13 [ 0.00, 6.55 ]
Subtotal (95% CI) 25 24 100.0 % 0.13 [ 0.00, 6.55 ]
Total events: 0 (Estrogen), 1 (No Rx)
Heterogeneity: not applicable
Test for overall effect: Z = 1.02 (P = 0.31)
2 Estr + Ant vs Ag
Franco Jr 2003 (1) 2/14 0/6 100.0 % 4.52 [ 0.20, 101.00 ]
Subtotal (95% CI) 14 6 100.0 % 4.52 [ 0.20, 101.00 ]
Total events: 2 (Estrogen), 0 (No Rx)
Heterogeneity: not applicable
Test for overall effect: Z = 0.95 (P = 0.34)
0.01 0.1 1 10 100
Favours estrogen Favours control
(1) No ITT. Data obtained from Dr. Franco Jr.
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Analysis 3.10. Comparison 3 Estrogen versus no Rx, Outcome 10 OHS syndrome.
Review: Oral contraceptive pill, progestogen or estrogen pre-treatment for ovarian stimulation protocols for women undergoing assisted reproductive techniques
Comparison: 3 Estrogen versus no Rx
Outcome: 10 OHS syndrome





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 Estr + Ant vs Ag
Franco Jr 2003 (1) 0/16 0/6 0.0 [ 0.0, 0.0 ]
Subtotal (95% CI) 16 6 0.0 [ 0.0, 0.0 ]
Total events: 0 (Estrogen), 0 (No Rx)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
0.01 0.1 1 10 100
Favours estrogen Favours control
(1) Data obtained from Dr. Franco Jr.
Analysis 4.1. Comparison 4 Combined OCP versus progestogen, Outcome 1 Live births.
Review: Oral contraceptive pill, progestogen or estrogen pre-treatment for ovarian stimulation protocols for women undergoing assisted reproductive techniques
Comparison: 4 Combined OCP versus progestogen
Outcome: 1 Live births





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 COCP + Ant vs Prog + Ant
C drin-Durnerin 2007 3/21 5/23 100.0 % 0.61 [ 0.13, 2.79 ]
Subtotal (95% CI) 21 23 100.0 % 0.61 [ 0.13, 2.79 ]
Total events: 3 (Combined OCP), 5 (Progestogen)
Heterogeneity: not applicable
Test for overall effect: Z = 0.63 (P = 0.53)
0.002 0.1 1 10 500
Favours progestogen Favours COCP
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Analysis 4.2. Comparison 4 Combined OCP versus progestogen, Outcome 2 Ongoing pregnancies.
Review: Oral contraceptive pill, progestogen or estrogen pre-treatment for ovarian stimulation protocols for women undergoing assisted reproductive techniques
Comparison: 4 Combined OCP versus progestogen
Outcome: 2 Ongoing pregnancies





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 COCP + Ant vs Prog + Ant
C drin-Durnerin 2007 (1) 3/21 5/23 100.0 % 0.61 [ 0.13, 2.79 ]
Subtotal (95% CI) 21 23 100.0 % 0.61 [ 0.13, 2.79 ]
Total events: 3 (Combined OCP), 5 (Progestogen)
Heterogeneity: not applicable
Test for overall effect: Z = 0.63 (P = 0.53)
0.01 0.1 1 10 100
Favours progestogen Favours COCP
(1) Data obtained from Dr. C drin-Durnerin.
Analysis 4.3. Comparison 4 Combined OCP versus progestogen, Outcome 3 Clinical pregnancies.
Review: Oral contraceptive pill, progestogen or estrogen pre-treatment for ovarian stimulation protocols for women undergoing assisted reproductive techniques
Comparison: 4 Combined OCP versus progestogen
Outcome: 3 Clinical pregnancies





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 COCP + Ant vs Prog + Ant
C drin-Durnerin 2007 (1) 5/21 7/23 100.0 % 0.72 [ 0.19, 2.68 ]
Subtotal (95% CI) 21 23 100.0 % 0.72 [ 0.19, 2.68 ]
Total events: 5 (Combined OCP), 7 (Progestogen)
Heterogeneity: not applicable
Test for overall effect: Z = 0.49 (P = 0.63)
0.01 0.1 1 10 100
Favours progestogen Favours COCP
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(1) Data obtained from Dr. C drin-Durnerin.
Analysis 4.4. Comparison 4 Combined OCP versus progestogen, Outcome 4 Oocytes retrieved.
Review: Oral contraceptive pill, progestogen or estrogen pre-treatment for ovarian stimulation protocols for women undergoing assisted reproductive techniques
Comparison: 4 Combined OCP versus progestogen
Outcome: 4 Oocytes retrieved





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 COCP + Ant vs Prog + Ant
C drin-Durnerin 2007 21 14 (8.3) 23 12.6 (7.3) 100.0 % 1.40 [ -3.24, 6.04 ]
Subtotal (95% CI) 21 23 100.0 % 1.40 [ -3.24, 6.04 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.59 (P = 0.55)
Test for subgroup differences: Not applicable
-4 -2 0 2 4
Favours progestogen Favours COCP
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Analysis 4.5. Comparison 4 Combined OCP versus progestogen, Outcome 5 Amount of gonadotrophins
administered.
Review: Oral contraceptive pill, progestogen or estrogen pre-treatment for ovarian stimulation protocols for women undergoing assisted reproductive techniques
Comparison: 4 Combined OCP versus progestogen
Outcome: 5 Amount of gonadotrophins administered





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 COCP + Ant vs Prog + Ant
C drin-Durnerin 2007 21 2174 (723) 23 2010 (670) 100.0 % 164.00 [ -249.03, 577.03 ]
Subtotal (95% CI) 21 23 100.0 % 164.00 [ -249.03, 577.03 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.78 (P = 0.44)
Test for subgroup differences: Not applicable
-500 -250 0 250 500
Favours COCP Favours progestogen
Analysis 4.6. Comparison 4 Combined OCP versus progestogen, Outcome 6 Pregnancy losses.
Review: Oral contraceptive pill, progestogen or estrogen pre-treatment for ovarian stimulation protocols for women undergoing assisted reproductive techniques
Comparison: 4 Combined OCP versus progestogen
Outcome: 6 Pregnancy losses





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 COCP + Ant vs Prog + Ant
C drin-Durnerin 2007 (1) 2/21 2/23 100.0 % 1.10 [ 0.14, 8.43 ]
Subtotal (95% CI) 21 23 100.0 % 1.10 [ 0.14, 8.43 ]
Total events: 2 (Combined OCP), 2 (Progestogen)
Heterogeneity: not applicable
Test for overall effect: Z = 0.09 (P = 0.92)
0.1 0.2 0.5 1 2 5 10
Favours COCP Favours progestogen
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(1) Calculated from the number of clinical pregnancies minus the number of live births.
Analysis 4.7. Comparison 4 Combined OCP versus progestogen, Outcome 7 Multiple pregnancies.
Review: Oral contraceptive pill, progestogen or estrogen pre-treatment for ovarian stimulation protocols for women undergoing assisted reproductive techniques
Comparison: 4 Combined OCP versus progestogen
Outcome: 7 Multiple pregnancies





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 COCP + Ant vs Prog + Ant
C drin-Durnerin 2007 2/21 1/23 100.0 % 2.22 [ 0.22, 22.56 ]
Subtotal (95% CI) 21 23 100.0 % 2.22 [ 0.22, 22.56 ]
Total events: 2 (Combined OCP), 1 (Progestogen)
Heterogeneity: not applicable
Test for overall effect: Z = 0.67 (P = 0.50)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours COCP Favours progestogen
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Analysis 5.1. Comparison 5 Combined OCP versus estrogen, Outcome 1 Live births.
Review: Oral contraceptive pill, progestogen or estrogen pre-treatment for ovarian stimulation protocols for women undergoing assisted reproductive techniques
Comparison: 5 Combined OCP versus estrogen
Outcome: 1 Live births





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 COCP + Ant vs Estr + Ant
C drin-Durnerin 2007 3/21 3/25 100.0 % 1.22 [ 0.22, 6.69 ]
Subtotal (95% CI) 21 25 100.0 % 1.22 [ 0.22, 6.69 ]
Total events: 3 (Combined OCP), 3 (Estrogen)
Heterogeneity: not applicable
Test for overall effect: Z = 0.23 (P = 0.82)
0.05 0.2 1 5 20
Favours estrogen Favours COCP
125Oral contraceptive pill, progestogen or estrogen pre-treatment for ovarian stimulation protocols for women undergoing assisted
reproductive techniques (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 5.2. Comparison 5 Combined OCP versus estrogen, Outcome 2 Ongoing pregnancies.
Review: Oral contraceptive pill, progestogen or estrogen pre-treatment for ovarian stimulation protocols for women undergoing assisted reproductive techniques
Comparison: 5 Combined OCP versus estrogen
Outcome: 2 Ongoing pregnancies





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 COCP + Ant vs Estr + Ant
C drin-Durnerin 2007 (1) 3/21 3/25 100.0 % 1.22 [ 0.22, 6.69 ]
Subtotal (95% CI) 21 25 100.0 % 1.22 [ 0.22, 6.69 ]
Total events: 3 (Combined OCP), 3 (Estrogen)
Heterogeneity: not applicable
Test for overall effect: Z = 0.23 (P = 0.82)
2 COCP + Ag vs Estr + Ant
Daly 2002 (2) 1/12 7/13 100.0 % 0.13 [ 0.03, 0.70 ]
Subtotal (95% CI) 12 13 100.0 % 0.13 [ 0.03, 0.70 ]
Total events: 1 (Combined OCP), 7 (Estrogen)
Heterogeneity: not applicable
Test for overall effect: Z = 2.39 (P = 0.017)
0.01 0.1 1 10 100
Favours estrogen Favours COCP
(1) Data obtained from Dr. C drin-Durnerin.
(2) Viable pregnancies
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Analysis 5.3. Comparison 5 Combined OCP versus estrogen, Outcome 3 Clinical pregnancies.
Review: Oral contraceptive pill, progestogen or estrogen pre-treatment for ovarian stimulation protocols for women undergoing assisted reproductive techniques
Comparison: 5 Combined OCP versus estrogen
Outcome: 3 Clinical pregnancies





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 COCP + Ant vs Estr + Ant
C drin-Durnerin 2007 (1) 5/21 4/25 100.0 % 1.62 [ 0.38, 6.90 ]
Subtotal (95% CI) 21 25 100.0 % 1.62 [ 0.38, 6.90 ]
Total events: 5 (Combined OCP), 4 (Estrogen)
Heterogeneity: not applicable
Test for overall effect: Z = 0.66 (P = 0.51)
2 COCP + Ag vs Estr + Ant
Daly 2002 2/12 8/13 100.0 % 0.17 [ 0.03, 0.80 ]
Subtotal (95% CI) 12 13 100.0 % 0.17 [ 0.03, 0.80 ]
Total events: 2 (Combined OCP), 8 (Estrogen)
Heterogeneity: not applicable
Test for overall effect: Z = 2.24 (P = 0.025)
0.01 0.1 1 10 100
Favours estrogen Favours COCP
(1) Data obtained from Dr. C drin-Durnerin.
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Analysis 5.4. Comparison 5 Combined OCP versus estrogen, Outcome 4 Oocytes retrieved.
Review: Oral contraceptive pill, progestogen or estrogen pre-treatment for ovarian stimulation protocols for women undergoing assisted reproductive techniques
Comparison: 5 Combined OCP versus estrogen
Outcome: 4 Oocytes retrieved





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 COCP + Ant vs Estr + Ant
C drin-Durnerin 2007 (1) 21 14 (8.3) 22 13.1 (7) 100.0 % 0.90 [ -3.70, 5.50 ]
Subtotal (95% CI) 21 22 100.0 % 0.90 [ -3.70, 5.50 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.38 (P = 0.70)
-10 -5 0 5 10
Favours estrogen Favours COCP
(1) No ITT in estrogen group.
Analysis 5.5. Comparison 5 Combined OCP versus estrogen, Outcome 5 Amount of gonadotrophins
administered.
Review: Oral contraceptive pill, progestogen or estrogen pre-treatment for ovarian stimulation protocols for women undergoing assisted reproductive techniques
Comparison: 5 Combined OCP versus estrogen
Outcome: 5 Amount of gonadotrophins administered





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 COCP + Ant vs Estr + Ant
C drin-Durnerin 2007 (1) 21 2174 (723) 22 1700 (524) 100.0 % 474.00 [ 95.10, 852.90 ]
Subtotal (95% CI) 21 22 100.0 % 474.00 [ 95.10, 852.90 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.45 (P = 0.014)
-1000 -500 0 500 1000
Favours COCP Favours estrogen
(1) No ITT in estrogen group
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Analysis 5.6. Comparison 5 Combined OCP versus estrogen, Outcome 6 Pregnancy losses.
Review: Oral contraceptive pill, progestogen or estrogen pre-treatment for ovarian stimulation protocols for women undergoing assisted reproductive techniques
Comparison: 5 Combined OCP versus estrogen
Outcome: 6 Pregnancy losses





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 COCP + Ant vs Estr + Ant
C drin-Durnerin 2007 (1) 2/21 1/25 100.0 % 2.43 [ 0.24, 24.79 ]
Subtotal (95% CI) 21 25 100.0 % 2.43 [ 0.24, 24.79 ]
Total events: 2 (Combined OCP), 1 (Estrogen)
Heterogeneity: not applicable
Test for overall effect: Z = 0.75 (P = 0.45)
2 COCP + Ag vs Estr + Ant
Daly 2002 1/12 1/13 100.0 % 1.09 [ 0.06, 18.49 ]
Subtotal (95% CI) 12 13 100.0 % 1.09 [ 0.06, 18.49 ]
Total events: 1 (Combined OCP), 1 (Estrogen)
Heterogeneity: not applicable
Test for overall effect: Z = 0.06 (P = 0.95)
0.01 0.1 1 10 100
Favours COCP Favours estrogen
(1) Calculated from the number of clinical pregnancies minus the number of live births.
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Analysis 5.7. Comparison 5 Combined OCP versus estrogen, Outcome 7 Multiple pregnancies.
Review: Oral contraceptive pill, progestogen or estrogen pre-treatment for ovarian stimulation protocols for women undergoing assisted reproductive techniques
Comparison: 5 Combined OCP versus estrogen
Outcome: 7 Multiple pregnancies





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 COCP + Ant vs Estr + Ant
C drin-Durnerin 2007 2/21 0/25 100.0 % 9.40 [ 0.56, 156.66 ]
Subtotal (95% CI) 21 25 100.0 % 9.40 [ 0.56, 156.66 ]
Total events: 2 (Combined OCP), 0 (Estrogen)
Heterogeneity: not applicable
Test for overall effect: Z = 1.56 (P = 0.12)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours COCP Favours estrogen
Analysis 6.1. Comparison 6 Progestogen versus estrogen, Outcome 1 Live births.
Review: Oral contraceptive pill, progestogen or estrogen pre-treatment for ovarian stimulation protocols for women undergoing assisted reproductive techniques
Comparison: 6 Progestogen versus estrogen
Outcome: 1 Live births





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 Prog + Ant vs Estr + Ant
C drin-Durnerin 2007 5/23 3/25 100.0 % 1.99 [ 0.44, 8.94 ]
Subtotal (95% CI) 23 25 100.0 % 1.99 [ 0.44, 8.94 ]
Total events: 5 (Progestogen), 3 (Estrogen)
Heterogeneity: not applicable
Test for overall effect: Z = 0.90 (P = 0.37)
0.005 0.1 1 10 200
Favours estrogen Favours progestogen
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Analysis 6.2. Comparison 6 Progestogen versus estrogen, Outcome 2 Ongoing pregnancies.
Review: Oral contraceptive pill, progestogen or estrogen pre-treatment for ovarian stimulation protocols for women undergoing assisted reproductive techniques
Comparison: 6 Progestogen versus estrogen
Outcome: 2 Ongoing pregnancies





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 Prog + Ant vs Estr + Ant
C drin-Durnerin 2007 (1) 5/23 3/25 100.0 % 1.99 [ 0.44, 8.94 ]
Subtotal (95% CI) 23 25 100.0 % 1.99 [ 0.44, 8.94 ]
Total events: 5 (Progestogen), 3 (Estrogen)
Heterogeneity: not applicable
Test for overall effect: Z = 0.90 (P = 0.37)
0.01 0.1 1 10 100
Favours estrogen Favours progestogen
(1) Data obtained from Dr. C drin-Durnerin.
Analysis 6.3. Comparison 6 Progestogen versus estrogen, Outcome 3 Clinical pregnancies.
Review: Oral contraceptive pill, progestogen or estrogen pre-treatment for ovarian stimulation protocols for women undergoing assisted reproductive techniques
Comparison: 6 Progestogen versus estrogen
Outcome: 3 Clinical pregnancies





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 Prog + Ant vs Estr + Ant
C drin-Durnerin 2007 (1) 7/23 4/25 100.0 % 2.23 [ 0.59, 8.44 ]
Subtotal (95% CI) 23 25 100.0 % 2.23 [ 0.59, 8.44 ]
Total events: 7 (Progestogen), 4 (Estrogen)
Heterogeneity: not applicable
Test for overall effect: Z = 1.18 (P = 0.24)
0.01 0.1 1 10 100
Favours estrogen Favours progestogen
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(1) Data obtained from Dr. C drin-Durnerin.
Analysis 6.4. Comparison 6 Progestogen versus estrogen, Outcome 4 Oocytes retrieved.
Review: Oral contraceptive pill, progestogen or estrogen pre-treatment for ovarian stimulation protocols for women undergoing assisted reproductive techniques
Comparison: 6 Progestogen versus estrogen
Outcome: 4 Oocytes retrieved





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Prog + Ant vs Estr + Ant
C drin-Durnerin 2007 (1) 23 12.6 (7.3) 22 13.1 (7) 100.0 % -0.50 [ -4.68, 3.68 ]
Subtotal (95% CI) 23 22 100.0 % -0.50 [ -4.68, 3.68 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.23 (P = 0.81)
-4 -2 0 2 4
Favours estrogen Favours progestogen
(1) No ITT in estrogen group.
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Analysis 6.5. Comparison 6 Progestogen versus estrogen, Outcome 5 Amount of gonadotrophins
administered.
Review: Oral contraceptive pill, progestogen or estrogen pre-treatment for ovarian stimulation protocols for women undergoing assisted reproductive techniques
Comparison: 6 Progestogen versus estrogen
Outcome: 5 Amount of gonadotrophins administered





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Prog + Ant vs Estr + Ant
C drin-Durnerin 2007 (1) 23 2010 (670) 22 1700 (524) 100.0 % 310.00 [ -40.60, 660.60 ]
Subtotal (95% CI) 23 22 100.0 % 310.00 [ -40.60, 660.60 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.73 (P = 0.083)
-500 -250 0 250 500
Favours progestogen Favours estrogen
(1) No ITT in estrogen group.
Analysis 6.6. Comparison 6 Progestogen versus estrogen, Outcome 6 Pregnancy losses.
Review: Oral contraceptive pill, progestogen or estrogen pre-treatment for ovarian stimulation protocols for women undergoing assisted reproductive techniques
Comparison: 6 Progestogen versus estrogen
Outcome: 6 Pregnancy losses





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 Prog + Ant vs Estr + Ant
C drin-Durnerin 2007 2/23 1/25 100.0 % 2.19 [ 0.22, 22.19 ]
Subtotal (95% CI) 23 25 100.0 % 2.19 [ 0.22, 22.19 ]
Total events: 2 (Progestogen), 1 (Estrogen)
Heterogeneity: not applicable
Test for overall effect: Z = 0.66 (P = 0.51)
0.01 0.1 1 10 100
Favours progestogen Favours estrogen
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Analysis 6.7. Comparison 6 Progestogen versus estrogen, Outcome 7 Multiple pregnancies.
Review: Oral contraceptive pill, progestogen or estrogen pre-treatment for ovarian stimulation protocols for women undergoing assisted reproductive techniques
Comparison: 6 Progestogen versus estrogen
Outcome: 7 Multiple pregnancies





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 Prog + Ant vs Estr + Ant
C drin-Durnerin 2007 1/23 0/25 100.0 % 8.06 [ 0.16, 407.60 ]
Subtotal (95% CI) 23 25 100.0 % 8.06 [ 0.16, 407.60 ]
Total events: 1 (Progestogen), 0 (Estrogen)
Heterogeneity: not applicable
Test for overall effect: Z = 1.04 (P = 0.30)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours progestogen Favours estrogen
A D D I T I O N A L T A B L E S
Table 1. Heterogeneity Analysis 1.4.2 + 1.5.2 + 1.6.2
Cédrin-Durnerin
2007
Huirne 2006b Kolibianakis 2006 Obruca 2001 Rombauts 2006
Inclusion criteria
Age limit used < 38 < 38 < 39 No limit < 39




Yes No Yes No Yes
Pre-treatment










Starting day CD 2 or 3 CD 2 or 3 CD 1 CD 1 CD 1
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Table 1. Heterogeneity Analysis 1.4.2 + 1.5.2 + 1.6.2 (Continued)
Duration 15-21 days 14-28 days 14 days 18-28 days 14-28 days
GnRH analogue
Type antagonist Ganirelix Antide Ganirelix Cetrorelix Ganirelix
Dose 0.25 mg/day 0.5 mg/mL Unknown 0.25 mg/day 0.25 mg/day
Starting day Follicle > 14 mm SD 6 Unknown SD 6 CD 21-24
Gonadotrophins
Type rFSH rFSH rFSH rFSH rFSH
Dose (IU/day) 150-300 150-300 200 150 200
CD = Cycle Day
SD = Stimulation Day
Table 2. Heterogeneity Analysis 1.5.3 + 1.6.3.
Huirne 2006a Hwang 2004 Rombauts 2006
Inclusion criteria
Only PCOS included No Yes No
Pre-treatment






Starting day CD 1 to 5 CD 5 CD 1
Duration 21 to 28 days three cycles 14 to 28 days
GnRH analogue
Type antagonist Cetrorelix Cetrorelix Ganirelix
Dose (mg/day) 0.25 0.25 0.25
Starting day SD 6 PD 3 SD 5 or 6
Type agonist Buserelin Buserelin Nafarelin
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Table 2. Heterogeneity Analysis 1.5.3 + 1.6.3. (Continued)
Dose (µg/day) 500 500 800
Starting day CD 18 to 22 CD 3 CD 21 to 24
Gonadotrophins
Type rFSH hMG rFSH
Dose (IU/day) 150 to 225 150 200
CD = Cycle Day
SD = Stimulation Day
PD = Post-treatment Day
Table 3. Heterogeneity Analysis 3.6.1
Cédrin-Durnerin 2007 Fanchin 2003a
Inclusion criteria
Age limit < 38 < 39
Pre-treatment
Type of oestrogen Micronized 17-βE2 Micronized 17-βE2
Starting day 10 days before presumed menses CD 20
Duration 10 to 15 days 11 days
GnRH analogue
Type antagonist Ganirelix Cetrorelix
Dose 0.25 mg/day 3 mg (single dose)
Starting day Follicle > 14 mm ≥ 1 follicle < 13 mm in diameter
Gonadotrophins
Type rFSH rFSH
Dose (IU/day) 150 to 300 225
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A P P E N D I C E S
Appendix 1. MDSG Specialised Register search strategy
Keywords CONTAINS ’IVF’ or ’in vitro fertilization’ or ’in-vitro fertilisation’ or ’in-vitro fertilization’ or ’ICSI’ or ’intracytoplasmic
sperm injection’ or ’embryo’ or ’ART’ or ’controlled ovarian’ or ’ COH’ or Title CONTAINS ’IVF’ or ’in vitro fertilization’ or ’in-
vitro fertilisation’ or ’in-vitro fertilization’ or ’ICSI’ or ’intracytoplasmic sperm injection’ or ’embryo’ or ’ART’ or ’controlled ovarian’
or ’ COH’
AND
Keywords CONTAINS ’oral contraceptive’ or ’oral contraceptives’ or ’OCP’ or ’oral contraceptive agent’ or ’combined oral contracep-
tives’ or ’progestagen’ or ’progesterone’ or ’progestin’ or ’progestogen’ or ’norgestrel’ or ’norethisterone’ or ’desogestrel’ or ’gestodene’
or ’oestrogen’ or ’oestrogen’ or ’oestrodiol’ or ’estradiol’ or ’pretreatment’ or Title CONTAINS ’oral contraceptive’ or ’oral contracep-
tives’ or ’oral contraceptive agent’ or ’combined oral contraceptives’ or ’progestagen’ or ’progesterone’ or ’progestin’ or ’progestogen’ or
’norgestrel’ or ’norethisterone’ or ’desogestrel’ or ’gestodene’ or ’oestrogen’ or ’oestrogen’ or ’oestrodiol’ or ’estradiol’ or ’pretreatment’
Appendix 2. CENTRAL search strategy
1 reproductive techniques/ or exp reproductive techniques, assisted/ or exp embryo transfer/ or exp fertilization in vitro/ or exp sperm
injections, intracytoplasmic/ or exp gamete intrafallopian transfer/
2 ART.tw.
3 (IVF or ICSI).tw.
4 embryo transfer.tw.
5 (in vitro fertilisation or in vitro fertilization).tw.





11 (OC or OCP$).tw.
12 (pretreatment$ or pre-treatment$).tw.
13 contraceptives, oral/ or exp gestrinone/ or exp contraceptives, oral, combined/ or exp ethinyl estradiol-norgestrel combination/ or
exp contraceptives, oral, hormonal/ or exp contraceptives, oral, sequential/ or exp contraceptives, oral, synthetic/ or exp desogestrel/ or
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34 30 not 33
Appendix 3. MEDLINE search strategy
1 reproductive techniques/ or exp reproductive techniques, assisted/ or exp embryo transfer/ or exp fertilization in vitro/ or exp sperm
injections, intracytoplasmic/ or exp gamete intrafallopian transfer/
2 ART.tw.
3 (IVF or ICSI).tw.
4 embryo transfer.tw.
5 (in vitro fertilisation or in vitro fertilization).tw.





11 (OC or OCP$).tw.
12 (pretreatment$ or pre-treatment$).tw.
13 contraceptives, oral/ or exp gestrinone/ or exp contraceptives, oral, combined/ or exp ethinyl estradiol-norgestrel combination/ or
exp contraceptives, oral, hormonal/ or exp contraceptives, oral, sequential/ or exp contraceptives, oral, synthetic/ or exp desogestrel/ or

















30 9 and 29
31 randomised controlled trial.pt.
32 controlled clinical trial.pt.







40 (animals not (humans and animals)).sh.
41 39 not 40
42 41 and 30
43 luteal support.ti.
44 luteal phase.ti.
45 43 or 44
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46 42 not 45
Appendix 4. EMBASE search strategy
1 reproductive techniques/ or exp reproductive techniques, assisted/ or exp embryo transfer/ or exp fertilization in vitro/ or exp sperm
injections, intracytoplasmic/ or exp gamete intrafallopian transfer/
2 ART.tw.
3 (IVF or ICSI).tw.
4 embryo transfer.tw.
5 (in vitro fertilisation or in vitro fertilization).tw.





11 (OC or OCP$).tw.
12 (pretreatment$ or pre-treatment$).tw.
13 contraceptives, oral/ or exp gestrinone/ or exp contraceptives, oral, combined/ or exp ethinyl estradiol-norgestrel combination/ or
exp contraceptives, oral, hormonal/ or exp contraceptives, oral, sequential/ or exp contraceptives, oral, synthetic/ or exp desogestrel/ or





















34 30 not 33
35 Clinical Trial/ (520486)
36 Randomized Controlled Trial/
37 exp randomization/
38 Single Blind Procedure/
39 Double Blind Procedure/
40 Crossover Procedure/
41 Placebo/
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46 allocated randomly.tw.
47 (allocated adj2 random).tw.
48 Single blind$.tw.
49 Double blind$.tw.






56 abstract report/ or letter/
57 or/54-56
58 53 not 57
59 34 and 58
60 limit 59 to yr=“2007 - 2008”
Appendix 5. CINAHL search strategy
1 reproductive techniques/ or exp reproductive techniques, assisted/ or exp embryo transfer/ or exp fertilization in vitro/ or exp sperm
injections, intracytoplasmic/ or exp gamete intrafallopian transfer/
2 ART.tw.
3 (IVF or ICSI).tw.
4 embryo transfer.tw.
5 (in vitro fertilisation or in vitro fertilization).tw.





11 (OC or OCP$).tw.
12 (pretreatment$ or pre-treatment$).tw.
13 contraceptives, oral/ or exp gestrinone/ or exp contraceptives, oral, combined/ or exp ethinyl estradiol-norgestrel combination/ or
exp contraceptives, oral, hormonal/ or exp contraceptives, oral, sequential/ or exp contraceptives, oral, synthetic/ or exp desogestrel/ or

















30 9 and 29
31 luteal phase.ti.
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32 luteal support.ti.
33 or/31-32
34 30 not 33
35 exp clinical trials/
36 Clinical trial.pt.
37 (clinic$ adj trial$1).tw.
38 ((singl$ or doubl$ or trebl$ or tripl$) adj (blind$3 or mask$3)).tw.








47 34 and 46
Appendix 6. PsycINFO search strategy
1 reproductive techniques/ or exp reproductive techniques, assisted/ or exp embryo transfer/ or exp fertilization in vitro/ or exp sperm
injections, intracytoplasmic/ or exp gamete intrafallopian transfer/
2 ART.tw.
3 (IVF or ICSI).tw.
4 embryo transfer.tw.
5 (in vitro fertilisation or in vitro fertilization).tw.





11 (OC or OCP$).tw.
12 (pretreatment$ or pre-treatment$).tw.
13 contraceptives, oral/ or exp gestrinone/ or exp contraceptives, oral, combined/ or exp ethinyl estradiol-norgestrel combination/ or
exp contraceptives, oral, hormonal/ or exp contraceptives, oral, sequential/ or exp contraceptives, oral, synthetic/ or exp desogestrel/ or

















30 9 and 29
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34 30 not 33
Appendix 7. Data extraction form (part 1)
Assessment










4. Published Yes / No
5. Journal
B. Criteria for eligibility YES NO
Design Described as randomised?
If
no, then exclude
Patients Women with subfertility, regard-
less of any cause, undergoing
ART
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(Continued)
Intervention · OCP prior to gonadotrophins
· OCP prior to gonadotrophins
+ GnRH agonist
· OCP prior to gonadotrophins
+ GnRH antagonist
· Estrogen prior to go-
nadotrophins
· Estrogen prior to go-
nadotrophins + GnRH agonist
· Estrogen prior to go-
nadotrophins + GnRH antago-
nist
· Progestogen prior to go-
nadotrophins
· Progestogen prior to go-
nadotrophins + GnRH agonist
· Progestogen prior to go-
nadotrophins + GnRH antago-
nist
B. Criteria for eligibility (continued) YES NO
Comparison · Placebo prior to go-
nadotrophins
· Placebo prior to go-
nadotrophins + GnRH agonist
· Placebo prior to go-
nadotrophins + GnRH antago-
nist
· No pretreatment prior to go-
nadotrophins
· No pretreatment prior to go-
nadotrophins + GnRH agonist
· No pretreatment prior to go-
nadotrophins + GnRH antago-
nist
· OCP prior to
gonadotrophins
· OCPprior to gonadotrophins
+ GnRH agonist
· OCPprior to gonadotrophins
+ GnRH antagonist
· Estrogen prior to go-
nadotrophins
· Estrogen prior to go-
nadotrophins + GnRH agonist
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(Continued)
· Estrogen prior to go-
nadotrophins + GnRH antago-
nist
· Progestogen prior to go-
nadotrophins
· Progestogen prior to go-
nadotrophins + GnRH agonist
· Progestogen prior to go-
nadotrophins + GnRH antago-
nist
Outcome Primary:
· number of live births
Secondary:
· no. of ongoing pregnancies
· no. of clinical pregnancies
· no. of oocytes retrieved
· total days of gonadotrophin
treatment
· amount of gonadotrophin ad-
ministered
Adverse:
· no. of pregnancy loss
· no. of ovarian cyst formation
· no. of multiple pregnancies






Setting Single Multicentre Unclear
Academic Non-academic Unclear
Duration of trial Y = M = D =
Design Parallel Crossover
Number of participants In-
ter-
ven-
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Poor response YES NO
Defined as: * Mature ovarian follicles:
< 3 with a mean diameter ≥ 17 mm
* Oocytes retrieved:
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C2. Flowchart of participants
Remarks:
C3. Protocol characteristics
















Analysis of loss to follow-up Per protocol Intention-to-treat
Remarks:
D. Risk of bias assessment
YES NO Unclear
Study size Was a power calculation
performed and adhered?
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(Continued)
Selection bias Was the allocation se-
quence adequately gen-
erated?
Was the patient alloca-
tion concealment ade-
quate?
Detection bias Was the length of follow-













Reporting bias Where there any sugges-
tions of selective report
of outcome?
Source of funding Is the source of funding
stated?
Remarks:
Appendix 8. Data extraction form (part 2)
D. Risk of bias assessment
YES NO Unclear
Study size Was a power calculation
performed and adhered?
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(Continued)
Selection bias Was the allocation se-
quence adequately gen-
erated?
Was the patient alloca-
tion concealment ade-
quate?
Detection bias Was the length of follow-













Reporting bias Where there any sugges-
tions of selective report
of outcome?




Comparison a. Define treatment:
b. Define control:
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No. of ongoing preg-
nancy
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No. of clinical preg-
nancy
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Embryo The product of conception from the time of fertilisation to the end of the embryonic stage eight weeks after fertilisation.
Embryo transfer (ET) Procedure of which embryos are placed in the uterus or fallopian tube.
Endogenous Developed or originated inside the organism. For example hormones produced by the pituitary gland would be an
endogenous supply, but hormones produced in the laboratory and then given to the body is called an exogenous supply.
Fertilisation The penetration of the ovum by the sperm cell and fusion of genetic materials, resulting in the development of an embryo.
Follicle The sac in which an egg develops in the ovary.
Follicle cohort synchronisation In the ovaries a few eggs are maturing at the same time. These eggs are all in a different stage of
maturation. If one egg reaches a threshold at the right time in the menstrual cycle, the final maturation process will start and this egg
will reach ovulation. For IVF/ICSI cycles it is important that more than one egg reaches this threshold at the same time, so they can
be retrieved at once before spontaneous ovulation occurs. This is called synchronisation of the follicle cohort.
Follicle Stimulating Hormone (FSH) A hormone produced and released from the pituitary gland. In women it stimulates the
production of oestrogen and follicles in the ovary ready for ovulation.
Gestational sac A fluid-filled structure containing an embryo that develops early in pregnancy, usually within the uterus.
Gonadotrophin Releasing Hormone (GnRH) A substance produced by the hypothalamus (part of the brain) to enable the pituitary
gland to secrete LH and FSH.
Gonadotrophins Pituitary hormones FSH and LH which stimulate the ovaries in women.
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Human Menopausal Gonadotrophin (hMG) An injectable preparation that is obtained from the urine of menopausal women and
has biological activity similar to that of FSH.
Luteal phase The last 14 days of the menstrual cycle.
Luteinising Hormone (LH) A hormone produced and released by the pituitary gland. In women it is responsible for ovulation and
progestogen production.
Negative feedback A common regulation mechanism to stabilise the body’s internal environment. An example is the temperature
control of the human body. When your temperature is too high, the body will react in such a way that you cool down, by opening pores
and sweating. In this way the body’s temperature will not fluctuate too much. The same kind of mechanism is used to keep hormone
values stable. An increase in gonadotrophin values will (through negative feedback) result in fewer GnRH receptors. The binding of
GnRH to a GnRH receptor in the pituitary gland will result in the release of gonadotrophins, but with fewer GnRH receptors, the
releasing process will be lowered and the gonadotrophin levels in the body will drop.
Oocyte The egg from a woman’s ovary.
Ova A woman’s reproductive cell, also known as egg or oocyte.
Ovarian Hyperstimulation (OHS) Syndrome A condition that occurs from fertility drugs when a large number of follicles in the
ovary are stimulated to develop and ovulate. This stimulation causes an enlargement of the ovaries.
Ovulation The release of an egg/ova from an ovarian follicle.
Ovulation induction Medical procedure to produce ovulation.
Polycystic Ovary Syndrome (PCOS)When a woman has enlarged ovaries with multiple cysts and the surface of the ovary is thickened.
The woman may ovulate infrequently or not at all.
Premature LH-surge In a normal menstrual cycle an increase in LH-levels (LH-surge) is needed to start ovulation. In IVF/ICSI cycles
it is important that the ovulation does not start before the oocytes are mature enough to be retrieved. A LH-surge that occurs too early
is called premature and is an unwanted event in IVF/ICSI cycles.
Recombinant (as in recombinant FSH or rFSH) A naturally occurring hormone which has been made in the laboratory with the use
of DNA technology.
Subfertility Failure to achieve pregnancy after at least one year of unprotected coitus.
Ultrasound Radiology sounds waves of a high frequency used to visualise the developing foetus in the uterus to check size, growth and
the presence of abnormalities.
All these definitions (except for follicle cohort synchronisation, negative feedback and premature LH-surge) were achieved from the
glossary of the MDSG Module 2008.
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Last assessed as up-to-date: 15 November 2008.
Date Event Description
20 September 2010 Amended Contact details updated.
H I S T O R Y
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Review first published: Issue 1, 2010
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Date Event Description
16 August 2010 Amended Minor edits made no change to conclusion
18 December 2008 Amended Title changed
23 November 2008 Amended New authors added
All aspects of original protocol revised
13 April 2008 Amended Converted to new review format.
19 May 2006 New citation required and major changes Substantive amendment
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Brechtje Smulders drafted the Background and Objectives of the review, and performed the search, selected the studies, extracted and
analysed the data, contacted the authors of trials and drafted the Results, Discussion and Authors’ conclusions of the review together
with Sanne M van Oirschot. BS also drafted half of the tables of Characteristics of included studies and drafted Table 1, Table 2 and
Table 3.
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
The biggest change between the protocol and the review is the formation of different subgroups. In the protocol we described that we
would perform subgroup analyses on women’s age; poor response; agonist long, short and ultra-short protocol; and the duration of
pre-treatment. After regarding the included studies, we thought it would make more sense to perform subgroup analyses on the type
of GnRH analogue used in the treatment cycles. After this, we could not perform any more subgroup analysis on the planned subjects,
because there were not enough studies per subgroup. Furthermore, we did not perform any sensitivity analyses due to the small number
of included studies per subgroup.
Other minor things that we changed in this review was the exclusion of oocyte donors as participants, we rewrote the interventions to
make them more understandable, we changed the outcome ’ovarian cysts per woman randomised’ to ’number of women with ovarian
cysts’ and we removed a few items of the data extraction because we thought they were less important. At last, we were unable to
perform a funnel plot because of the limited number of included studies to each subgroup.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Contraceptives, Oral [∗administration & dosage]; Estrogens [∗administration & dosage]; Fertilization in Vitro [∗methods]; Go-
nadotropin-Releasing Hormone [antagonists & inhibitors]; Live Birth; Ovulation Induction [∗methods]; Pregnancy Rate; Progestins
[∗administration & dosage]; Randomized Controlled Trials as Topic; Sperm Injections, Intracytoplasmic; Treatment Outcome
MeSH check words
Female; Humans; Pregnancy
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